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Abstract 
This thesis consists of seven scientific articles and is preceded by an overview that 
contextualises all of this submitted/published work. 
The first part of this thesis is comprised of Publication 1. It is concerned with the 
cyclisation of 1,6-enynes of the general form A to bicyclic isomer B.  
Specifically, Publication 1 describes an extensive literature review on the 
chemistry of the palladium-catalysed intramolecular Alder-ene (IMAE) reaction, 
a powerful method for the construction of carbon-carbon bonds. This review 
focusses only on the cyclisation reactions of hetero-atom linked 1,6-enynes to 
form cis-fused hexahydro-indoles and -benzofurans. It serves to contextualise 
some of the author’s other published research in the area.  
The second part of the thesis is comprised of Publications 2 and 3 that focus on 
a novel synthesis of the potent and reversible acetylcholine esterase inhibitor 
galanthamine. 
Specifically, Publication 2 consists of an invited book chapter that details the 
Banwell Group’s efforts to synthesis the Amaryllidaceae alkaloid galanthamine, as 
well as analogues thereof, in order to further investigate the biological properties 
of these compounds.  
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Similarly, Publication 3 reports a seventeen-step reaction sequence that was 
used to synthesise (±)-galanthamine. This route featured an intramolecular 
Alder-ene cyclisation of propargyl acetate C to form allylic acetate D, an 
intermediate embodying the AB ring system of the natural product.  
The third part of this thesis consists of Publications 4 and 5. These detail the 
application of allylic alcohol E in the synthesis of the sesquineolignan simonsol C 
and in a second-generation synthesis of (±)-galanthamine. 
Specifically, then, Publication 4 highlights the first total synthesis of the 
Illicium-derived sesquineolignan simonsol C, a natural product that displays 
structural similarities to galanthamine. This twelve-step synthesis of simonsol C 
featured an intramolecular Heck reaction of aryl iodide F, itself the product of a 
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Mitsunobu reaction using allylic alcohol E, to establish the tetracyclic framework 
of simonsol C.  
A second-generation synthesis of (±)-galanthamine is reported in Publication 5. 
This investigation, which used methodology developed in the aforementioned 
synthesis of simonsol C, involved, as a key step, an intramolecular Heck reaction 
of aryl iodide G, an intermediate derived from precursor E, to install the tricyclic 
framework of (±)-galanthamine. 
The final section of this thesis is comprised of Publications 6 and 7. These focus 
on the formation and application of N-methoxy-N-methylcyanoformamide (H) in 
organic synthesis.  
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Publication 6 describes investigations concerned with establishing the reactivity 
profile of N-methoxy-N-methylcyanoformamide and its capacity to introduce the 
Weinreb amide functionality into organic frameworks. Specifically, it describes 
the reaction of this cyanoformamide with various enolates and organometallic 
species. Publication 7 details the synthesis of N-methoxy-N-
methylcyanoformamide (a previously unreported compound) via a two-step 
procedure. 
 
The Appendix to the thesis is comprised of a report arising from single-crystal X-
ray analysis of a key compound synthesized by the author. This analysis and the 
derived reports are the result of studies carried out by Dr Brett Schwartz. 
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Thesis Overview 
Publication 1: The Palladium-Catalysed Intramolecular Alder-ene (IMAE) 
Reactions of Certain Heteroatom-Linked 1,6-Enynes: The Formation of 
Hexahydro-Indoles and -Benzofurans  
The intramolecular Alder-ene reaction is a powerful and often underutilised 
method for the formation of carbon-carbon bonds in organic synthesis. This 
publication reviews the applications of this reaction in organic synthesis with a 
particular emphasis on the research conducted within the author’s research 
group. 
Cycloisomerizations of carbon- and heteroatom-linked 1,6-enynes have been 
employed within the Banwell research group for the total synthesis of various 
natural products. This review describes, inter alia, studies directed towards the 
syntheses of galanthamine1, hamayne2 as well as haemultine3 and wherein the 
quaternary carbon centre of these alkaloids was formed via a palladium-catalysed 
IMAE reaction. 
This review also presents some recent investigations within the Banwell research 
group where it was discovered that certain heteroatom-linked 1,6-enynes bearing 
alkynyl silanes (1) efficiently engaged in the intramolecular Alder-ene reaction to 
afford the expected heterocycles (2). These products could then be transformed 
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into the related and more synthetically useful alkenyl halides (3) on treatment 
with either NBS or NIS (Scheme 1). 
 
 
Scheme 1: The IMAE reaction of 1,6-enynes of the general form 1 and the 
manipulation of the product alkenylsilanes 2 to give halides 3. 
 
Publication 2: Devising New Syntheses of the Alkaloid Galanthamine, a 
Potent and Clinically Deployed Inhibitor of Acetylcholine Esterase 
 
The Amaryllidaceae alkaloid (–)-galanthamine,4, 5 which has been isolated from, 
inter alia, the bulbs and flowers of the Caucasian snowdrop (Galanthus 
woronowii), is a potent, competitive and reversible inhibitor of acetylcholine 
esterase (AChE).6 As a result, this alkaloid is now used for the clinical treatment 
of mild to moderate forms of Alzheimer’s disease in Europe, Japan and the United 
States.7 Synthetic chemists and pharmacologists alike have been attracted to this 
alkaloid for these reasons with efforts aimed at developing more potent 
analogues for the treatment of Alzheimer’s disease. In addition, the significant 
costs associated with the isolation and purification of (–)-galanthamine from 
plant sources means that there is a high demand for the development of practical 
and efficient total syntheses of this alkaloid.7 
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Publication 2 is an invited book chapter that highlights a number of syntheses 
of galanthamine that have been reported in the literature.8-10 The first of these 
was by Barton and co-workers8 in 1962 who established a biomimetic approach to 
galanthamine through an intramolecular oxidative phenolic coupling of N-
methylnorbelladine. Specifically, when N-methylnorbelladine (4) was treated 
with potassium ferricyanide in aqueous NaHCO3 solution it afforded (±)-
narwedine, albeit in just 1.4% yield. The latter was then reduced to a mixture of 
(±)-galanthamine and its epimer through exposure to LiAlH4. This publication 
also outlines the investigations conducted by the Banwell research group into 
new syntheses of galanthamine1, 11 as well as various analogues12 of this alkaloid. 
Scheme 2: The original and biomimetic synthesis of (±)-galanthamine. 
Publication 3: A Total Synthesis of Galanthamine Involving De Novo 
Construction of the Aromatic C-Ring. 
This publication details the author’s investigations into the total synthesis of (±)-
galanthamine using the intramolecular Alder-ene-mediated conversion of 
propargyl acetate 9 to allylic acetate 10 as a key step for installing the quaternary 
carbon centre of the target. Overall, a seventeen-step reaction sequence was 
employed starting from ketone 5 that was transformed into enol triflate 6 
through two functional group interconversions. A hydroboration-Suzuki-Miyaura 
cross-coupling sequence involving enamine 7 was used to install the aminoethyl 
sidechain that would later be used for the formation of the seven-membered 
heterocyclic D-ring present in the title compound. Other key steps in the 
synthesis included applying a Tsuji-Trost-type elimination reaction within 
compound 10 so as to form diene 11 and a one-pot Diels-Alder 
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cycloaddition/aromatisation reaction of the latter compound to give 
benzaldehyde 13. Six subsequent steps delivered (±)-narwedine, an established 
precursor to both (+)- and (–)-galanthamine. 
Scheme 3: Key steps involved in the synthesis of galanthamine from ketone 5. 
Publication 4: Total Synthesis of the Illicium-derived Sesquineolignan 
Simonsol C. 
The Illicium genus of flowering plant is found throughout Southwest China and is 
known to produce a diverse range of natural products. Amongst these are various 
compounds which are known to display useful neurological effects including 
neurite-outgrowth-promoting activity and acetylcholine-esterase-inhibiting 
properties.13-15 In 2012, Wang and co-workers16 isolated the sesquineolignan 
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simonsol C from the toxic shrub Illicium simonsii. The strong structural 
resemblance of this natural product to (–)-galanthamine led us to speculate that 
simonsol C may demonstrate similar biological properties and so prompting the 
author’s investigations into the synthesis of simonsol C. 
A twelve-step total synthesis of simonsol C is reported in Publication 4. This 
started with the elaboration of previously reported enol triflate 6, over three 
steps, to allylic alcohol 14. A Mitsunobu reaction using this allylic alcohol and 
iodophenol 15 efficiently afforded the expected product, aryl iodide 16. This last 
compound was exposed to Pd(OAc)2 and dppp and by such means engaged in the 
crucial intramolecular Heck cyclisation to afford acetal 17, a compound that 
embodies the tetracyclic framework of simonsol C. The total synthesis of the title 
compound was completed in a further five steps from this intermediate. 
9
 Scheme 4: Key steps involved in the synthesis of simonsol C from enol triflate 6. 
 
Publication 5: An Eleven-step Synthesis of Galanthamine from 
Commercially Available Materials 
 
The aforementioned investigations into the synthesis of simonsol C suggested 
that (±)-galanthamine could be prepared by similar means. To this end the 
author explored the possibility of using the previously reported allylic alcohol 14 
in a second-generation synthesis of (±)-galanthamine. Specifically, allylic alcohol 
14 was engaged in a Mitsunobu reaction with iodophenol 18, itself formed 
through the iodination of isovanillin, to afford the expected aryl iodide 19. On 
exposure of this product to the previously defined intramolecular Heck reaction 
conditions acetal 20 was formed. Compound 20 embodies the tricyclic 
framework of the natural product and could be transformed into (±)-narwedine 
over a further three steps. 
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 Scheme 5: Key steps involved in the second-generation synthesis of (±)-
galanthamine. 
 
Publication 6: N-Methoxy-N-methylcyanoformamide, a Highly Reactive 
Reagent for the Formation of -Keto Weinreb Amides and Unsymmetrical 
Ketones. 
 
Since the initial report by Mander,18 methyl cyanoformate (Mander’s reagent) has 
been used extensively in organic synthesis, especially for the formation of -
ketoesters from the corresponding ketone enolates. Indeed, it is the preferred 
reagent for this transformation since other methods give varying amounts of 
corresponding O-acylation products.19, 20 More recently, ethyl21, benzyl22 and 
allyl23 cyanoformates have all been successfully exploited for the synthesis of 
their corresponding -ketoesters. Despite the popularity and widespread use of 
cyanoformates in this regard, it is surprising that the analogous cyanoformamides 
have not been exploited in the synthesis of -ketoamides from the corresponding 
ketone enolates.  
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The work described in Publication 6 is concerned with exploring the reactivity 
profile of N-methoxy-N-methylcyanoformamide (21). It details the various 
synthetic applications of this compound. Specifically, this report highlights the 
use of N-methoxy-N-methylcyanoformamide in the efficient synthesis of -keto 
Weinreb amides (22) from the corresponding ketone enolates in a manner 
analogous to that used in the preparation of the related -ketoesters. In addition, 
it was established that when treated with the relevant organometallic species, 
cyanoformamide 21 could provide either the one-carbon homologated Weinreb 
amide 23 or the unsymmetrical ketone 24. 
 
 
 
Scheme 6: Applications of N-methoxy-N-methylcyanoformamide in synthesis. 
 
Publication 7: Preparation of N-Methoxy-N-methylcyanoformamide. 
 
Publication 7 describes, in detail, a two-step synthesis of N-methoxy-N-
methylcyanoformamide. The sequence starts with the ‘in-water’ reaction17 of N-
methoxy-N-methylamine hydrochloride (25) with CDI to form N-methoxy-N-
methyl-1H-imidazole-1-carboxamide (26). Treating the latter compound with a 
neat solution of 1.05 equivalents of trimethylsilyl cyanide efficiently afforded the 
desired cyanoformamide 21 in excellent yield.  
 
 
 
Scheme 7: Synthesis of N-methoxy-N-methylcyanoformamide. 
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Introduction
Palladium-catalysed processes are amongst the most important 
reactions in organic chemistry today.[1] Particularly notable 
examples include the Tsuji–Trost and Mizoroki–Heck reactions as 
well as the suite of related cross-coupling processes bearing 
names such as Sonogashira, Stille, Kumada, Suzuki–Miyaura, 
and Negishi.[2,3] Of course, the range of palladium-catalysed 
processes extends well beyond these, with this metal being used 
(often ‘suspended’ on an inert solid support such as charcoal) to 
effect the addition of dihydrogen to unsaturated organic 
compounds.[4] Indeed, these venerable and completely atom-
economical processes,[5] in which all of the constituent atoms of 
the reacting partners end up in the product(s), represent some of 
the most important industrial processes known and the com-
mercial value of them can be measured in the billions of dol-
lars.[6] A perhaps less well-known type of process that can be 
catalysed by various palladium-based species are cycloisome-
risations wherein polyunsaturated, open-chain or semi-cyclic 
species are converted, through intramolecular sigma-bond-
forming processes, into cyclic or even polycyclic products.[7] 
These processes are not only completely atom-economical ones 
but they often also proceed with exquisite levels of regio- and/or 
stereo-chemical control. Furthermore, and as is often the case 
with other palladium-catalysed reactions, changing the nature of 
the ligands co-ordinating to the metal can have a profound 
influence not only on the type of product formed but also on the 
enantioselectivities that might be observed when potentially 
desymmetrising transformations are involved.[7] The primary 
focus of this short review is on one such cycloisomerisation 
process, namely the palladium-catalysed intramolecular Alder-
ene (IMAE) reaction[8] of 1,6-enynes.
This has been described as the archetypal cycloisomerisation 
reaction.[7d] Two distinct variants are possible depending upon 
whether the atom-chain linking the reacting centres of unsatura-
tion is an all-carbon unit or one incorporating heteroatoms such as 
nitrogen or oxygen. In the latter cases the products of reaction are 
substituted pyrrolidines and tetrahydrofurans, respectively.
The Alder-ene-Based Cycloisomerisation Reactions of 
‘All Carbon’ 1,6-Enynes and Related Systems
While thermally-promoted variants of the title process have 
been known for well over half a century,[7d,8] a metal-catalysed 
form that proceeded efficiently and under mild conditions was 
only discovered in 1985 by Trost and Lautens and co-workers.[9] 
So, for example, these researchers established (Scheme 1) that 
treatment of the 1,6-enyne 1 (itself prepared via a Tsuji–Trost 
reaction) with 5 mol-% of the PdII species (Ph3P)2Pd(OAc)2 in 
hot d6-benzene affords the bicyclic diene 2 in 85 % yield.
[9a]
Many useful variants of this type of process, including 
asymmetric ones, followed thereafter,[10] as did the discovery 
and application of homologous processes employing 1,7-enynes as 
substrates.[11] Interestingly, in those substrates lacking a
*
The corresponding author, Martin G. Banwell, is the winner of the 2014 RACI H. G. Smith Memorial Medal.
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hydrogen-bearing substituent at the ‘outer’ allylic position or
where there is branching at C3, the isomerisation reaction often
yields 1,3-dienes. This is exemplified by the conversion of the
1,6-enyne 3 into the isomer 4 (Scheme 2) when N,N-bis-
(benzylidene)ethylenediamine (BBEDA) is used as ligand.[9d]
Elegant applications of such processes in natural products
synthesis abound.[7,10–13]
Since the original discovery of Trost and Lautens,[9] a range of
other metal catalysts has been shown to effect the cyclo-
isomerisations of 1,6- and 1,7-enynes and often in ways that are
complementary to the processes observed using palladium. So, for
example, when 1,6-enyne 5 (Scheme 3) is treated under ‘conven-
tional’ conditions with (Ph3P)2Pd(OAc)2 then the 1,3-diene 6 is
formed[12] while reaction of the same substrate with the cationic
ruthenium catalyst CpRu(MeCN)3
þPF6
– affords the isomeric 1,4-
diene 7 in a completely regio- and stereo-selectivemanner.[14] The
latter conversion isnotable for theefficient and selective formation
of a silylenol ether in the presencea freehydroxyl groupand stands
as testimony to the mild nature of the reactions involved.
A new reaction pathway is observed when a quaternary
carbon centre is introduced at the propargylic (C5) position of
the substrate. For example, compound 8 is transformed into
isomer 9 (40%) (Chart 1) upon treatment under the same
reaction conditions as employed for the conversion 5- 7.
A complete change in the mechanism of the cycloisomerisation
is occurring in such instances with a C–H insertion pathway now
being followed.[14b]
Stereochemically divergent outcomes have been observed in
the ruthenium- and palladium-catalysed cycloisomerisations of
cyclohexene-derived 1,7-enynes leading to decalin-containing
products.[15] Extensions of such Ru-catalysed processes to the
synthesis of certain alkaloid frameworks have been reported
recently.[16]
Reductive cycloisomerisations of 1,6-enynes catalysed by
either palladium or rhodium have been reported by Trost and
Rise[17] and Jang and Kirsche,[18] respectively. In the first case
(involving palladium) either triethylsilane or polymethylhydro-
siloxane (PMHS) serves as the reducing agent, while dihydro-
gen is employed for the same purpose in the second (i.e. when
rhodium is the catalyst). The conversion 10- 11 (Scheme 4) is
illustrative of the types of transformations that can be achieved by
such means. Recently, the ‘Trost variant’ of this process has been
used to construct the A-ring of various daphnane congeners.[19]
Cp2Ti(CO)2
[ 20] and certain iron(0)-ate complexes[21] have
also been shown to effect the cycloisomerisation of a range of
1,6-enynes to the corresponding cyclic 1,4-dienes in toluene at
temperatures between 80 and 1058C. A novel nickel-chromium
catalyst system supported on an insoluble phosphinylated poly-
mer has also been described.[22]
The Alder-ene-Based Cycloisomerisation Reactions
of Heteroatom-Linked 1,6-Enynes and Related Systems
Substrates in which heteroatom linkers connect the reacting
olefinic and acetylenic residues of 1,6-enynes can also be
engaged in palladium-catalysed cycloisomerisation reactions[7]
and, as illustrated below, the products of such processes have
served as precursors to a range of natural products. One of the
earliest examples of the title process was reported in 1992 by
Trost and Pedregal[23] who demonstrated that the alkynylN-acyl
enamine 12 (Scheme 5) is converted into the isomeric indoli-
zidine 13 (90%) on exposure to 2.5mol-% (dba)3Pd2CHCl3
and 10%BBEDA in d6-benzene at temperatures between 60 and
658C. In stark contrast, when the same substrate is exposed to
formic acid at room temperature (rt) it undergoes cationic
cyclisation to generate the quinolizidine 14 in 77% yield.
C6H6,
45–50C, 1 h
3 4
83 %
cat. BBEDA
Pd(OAc)2
CO2Me
CO2Me
Scheme 2.
5 6
∼80 %
HO OTBDMS
OTBDMS
HO
7
72 %
HO
CpRu(MeCN)3PF6
acetone, rt
OTBDMS
(Ph3P)2Pd(OAc)2
d6-benzene
80C, 1 h
Scheme 3.
8 9
CO2Me
CO2Me
Chart 1.
10 11
C6H6,
rt, 6 h
88 %
MeO2C
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Naturally enough, reports detailing attempts to effect these
types of conversions in an enantioselective manner soon fol-
lowed with enantiomeric excesses of .99% being observed in
certain cases.[24,25] Related palladium(II)-catalysed IMAE reac-
tions have been described in which accompanying acetoxy
group transfer is observed as highlighted by the enantioselective
conversion 15- 16 (Scheme 6).[26,27]
Tandem IMAE cross-coupling reactions involvingN- andO-
linked 1,6-enynes and aryl halides have been reported[28,29] as
have oxidative variants wherein diarylation of the cyclisation
product is achieved.[29] An example of the former process is
shown in Scheme 7. Thus, the N-linked system 17 is engaged in
an IMAE reaction and the palladated product of this process is
intercepted in a cross-coupling reaction with bromoarene 18
such that the (presumably cis-ring fused) polycyclic product 19
can be obtained in 66% yield.[28]
When the olefinic component of the substrate is part of a
terminal allylic alcohol then the enolic residue in the product
tautomerises to the corresponding aldehyde that can be engaged,
in situ, in reductive amination reactions. So, for example,
treatment of sulfonamide 20 under the conditions shown in
Scheme 8 leads to the pyrrolidine aldehyde 21 (96%) that on
exposure, in the same reaction vessel, to a range of secondary-
amines in the presence of dihydrogen affords the expected
tertiary-amines such as 22.[30]
As was the case with the corresponding all carbon-linked
1,6-enynes detailed above, when the heteroatom-linked systems
lack allylic hydrogens at the ‘outer’ position then 1,3-dienes
(rather than 1,4-dienes) are formed in the cycloisomerisation
process. The conversion23- 24 (Scheme9) exemplifiesmatters
and the products of such processes (e.g. 24) can participate in
successive Diels–Alder cycloaddition and allylboration reactions
with dienophiles and aldehydes, respectively.[31]
Anderson and co-workers have recently shown[32] that in
certain heteroatom linked 1,6-enynes where a sulfonamide
nitrogen is attached to the internal carbon of the alkyne residue
(i.e. the substrate contains an ynamide residue) then 1,3-dienes
incorporating an enamine unit are formed exclusively when a
combination of Pd(OAc)2 and BBEDA is used to effect the
cycloisomerisation process. In some instances, ruthenium-based
catalysts can be used to effect the same conversions.[32]
Rhodium(I)-based catalysts can also effect the IMAE reactions
of heteroatom linked 1,6-enynes.[33–38] These can proceed in a
highly enantioselectivemannerwhenappropriate chiral ligandsare
deployed. Zhang and co-workers have used such protocols in
developinganelegant synthesis[34] of the butyrolactone-containing
natural product (þ)-pilocarpine (25) (Chart 2).
In 2010 we reported[39] the outcomes of our initial studies on
the palladium-catalysed IMAE reactions ofN-linked 1,6-enynes
as a means for constructing the C3a-arylhexahydroindole sub-
structure associated with the Amaryllidaceae alkaloid tazettine
(26). While we rapidly established a method for preparing an
enyne, 27, that seemed suitable for participation in the desired
cycloisomerisation reaction, this process was overwhelmed by a
15 16
AcOH,
60°C, 22 h
85 %
(85 % ee)
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OO
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Scheme 6.
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competing coupling of the terminal alkyne residues of two
separate substrate molecules to afford a 1,3-enyne-containing
heterodimer (Chart 3).
In order to avoid such an event, a substrate incorporating a
‘capping’ methyl group was prepared by the pathway shown in
Scheme 10. Thus, commercially available diallyl ketone (28) was
converted into the ketal 29 under standard conditions and this
was, in turn, subjected to a ring-closing metathesis (RCM) using
Grubbs’ second-generation catalyst to afford cyclopentene 30.
Addition of dibromocarbene, generated under phase-transfer
conditions using triethylbenzylammonium chloride (TEBAC)
as catalyst, to compound 30 then afforded adduct 31 that could
be engaged in a silver cyanate promoted electrocyclic ring-
opening reaction. The p-allyl cation so-formed was trapped as
the corresponding isocyanate that was itself treated, in situ,
with t-butanol and thereby affording the Boc-protected amino-
cyclohexene 32. This was converted into the corresponding
nosyl-based sulfonamide, 33, in a straightforward manner. Com-
pound 33 participated in a Suzuki–Miyaura cross-coupling reac-
tion with the relevant arylboronic acid to afford the arylated
cyclohexene 34 that was N-propargylated using 1-bromobut-2-
yne in the presence of sodium hydride to give the ‘capped’
substrate 35 required for the IMAE reaction. In the event, when
compound 35 was treated with Pd(OAc)2 and BBEDA an
essentially quantitative yield of the desired C3a-arylhexa-
hydroindole 36 was obtained. Interestingly, and in keeping with
the observationsmade byTrost and Jebaratnam,[40] this particular
ligand/palladium(II) catalyst combination has proven to be the
most effective one we have encountered so far.
Using protocols related to those detailed immediately above
we have been able to complete a total synthesis of the racemic
modifications of the crinine alkaloid hamayne (37)[41] and the
structure assigned to the related natural product haemultine (38)
(Chart 4).[42] In each instance the exocyclic olefin associated
with the product of the relevant IMAE reaction wasmanipulated
in order to introduce the C-ring hydroxyl group with the B-ring
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being established by subjecting a late-stage derivative of the
product of the IMAE process to a Pictet–Spengler reaction.
Very recently we have completed total syntheses of both the
(þ)- and ()- forms of tazettine [viz. (þ)- and ()-26] using the
same types of protocols as shown in Scheme 10 and utilising
commercially available chiral amines for resolving the products
of the desymmetrising electrocyclic ring opening of 6,6-
dibromobicyclo[3.1.0]hexane (viz. the non-oxygenated conge-
ner of compound 31) (M. G. Banwell, P. Lan, A. C. Willis,
unpubl. data).
Encouraged by our successes in constructing hexahydroin-
doles using the palladium-catalysed IMAE reactions of N-linked
1,6-enynes, we sought to establish if the analogous oxygen
heterocycles (viz. hexahydrobenzofurans) could be assembled
by analogous means. In an extensive and just completed survey
(J. Nugent, E. Matousˇova´, J. Li, M. G. Banwell, A. C. Willis,
unpubl. data) that included an exploration of alternative and
synthetically more useful alkyne capping groups, we prepared,
inter alia, triethylsilyl (TES)-containing substrates such as 39
(Chart 5) and established that on exposure to Pd(OAc)2 and
BBEDA in benzene under microwave irradiation conditions this
affords the expected heterocycle, 40, in 80% yield (the analogous
conversion of the substrate lacking the TES group proceeds in just
16% yield under the same conditions) (Chart 5). Furthermore, on
treatment with N-iodosuccinimide in acetonitrile at 608C alke-
nylsilane 40 undergoes an ipso-substitution reaction to give, in
82% yield, the corresponding iodide 41 that is itself capable of
engaging in a range of metal catalysed cross-coupling processes.
Acyclic substrates also participate in the IMAE reaction
under analogous conditions giving highly substituted furans
as exemplified by the conversion 42- 43 (the illustrated product
was obtained in 74% yield as a single diastereoisomer of yet-
to-be determined configuration) (Chart 6). Spirocyclic furans are
available by related means. Interestingly, various attempts
to effect the same conversions using a range of seemingly relevant
ruthenium and rhodium based systems were unsuccessful.
Our continuing interest in the natural product galanthamine
(44) (Chart 7), a hexahydrobenzofuran-containing alkaloid used
clinically in the treatment of the early stages of Alzheimer’s
disease,[43] prompted us to consider its assembly using the title
protocols.
In the event,[44] we were able to effect the IMAE reaction of
the readily accessibleO-linked 1,6-enyne 45 (Scheme 11) under
our now standard conditions and thereby generate the bicyclic
compound 46 in 71% yield. On treatment with (Ph3P)4Pd and
the non-nucleophilic baseDBU, the elements of acetic acidwere
lost from compound 46 and the semi-cyclic and electron-rich
diene 47 thereby obtained in 85% yield. Compound 47 readily
participated in a completely regioselective Diels–Alder reaction
with propynal and the initially formed adduct was aromatised by
treatment with manganese oxide and thus forming the benzal-
dehyde 48 in 61% yield. On exposure to m-chloroperbenzoic
acid (m-CPBA) compound 48 participated in a Dakin oxidation
reaction and the product formate ester was immediately hydro-
lysed with potassium carbonate in methanol to give phenol 49 in
69% yield over the two steps involved. O-Methylation of
compound 49 under standard conditions then afforded the
anisole 50 in quantitative yield. The construction of the seven-
membered D-ring of galanthamine was straightforward and
involved the two step conversion of sulfonamide 50 into
formamide 51 (83%) that was engaged in a modified Bis-
chler–Napieralski type cyclodehydration reaction to give, after
a reductive ‘workup’ using sodium triacetoxy(hydrido)borate
and subsequent treatment with aqueous sodium bicarbonate,
()-narwedine 52 (44%), an established precursor to both (þ)-
and ()-galanthamine.
While this synthesis of galanthamine is not the shortest one
reported it is nevertheless notable for several reasons. It is the
first synthesis in which the aromatic C-ring has been constructed
de novo. Perhaps more significantly, especially in terms of the
general theme of this article, the Pd(OAc)2-catalysed IMAE
reaction that results in the formation of compound 46 proceeds
effectively within a multi-functional substrate 45. It also allows
for the construction of the quaternary carbon centre of galanth-
amine and establishes an allylic acetatemoiety that only engages
in Tsuji–Trost type chemistry on exposure to a palladium(0)-
species. In other words, the IMAE and Tsuji–Trost reactions
involved here are effectively ‘orthogonal’ processes.
Conclusions and Future Prospects
The palladium(II)-catalysed IMAE reactions of N- andO-linked
1,6-enynes offer extraordinary capacities for the construction,
under relatively mild and highly chemoselective conditions, of
complex hexahydro-indoles and -benzofurans, respectively.
The opportunities for the application of such processes to the
synthesis of natural products and various analogues seem almost
boundless. An important area of future endeavour will be the
identification of enantioselective variants of broad scope and
that can be conducted in operationally simple ways.
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5. An Abortive, Radical-Based Approach to (±)-Galanthamine 
6. Doing Things the Hard Way – De Novo Construction of the Aromatic C-ring as a 
Focal Point  
7. Conclusions 
 
Abstract: The alkaloid (–)-galanthamine (1), a potent inhibitor of acetylcholine esterase 
(AChE), is used clinically for the symptomatic treatment of mild to moderate forms of 
Alzheimer’s disease. The clinical demand for (–)-galanthamine together with the erosion of 
habitat of at least some of the source plants has created supply issues that have prompted 
numerous synthetic studies. Four distinct approaches for the assembly of the tetracyclic 
framework of compound 1 developed in the authors’ laboratories are described here. Two of 
these exploit an enantiomerically pure metabolite produced through the whole-cell 
dihydroxylation of bromobenzene as a precursor to the A-ring of natural product 1. The second 
of these rapidly provides enantiomerically pure compounds that molecular docking studies 
suggest should be strong inhibitors of AChE. A third synthesis of (–)-galanthamine involving 
the de novo assembly of the aromatic C-ring is also described, as is a failed radical cyclization-
based approach. 
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1. Introduction 
 The alkaloid (–)-galanthamine (a.k.a. galantamine, 1) has been obtained from a variety of 
plant sources including Caucasian snowdrops (Galanthus woronowii), the summer snowflake 
(Leucojum aestivum), the wild daffodil Narcissus pseudonarcissus and the Red Spider Lily 
(Lycoris radia).1 Various mythologies suggest that crude extracts of such plants have been used 
for millennia to treat a range of ailments but it was only in 1950 that a rather more specific 
report seems to have emerged on the utility of these materials. In particular, at this time a 
Bulgarian pharmacologist was supposed to have noted that rural populations in certain parts of 
Eastern Europe would rub snowdrops on their foreheads to alleviate headaches.1a,d Within a few 
years, and perhaps prompted in part by these observations, Russian researchers extracted (–)-
galanthamine from Galanthus woronowii and were using it as a treatment for poliomyelitis, and 
seemingly to considerable effect.1a,d,2 At about the same time it was also being employed in 
anaesthesiology as a curare reversal agent, as a treatment for myasthenia (an autoimmune or 
congenital neuromuscular disease) and myopathy (a muscular disease resulting in weakness) as 
well as for sensory and motor dysfunctions associated with CNS disorders.1,3 However, it was 
the recognition that this alkaloid is a selective, competitive and reversible inhibitor of the 
enzyme acetylcholinesterase (AChE)1 that can cross the blood-brain barrier that propelled it into 
the limelight and thence into the clinic (in the US, Europe and Japan) as an agent for the 
symptomatic treatment of mild to moderate vascular dementia and Alzheimer’s disease.1,4 It has 
also been shown to act at the nicotinic acetylcholine receptor as an allosteric potentiation ligand 
with the result that it triggers increased release of dopamine, serotonin, γ-aminobutyric acid, 
norepinephrine and related neurotransmitters.1,5 The HBr salt of compound 1 (marketed as, inter 
alia, Nivalin, Razadyne and Reminyl) is now considered a frontline drug in helping combat the 
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emerging dementia pandemic. Various recent clinical case studies stand as testimony to its 
utility in this regard.6  
 
 
 
 The clinical demand for (–)-galanthamine together with the erosion of habitat of at least 
some of the source plants has created supply issues.1b,7 As a result new means of production of 
the alkaloid are being sought with in vitro cultivation and pathway optimization techniques7 (in 
which the biosynthetic pathway8 is “tweaked”) being prominent amongst these. To date no 
industrially applicable (cost-effective) chemical synthesis of compound 1 has emerged9 that 
addresses this supply problem although a pilot scale and biomimetic production process has 
been reported.10  
 As is almost invariably the case with natural-product based drug development programs, 
significant effort has been directed towards the identification of analogues of (–)-galanthamine 
with improved efficacy and/or reduced side effects (compound 1 causes, inter alia, 
gastrointestinal problems). Such studies, which are now assisted by high-resolution X-ray 
structures of AChE/1 and related complexes,11 have involved traditional medicinal 
chemistry,1b,12 sophisticated QSAR analyses,13 “biomimetic diversity-oriented synthesis”14 and 
related techniques exploiting various multicomponent reactions.15 In parallel, natural products 
chemists continue to screen extracts from various biological sources for new metabolites 
(notably alkaloids) that display AChE inhibitory properties.16  
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 The circumstances described in the preceding paragraphs when considered together with 
the intriguing molecular architecture of (–)-galanthamine have, unsurprisingly, prompted a 
significant number of research groups to undertake total synthesis studies. In order to put our 
own group’s contributions to this area into an appropriate context, some commentary on other 
studies of the synthesis of galanthamine is warranted. This is provided in the following section.   
 
2. Studies on the Synthesis of Galanthamine – A Potted History 
 In 1960 Barton and Kirby reported17 the first synthesis of (±)-galanthamine and thereby 
confirming its structure. This involved a biomimetic but low yielding (1.4%) intramolecular 
phenolic oxidative coupling of compound 2 (Scheme 1) to generate the spiro-fused dienone 3 
that engages in a reversible intramolecular hetero-Michael addition reaction to give narwedine 
(4) that was itself converted into (±)-galanthamine on exposure to LiAlH4.17  
 
 
SCHEME 1: The Barton–Kirby Biomimetic Synthesis of Narwedine (4). 
 
 Various improvements to this process have been achieved by using, inter alia, slightly 
different substrates and/or other oxidants (notably hypervalent iodine compounds) in the pivotal 
coupling step.18 An asymmetric variant of this process has been introduced19 although this is not 
essential because racemic narwedine is resolved, through crystallization, into its (–)-form in the 
presence 1% (+)-galanthamine (viz. ent-1).20,21 Reduction of (–)-narwedine with L-Selectride 
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then affords (–)-galanthamine in 99% yield.20,22 In 2009 Magnus and co-workers reported23 a 
somewhat related synthesis of compound 1 in which an intramolecular phenol alkylation was 
applied to a biphenyl-containing substrate and thus affording a spiro-dienone that could be 
converted, over three simple and efficient steps, into (±)-narwedine (4).  
 The ABC-ring system of (–)-galanthamine has also been constructed using 
intramolecular Heck reactions with a particularly notable and early example being described by 
Trost and Toste.24 Specifically, they showed (Scheme 2) that on exposure to 15 mol % 
Pd(OAc)2, 15 mol % of the ligand diphenylphosphinopropane (dppp) and 3 mole equiavlents of 
Ag2CO3 the allylic ether 5, itself the product of an asymmetric allylic alkylation (AAA) 
reaction, was converted into compound 6 (91%). This was then carried forward over a further 
four steps into (–)-galanthamine.  
 
 
SCHEME 2: The Pivotal Intramolecular Heck Reaction Associated with the Trost/Toste 
Synthesis of (–)-Galanthamine (1). 
 
 Several variations on this type of approach have been reported25 as have other ingenious 
schemes26,27 leading to compound 1, the corresponding racemate or its optical antipode (viz. ent-
1). Of particular relevance to the present discussion is Chida’s synthesis of (+)-galanthamine 
from D-glucose using a combination of type-II Ferrier and Claisen rearrangement protocols. 
Details of this elegant work have recently been described in a personal account27b and are not, 
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therefore, presented here. It is, however, appropriate to note that, like Chida’s, a significant 
fraction of our research effort has been devoted to devising means by which certain chiral-pool 
derived starting materials can be elaborated to a range of biologically active natural products. 
The chirons we have chosen to investigate for this purpose, including in developing certain of 
the various approaches to galanthamine reported here, are the cis-dihydrocatechols of the 
general form 7.28 Many of these compounds are available in kilogram quantities and essentially 
enantiomerically pure form through the whole-cell biotransformation of the corresponding 
aromatic, e.g. bromobenzene.  
 
 
 
3. A First-Generation Chemoenzymatic Synthesis of (+)-Galanthamine 
 Our initial foray into the area of galanthamine synthesis was motivated a desire to see if 
we could parlay our knowledge28e of the chemistry of cis-1,2-dihydrocatechols into a reaction 
sequence that would allow for the elaboration of compound 7 (X = Br) into the A-ring of (+)-
galanthamine (ent-1). This non-natural form of the alkaloid was targeted in the first instance 
simply because this seemed to “map” more appropriately onto the chirality of the proposed 
starting material. That having been said, the compound ent-7 (X = Br) is also available28e 
(although it is not quite as accessible as its enantiomer) and so any success achieved in gaining 
access to (+)-galanthamine from cis-1,2-dihydrocatechol 7 (X = Br) automatically “translates” 
into a means for obtaining the natural product, viz. compound 1.  
O
HO
N Me
MeO
A
B
C
D
ent-1
[(+)-galanthamine]
X
OH
OH
7
(X = Me, Cl, Br, I...)
33
 8 
 The opening steps of our ultimately successful synthesis of (+)-galanthamine (ent-1)29 
from metabolite 7 (X = Br) are shown in Scheme 3 and involved the initial conversion of the 
latter into the corresponding and well known acetonide 8.  
 
 
SCHEME 3: Opening Stages of a First-Generation Chemoenzymatic Synthesis of  
(+)-Galanthamine (ent-1). 
 
 This step provides a trap for young players in that if not carried out carefully an almost 
explosive acid-catalyzed dehydration and re-aromatization reaction of the substrate and/or 
product occurs. Regio- and stereo-controlled epoxidation at the β-face of the non-halogenated 
double bond within compound 8 is readily effected using m-chloroperbenzoic acid (m-CPBA) 
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and the epoxide 9 (90% over two steps) so-formed is then engaged in a completely selective and 
mineral acid catalyzed ring opening reaction with acetic acid serving as the nucleophile so as to 
generate alcohol 10 (81%). This is immediately protected as the corresponding MOM-ether 11 
(91%) (forcing conditions required) and the associated acetate group hydrolyzed to the 
corresponding alcohol 12 (95%). This cyclohexenyl bromide participated in a Suzuki–Miyaura 
cross-coupling reaction with the readily obtained boronic acid 13 to afford the arylated 
cyclohexene 14 (98%). The single free hydroxyl group embedded within this last compound was 
engaged in a Mitsunobu reaction using α-chloroacetic acid as the nucleophile and the product 
ester immediately hydrolyzed using potassium carbonate in methanol to give the epimeric 
compound 15 (93% over two steps).  
 The next and particularly crucial phase of the synthesis was the construction of the 
quaternary carbon center associated with galanthamine as well as the formation of the furan or B 
ring. While it took sometime to establish the right sequence of reactions to realize such an 
outcome, this was eventually achieved in just three steps (Scheme 4), the first being the 
engagement of the allylic alcohol moiety within compound 15 in an Eschenmoser–Claisen (EC) 
rearrangement by treating it with the dimethyl acetal of N,N-dimethylacetamide in refluxing 
toluene for seven days. The amide 16 (89%) so-formed now embodies the requisite quaternary 
carbon center with the illustrated configuration and thus dictating that it is the (+)-form of 
galanthamine that will ultimately be obtained by this route.  
35
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SCHEME 4: Establishing the Quaternary Carbon Center and B-ring of (+)-Galanthamine 
 
 Notably, the epimer of and precursor to allylic alcohol 15, namely compound 14, also 
engages in an analogous but even more sluggish EC rearrangement and thereby delivering the 
epimer of compound 16. In principle, this epimer could serve as a precursor to (–)-
galanthamine. Treatment of compound 16 with molecular bromine in toluene resulted in three 
distinct events: (i) cleavage of both the isopropyl aryl ether and acetonide residues; (ii) a bromo-
etherification reaction (to form the desired B-ring) and, (iii), a SEAr reaction at the electron-rich 
arene moiety. As a result compound 17 (69%) was obtained but on attempting to reductively 
debrominate it through exposure to dihydrogen in the presence of 10% Pd on C and potassium 
carbonate then, inter alia, a transannular etherification reaction took place and so producing the 
undesired 7-oxabicyclo[2.2.1]heptane 18 (67%). However, through the simple expedient of 
treating substrate 15 with molecular bromine in the presence of a mixture of toluene and acetone 
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then the acetonide residue could be retained while the isopropyl aryl ether was still cleaved and 
with the product phenol participating, once again, in a bromoetherification reaction involving 
the pendant double bond of the A-ring and so affording the dibromide 19 (93%). Reductive 
debromination of this last compound now proceeded as desired to afford compound 20 (68%) 
that embodies the desired ABC-ring substructure of target ent-1.  
The next phase of what was rapidly becoming a distinctly lengthy synthesis was the 
replacement of the now “longstanding” acetonide residue within the developing A-ring by a 
double bond residue. As is almost inevitable, a Corey–Winter olefination protocol was 
employed for this purpose. Thus, the free hydroxyl group within the A-ring of compound 20 
was protected (Scheme 5) as the corresponding acetate 21 (90%) and the acetonide residue 
within the latter was cleaved and the diol so-formed immediately converted into the 
corresponding cyclic thiocarbonate, 22 (99%), by treating it with thiophosgene in the presence 
of 4-(N,N-diemthylamino)pyridine (DMAP). Exposure of compound 22 to a large excess of 
trimethylphosphite in toluene then gave the desired olefin 23 (72%).  
SCHEME 5: Installing the A-Ring Double Bond 
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 The heroic end-game “played” by Dr Xinghua Ma in completing our first generation 
chemoenzymatic synthesis of (+)-galanthamine is outlined in Scheme 6 and involved, as the first 
steps, subjecting compound 23 to an initial cleavage of the A-ring acetate group and 
reprotection of the resulting alcohol 24 (95%) as the corresponding tert-butyldiphenylsilyl 
(TBDPS) ether 25 (95%). This was a necessary prelude to using Superhydride™ to reduce the 
associated amide residue to the corresponding 2°-alcohol and thus forming compound 26 (95%). 
A two-pot reaction sequence followed wherein the alcohol 26 was oxidized to the corresponding 
aldehyde (using the Dess–Martin periodinane – DMP) that was itself subjected to a free-radical 
bromination with the product acyl bromide then being trapped in situ by added methylamine. 
This afforded the mono-N-methylated amide analogue 27 (76%) of precursor 25. Desilylation of 
compound 27 using tetra-n-butylammonium fluoride (TBAF) and engagement of the product 28 
(85%) in a Pictet–Spengler reaction using paraformaldehyde in trifluoroacetic acid (TFA) 
resulted in closure of the D-ring and, thereby, formation of the lactam 29 (88%). The final two 
steps were devoted to establishing the correct stereochemistry of the A-ring hydroxyl group and 
this required engagement of compound 29 in a Mitsunobu reaction using α-chloroacetic acid as 
the nucleophile and then subjecting the product ester/lactam 30 (93%) to a “global” reduction 
using LiAlH4 and so providing (+)-galanthamine (ent-1) (85%), the high-field NMR spectral 
data for which matched those recorded on an authentic sample of its enantiomer.  
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SCHEME 6: The End-Game Associated with the First-Generation Chemoenzymatic Synthesis 
of Galanthamine (ent-1). 
 
 Clearly there are many deficiencies associated with this synthesis. While it could be 
certainly be tweaked in various ways (perhaps most notably by “fiddling” with protecting group 
regimes), the more important aspects of this work were the lessons learnt en route. In particular, 
the EC rearrangement reaction “shone through” as an almost uniquely effective means for 
establishing the quaternary carbon center of (+)-galanthamine from a precursor 2-cyclohexen-1-
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generation chemoenzymatic approach to galanthamine. How all this unfolded is described in the 
following section.  
 
4. Total Syntheses of Members of the Ribisin Class of Neurologically Active Natural 
Product Inspire a Second-Generation Chemoenzymatic Approach to 
(+)-Galanthamine 
 4.1  The Ribisins 
 In 2012 Fukuyama and co-workers reported30 the isolation of four new and structurally 
novel natural products from the fungus Phellinus ribis, the fruiting bodies of which are 
employed in traditional Chinese medicine for enhancing immunity and treating gastrointestinal 
cancer. On the basis of various spectroscopic analyses the benzofuran structures 31, 32, 33 and 
34 were assigned to these compounds that were named ribisins A–D, respectively.  
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 It was also noted that at 1 to 30 µM concentrations these natural products promote 
neurite outgrowth in NGF-mediated PC12 cells and could thus represent new leads for 
developing drugs to treat various neurodegenerative diseases. 
 The resemblance of the polyoxygenated rings of the ribisins to the cis-1,2-
dihydrocatechols of the general form 7 immediately struck us and prompted consideration of 
methods by which we could effect the necessary conversion. Our initial efforts31 were focused 
on synthesizing the structure, 33, assigned to ribisin C since this was the most active of the four 
compounds in the PC12-based assay. The reaction sequence used to obtain this compound is 
shown in Scheme 7.  
 
 
SCHEME 7: A Chemoenzymatic Synthesis of the Structure 33, Assigned to Ribisin C 
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 As with our first-generation synthesis of (+)-galanthamine, the reaction sequence leading 
to compound 33 started with the same cis-1,2-dihydrocatechol and this was first converted into 
the previously described epoxide 9. Opening of this with aqueous HCl then provided the 
expected trans-diol 35 (63%) that was subjected to a two-fold methylation reaction and so 
generating compound 36 (90%) embodying the two trans-related methoxy residues associated 
with target compound 33. Hydrolysis of the acetonide residue within bis-O-methyl ether 36 then 
afforded the cis-diol 37 (90%) that participated in a Suzuki–Miyaura cross-coupling reaction 
with the commercially available o-hydroxyphenyl boronic acid ester 38. As a result the 
cyclohexannulated benzofuran-type system 39 (24%) was obtained and this presumably arises 
from the spontaneous cycloetherification of the initially formed cross-coupling product. In 
anticipation of introducing a hydroxyl group as a precursor to the required ketone carbonyl, 
alcohol 39 was protected as the corresponding α-chloroacetate 40 that we knew, from previous 
experience, could be removed under exceptionally mild conditions. Treatment of cyclohexene 
40 with m-CPBA afforded the benzofuran 41 (49% from 39) that presumably arises through 
rearrangement of the initially formed epoxide, a process driven by rupture of the strained three-
membered ring and accompanying formation of the aromatic heterocycle associated with the 
observed product. Swern of oxidation of the alcohol residue within compound 41 and cleavage 
of the α-chloroacetate moiety within the product ketone using zinc acetate in methanol then 
gave target 33 (47% from 41), the structure and relative stereochemistry of which were 
established by single-crystal X-ray analysis. While the 1H and 13C NMR data acquired on 
compound 33 matched those reported for ribisin C, the similar magnitudes but opposite signs 
associated with the specific rotations of these two materials clearly indicated that the absolute 
stereochemistry of the natural product had been assigned incorrectly.  
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 As a result of the outcome just described, and because of a desire to acquire biologically 
active materials for testing for their neurite outgrowth promoting properties, we rapidly 
established31 a reaction sequence that enabled the synthesis of compound ent-33 and thus 
determining that this is the true structure of ribisin C. Once again, the staring material used for 
this purpose was the cis-1,2-dihydrocatechol 7 (X = Br). Using related chemistries we also 
prepared compounds 31, 32 and 34 and thereby establishing32 that the first and third of these do 
indeed represent the structures of ribisins A and D. Such work also enabled us to identify the 
true constitution of ribisin B as being represented by structure 42 and not 32. The substantial 
collection of compounds produced during the course of our work on the synthesis of the ribisins 
has been submitted for testing in a range of relevant assays.  
 
 
 
 
 4.2  A Second-Generation Chemoenzymatic Approach to the Synthesis of (+)-Galanthamine  
 Rather belatedly, it occurred to us that our synthetic work on the ribisins might provide a 
means of readily assembling the ABC-ring system associated with galanthamine and perhaps 
even the alkaloid itself. There certainly appears to be some validity to this proposition as 
evidenced by the completion of the reaction sequence shown in Scheme 8.33  
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SCHEME 8: A Second-Generation Chemoenzymatic Approach to (+)-Galanthamine (ent-1). 
 
 Once again, the reaction sequence starts with the cis-1,2-dihydrocatechol derived from 
the whole-cell biotransformation of bromobenzene, viz. compound 7 (X = Br), but the derived 
epoxide 9 is now opened with p-methoxybenzyl alcohol (PMBOH) in the presence of BF3•Et2O 
to give the tri-protected bromoconduritol 43 that upon exposure to pyridinium 
p-toluenesulfonate (PPTS) in methanol affords its mono-protected counterpart 44 (70% from 9). 
Reaction of this last compound with 2,2,3,3-tetramethoxybutane in the presence of catalytic 
quantities of p-TsOH then provided the Ley-type34 bis-ketal 45 (86%) in which, by virtue of the 
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operation of the anomeric effect, completely selective protection of the vicinally-related and 
trans-oriented hydroxyl groups within substrate 44 had occurred together with cleavage of the 
PMB ether moiety. Suzuki–Miyaura cross coupling of compound 45 with the arylboronic acid 
ester 46, a compound that is readily obtained in a one-pot process from o-methoxyphenol using 
a protocol described by Hartwig,35 afforded the anticipated product (60%) that readily engaged 
in an intramolecular Mitsunobu reaction to give the targeted ABC-ring containing product 47 
(96%). This last compound might have been expected to be vulnerable to double-bond migration 
and thereby forming the isomeric and fully aromatic benzofuran. Nevertheless, and gratifyingly, 
it engaged in a very efficient and remarkably facile EC rearrangement reaction on being heated 
with dimethyl acetal of N,N-dimethylacetamide and so affording compound 48 in 86% yield. A 
distinctly cumbersome four-step sequence closely related to that deployed in the end-game 
associated with our first generation galanthamine synthesis (Scheme 6) was then used to convert 
this N,N-dimethylacetamide derivative into its mono-methylated counterpart 49 (73% over four 
steps). This last compound participated in a Pictet–Spengler reaction on treatment with 
paraformaldehyde in TFA, a process that was accompanied by cleavage of the associated bis-
ketal moiety, and so forming the galanthamine analogue 50 (47%). 
 Efforts are now underway to effect the conversion of lactam 50 into (+)-galanthamine 
(ent-1). Interestingly, molecular docking studies similar to those reported previously36 suggest 
this compound (viz. 50) should bind at the active site of AChE with similar affinity to (–)-
galanthamine itself. This is because the cyclohexene C-ring (of 50) is oriented almost identically 
to its counterpart in (–)-galanthamine and so maintaining an architecture complementary to that 
of the active site of AChE and whereby it stacks against the indole ring of Trp84. Whether or 
not this rather tantalizing prediction is indeed correct remains to be tested experimentally. 
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5. An Abortive, Radical-Based Approach to (±)-Galanthamine 
 During the course of studies focused on the synthesis of certain crinine alkaloids we 
conceived of another and now exceptionally concise route to the ABC-ring substructure of 
galanthamine and hoped that the product so-formed would be capable of elaboration in such a 
way that the nitrogen-containing D-ring of the alkaloid could be annulated to it. The steps 
associated with the first stage of this study36 are shown in Scheme 9 and involved a thermally-
induced electrocyclic ring-opening of the readily available C3-oxygenated 6,6-
dibromocyclopropane 51 and engagement of the product dibromocyclohexene 52 in an SN2 
reaction with phenol 53 to give the allyl aryl ether 54 (ca. 80% from 51). This last compound  
 
 
SCHEME 9: A Concise, Cyclopropane-Based Route to the ABC-Ring Substructure of 
Galanthamine 
 
then participated in a Pd-catalyzed and intramolecular arylation reaction under conditions 
developed by Willis et al.37 to give the tetrahydrodibenzo[b,d]furan 55 (ca. 65%). Reductive 
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borohydride gave the desired 3°-amine 56, the hydroxyl group within which was subjected to an 
Appel reaction using Ph3P/CBr4 and so affording bromide 57 (61% over two steps).  
 With compound 57 to hand we hoped that on treating it with tri-n-butyltin hydride this 
would form, through homolysis of the associated C–Br bond, the corresponding 1°-radical that 
would, in turn, engage in a 7-exo-trig cyclization reaction and so generating the D-ring of 
galanthamine. Alas, this was not to be. So, when bromide 57 was subjected to the relevant 
conditions two unexpected events took place (Scheme 10). First of all, the initially formed 
radical 58 participated in a spirocyclization onto the pendant and electron-rich arene residue and 
the resulting and extensively delocalized radical 59 then fragmented to give the nitrogen-
stabilized congener 60 (overall a radical-based Smiles rearrangement) that now engaged in an 
8-endo-trig radical cyclization to give isomer 61. 
 
 
SCHEME 10: The Unexpected Radical-Based Reactions of the Tricyclic Iodide 57 – Formation 
of the D-Ring Galanthamine Isomer 63. 
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 This latter mode of cyclization is presumably driven by the formation of a benzylic 
radical rather than a homobenzylic one (that would have arisen from the hoped for but 
unobserved 7-exo-trig cyclization process). Reduction of radical 61 would then deliver, after 
desilylation with TBAF, the observed dihydrobenzofuran 62 (<1%) while loss of a hydrogen 
atom from the former species would afford, again after a TBAF treatment, benzofuran 63 
(12%). The structures of products 62 and 63 were established by single-crystal analyses. Given 
the latter is a D-ring isomer of galanthamine we wondered if it would act as an inhibitor of 
AChE. Molecular docking studies predicted it wouldn’t because of the distinctly different 
molecular shapes of the two compounds and in the event this prediction was borne out – 
tetracycle 63 is not an effective inhibitor of the enzyme.36  
 
6. Doing Things the Hard Way – De Novo Construction of the Aromatic C-Ring as a 
Focal Point   
 In 2010 we reported38 that various nitrogen-linked 1,6-enynes including compound 64 
engage in rather efficient palladium-catalyzed intramolecular Alder-ene (IMAE) reactions so as 
to generate angularly substituted polyhydroindoles such as 65. Subsequently, we exploited this 
kind of transformation as a key step in the synthesis of the racemic modification of the crinine 
alkaloid hamayne.39 A notable feature of these processes is the need to “cap” the alkyne residue 
of the substrate with, for example, a methyl group (as seen in 64) so as to prevent competing 
hetero-dimerization reactions. 
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 In seeking to understand the scope and limitations of such IMAE-based processes we 
wondered whether or not the corresponding oxygen-linked systems would undergo an analogous 
isomerization and thus affording angularly substituted perhydrobenzofurans related to the AB-
ring system associated with galanthamine. It quickly became apparent that this was so as 
illustrated by the successful execution of the reaction sequence shown in Scheme 11.40 Thus, the 
commercially available monoketal, 66, of cyclohexane-1,4-dione was subjected to an α-
oxidation protocol developed by Tomkinson and co-workers41 and thus affording, in racemic 
form, the acyloin derivative 67 that was converted into the corresponding enol triflate 68 (73% 
over two steps) under standard conditions. Using a very effective procedure developed by 
Kamatani and Overman,42 this last compound could then be cross-coupled with an organoborane 
derived from enamine 69 and so affording the β-aminoethyl-substituted compound 70 (79%). 
Saponification of the benzoate residue within the last compound proceeded uneventfully to give 
the corresponding alcohol 71 (71%) that was immediately reacted with propargyl bromide in the 
presence of sodium hydride to give the anticipated ether 72 (89%), the terminal alkyne moiety 
of which was “capped” by successive treatment with n-BuLi then paraformaldehyde and so 
giving the 1°-alcohol 73 (ca. 85%). This was then acetylated to give ester 74 (93%). 
Gratifyingly, on subjection to the types of conditions we have used previously for effecting 
IMAE reactions of related but somewhat simpler substrates, compound 74 could be efficiently 
isomerized to the benzofuran derivative 75 (71%). 
NTs O
O
64 65
NTs
O
O
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SCHEME 11: The IMAE Route to the AB-Ring System of Galanthamine. 
 
 Compound 75 embodies the A and B rings of galanthamine as well as an angular 
substituent that could serve as a precursor to the D-ring. Of course, a significant challenge 
associated with seeking to exploit the results shown in Scheme 11 concerns the matter of 
incorporating the aromatic C-ring, a structural element that has been present from the outset in 
all previous syntheses of this alkaloid. As such, we became intrigued by the possibility that we 
could benzannulate compound 75 in some way and so assemble the requisite ABC-ring 
substructure by such means. Provided relevant protocols could be identified then novel C-ring 
variants of galanthamine might become accessible using this type of approach. In the event, and 
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as shown in Scheme 12, a suitable benzanulation protocol was identified and a synthesis of (–)-
galanthamine thereby established. Thus, treatment of allylic acetate 75 with a Pd[0] catalyst in 
the presence of the base DBU resulted in elimination of the elements of acetic acid and, thereby, 
formation of the electron-rich and semi-cyclic 1,3-diene 76 (85%). This was readily engaged in 
a regio-selective Diels–Alder reaction with propynal and the rather unstable primary adduct so-
formed treated, in situ, with manganese dioxide to effect its aromatization and thereby 
generating benzaldehyde 77 (61%). Dakin oxidation of this last compound using m-CPBA and 
cleavage of the resulting formate using potassium carbonate in methanol then gave phenol 78 
(69%) that upon O-methylation afforded ether 79 (quantitative) that now embodies the essential 
“elements” of the ABC-ring substructure of galanthamine. As such it proved to be a relatively 
simple matter to elaborate compound 79 to (±)-narwedine, an established precursor (+)- or (–)-
galanthamine.20 Specifically, then, treatment of this last compound with magnesium turnings in 
methanol resulted in cleavage of the sulfonamide residue and the ensuing 2°-amine 80 (83%) 
was then reacted with ethyl formate to give the expected amide 81 (quantitative). Finally, 
subjection of compound 81 to a modified Bischler–Napieralski reaction using triflic anhydride 
and 2-chloropyridine,43 reduction of the resulting acyliminium ion with NaBH(OAc)3 and a mild 
acidic work-up (to cleave the ethylene ketal moiety) gave (±)-narwedine (4) albeit in an as yet 
unoptimized yield of 24%. 
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SCHEME 12: Assembling the Aromatic C-Ring of Galanthamine Using Diels–Alder 
Cycloaddition Chemistry and Completion of a Synthesis of (±)-Narwedine (4) 
 
7. Conclusions 
 Only one of the synthetic sequences reported above has any reasonable prospect of 
providing an especially useful route to (–)-galanthamine and that is the so-called second-
generation chemoenzymatic approach shown in Scheme 8. This was inspired by our work on the 
ribisins. Of course, and almost by definition, this chemistry was informed by the lessons learnt 
during the course of developing its first-generation counterpart. Currently the IMAE approach to 
the title alkaloid, as outlined in Schemes 11 and 12, is too long to be a useful means for 
obtaining significant quantities of galanthamine. However, and regardless of whether 
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refinements of it give any cause to change this assessment, it offers the capacity to construct 
novel aromatic C-ring analogues that might act as even more effective AChE inhibitors than 
(−)-galanthamine. As such it provides a quite distinct, if not a unique approach to the 
galanthamine framework. 
In each of the instances discussed above, the successful construction of the D-ring 
associated galanthamine has relied on engaging an angular β-aminoethyl moiety (located at the 
junction between the A and B rings) in a Pictet–Spengler or Bischler–Napierlaski reaction. In 
two instances, the precursor to this moiety is obtained through an EC rearrangement reaction 
and several steps were necessary to convert the initially formed N,N-dimethylamide moiety into 
its mono-methyl counterpart. Clearly, then, there would be great merit in identifying a 
replacement for the dimethyl acetal of N,N-dimethylacetamide used in the EC rearrangement 
reaction with a species that generates the required mono-methylated amide directly. An even 
more attractive possibility would be to identify one that generates an acyl imminium ion 
immediately after the EC rearrangement and that thus engages in an in situ cyclization reaction 
to produce the D-ring directly. Such possibilities are under active investigation in our 
laboratories. 
Another focus of efforts to extend our work in this area will be generating compounds 
such as 50 and the diol, 82, derived from hydrolysis of bis-acetal 48. These readily accessible 
systems could be regarded as hybrids of the ribisin and galanthamine structures44 and might be 
expected to act as effective inhibitors of AChE. Certainly, as noted above, molecular docking 
studies suggest compound 50 should be active in this regard.  
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 Regardless of the outcomes of the studies foreshadowed immediately above, it is clear 
that the intriguing molecular architecture of galanthamine has prompted a significant number of 
research groups to develop new strategies and tactics for its synthesis. Not all of these have been 
successful but in essentially every instance important lessons have been learnt along the way 
and these may well provide solutions to other, yet to be recognized challenges.  
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The tetracyclic alkaloid galanthamine is used clinically in a 
number of countries for the symptomatic treatment of mild 
to moderate forms of Alzheimer’s disease, and this feature 
coupled with its novel molecular architecture has prompted 
an extensive focus on its synthesis. The present study reports a 
new and distinct synthesis of galanthamine wherein the 
AB-ring substructure and associated quaternary carbon cen-
tre are constructed by using a palladium-catalyzed intramo-
lecular Alder-ene reaction. The product of this process is en-
Introduction
The tetracyclic Amaryllidaceae alkaloid (–)-galanth-
amine (1) (Figure 1) has been isolated from a range of plant 
sources including the Caucasian snowdrop (Galanthus 
woronowii) and the Red Spider Lily (Lycoris radia).[1] Since 
the early 1950s it has been used in various clinical settings 
and is currently marketed in many countries for the symp-
tomatic treatment of the early stages of Alzheimer’s dis-
ease.[1,2] Galanthamine’s effectiveness in this regard derives, 
at least in part, from its capacity to cross the blood-brain 
barrier and inhibit acetylcholine esterase in a selective, com-
petitive and reversible manner.[1] The compound has also 
been shown to act at the nicotinic acetylcholine receptor.[3]
Figure 1. Structure of (–)-galanthamine (1).
The significant and increasing clinical demand for galan-
thamine together with the erosion of the habitat of certain 
of the producing plants is creating supply issues. Various
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gaged in a Tsuji–Trost-type reaction to generate a semicyclic 
diene that participates in a normal-electron-demand Diels–
Alder reaction to generate, after oxidation of the initially 
formed adduct, the aromatic C-ring of the target alkaloid. 
Modified Bischler–Napieralski chemistry is then deployed to 
construct the seven-membered D-ring and thereby furnish-
ing narwedine, an established precursor to both (+)- and (–)-
galanthamine.
attempts are being made to address these[4] but, thus far, 
no commercially viable synthesis of the alkaloid has been 
established.[5] Nevertheless, a range of ingenious approaches 
to galanthamine has been described with the first of these, 
reported by Barton and Kirby in 1962,[6] involving a biomi-
metic but low yielding intramolecular oxidative phenolic 
coupling reaction that established the entire ABCD-ring 
framework from an AC-ring precursor. Certain refinements 
of this basic process have been described,[7] including asym-
metric variants,[8] and one has served as the basis for a pilot 
plant-scale production process.[9] Intramolecular Heck reac-
tions that result in the formation of the ABC-ring substruc-
ture, including the pivotal quaternary carbon center of gal-
anthamine, from an AC-ring precursor represents another 
effective approach.[10] Various others have been described[11] 
including ones that exploit d-glucose[12] or an enantiopure 
and enzymatically derived cis-1,2-dihydrocatechol[13] as pre-
cursors to the A-ring. Syntheses of a range of biologically 
active analogues of galanthamine have also been re-
ported.[14]
Herein we report a synthesis of galanthamine that is dis-
tinct from all previous ones in that a de novo construction of 
the aromatic C-ring is involved and by which means a range 
of hitherto inaccessible analogues of this natural product 
should become available. The pivotal features of our 
approach are, (i) the use of a Pd-catalyzed intramolecu-lar 
Alder-ene (IMAE) reaction to construct the AB-ring 
substructure bearing an angular β-aminoethyl group, (ii) a 
Tsuji–Trost-type reaction leading to a diene that partici-pates 
in a completely regioselective Diels–Alder reaction with 
propynal and (iii) the ready elaboration of the Diels–Alder 
adduct to the aromatic and methoxylated C-ring of 
galanthamine.
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Results and Discussion
The opening stages of the synthesis, including the IMAE
reaction, are shown in Scheme 1 and involve, as the first
step, reaction of the commercially available monoethylene
ketal 2 of cyclohexane-1,4-dione with N-methyl-O-benzoyl-
hydroxylamine (MeNHOBz)[15] and thus affording the α-
benzoyloxy derivative 3[15] in 78% yield. This last com-
pound was then converted, under standard conditions and
Scheme 1. Reaction sequence leading to the IMAE product 11.
Reagents and conditions: (a) MeNHOBz, DMSO, room temp., 2 h;
(b) LiHMDS, then PhNTf2, THF, –78 °C to room temp., ca. 4 h;
(c) compound 5, 9-BBN, THF, then NaOH (aq.), 0 °C to room
temp., ca. 16 h; (d) compound 4, PdCl2dppf·CH2Cl2, THF, room
temp., 2 h, then H2O2; (e) NaOH, MeOH, 65 °C, 3 h;
(f) HCCCH2Br, nBu4NI, NaH, THF, 0 °C to room temp., 48 h;
(g) nBuLi then (H2CH)n, THF, –78 °C to room temp., 48 h; (h)
Ac2O, Et3N, DMAP, CH2Cl2, 0 °C, 6 h; (i) Pd(OAc)2, BBEDA,
C6H6, 80 °C, 5 h.
www.eurjoc.org © 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 2015, 3771–37783772
in 93 % yield, into the corresponding enol triflate 4 that was
itself subjected to a Pd0-catalyzed cross-coupling reaction
with the in situ generated organoborane derived from 9-
BBN and enamine derivative 5[16] and thus delivering a mix-
ture of amine derivative 6 (79%) and the corresponding
alcohol 7 (10%).[17] Saponification of the benzoate residue
within the former product with aqueous sodium hydroxide
afforded additional quantities of alcohol 7 (71 %) that was
readily converted into the corresponding propargyl ether 8
(89%) upon treatment with propargyl bromide in the pres-
ence of sodium hydride. In anticipation of the above-men-
tioned diene-forming event and also in order to prevent di-
merization of terminal alkyne 8[18] this was “capped” with
a hydroxymethyl group through its deprotonation with
nBuLi, followed by reaction of the ensuing anion with para-
formaldehyde. The resulting alcohol 9 (73%) was acetylated
under standard conditions, and the ensuing ester 10 (93 %)
then engaged in a Pd(OAc)2-mediated IMAE reaction un-
der conditions originally defined by Trost and Pedregal in
1992[19] and exploited by us on various occasions more re-
cently.[18,20] As a result, the hexahydrobenzofuran 11 em-
bodying the AB-ring substructure of galanthamine was ob-
tained in 71% yield. The use of the strong σ-donating li-
gand N,N-bis(benzylidene)ethylenediamine (BBEDA) in
this reaction was essential to its success.
Scheme 2. Construction of the aromatic C-ring: formation of com-
pound 15. Reagents and conditions: (a) Pd(Ph3P)4, DBU,
C6H5CH3, room temp. to 112 °C, ca. 2 h; (b) HCCCHO, DTBMP,
then MnO2, C6H6, room temp., 96 h; (c) m-CPBA, CH2Cl2, room
temp., 46 h; (d) K2CO3, MeOH, room temp., 16 h; (e) MeI, NaH,
THF, 0 °C to room temp., 25 h.
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The next phase of the synthesis was the benzannulation
of compound 11 in order to establish the aromatic C-ring
of galanthamine. The means for doing so was achieved as
shown in Scheme 2 and involved first treatment of this sub-
strate with Pd(Ph3P)4 in the presence of the nitrogenous
base 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), thus ef-
fecting the elimination of the elements of acetic acid and so
generating the diene 12 (85%). This last compound partici-
pated in a Diels–Alder cycloaddition reaction with prop-
ynal[21] at room temperature, and the so-formed adduct was
immediately oxidized with manganese dioxide to afford
benzaldehyde 13 (61%). The hindered base 2,6-di-tert-
butyl-4-methylpyridine (DTBMP) was added to prevent
acid-catalyzed fragmentation of the initially formed adduct.
On reaction with m-chloroperbenzoic acid, compound 13
engaged in a Dakin oxidation reaction, and the product
aryl formate was cleaved with potassium carbonate in meth-
anol. The resulting phenol 14 (69 %) was then O-methylated
with methyl iodide in the presence of sodium hydride, thus
producing the methoxyarene 15 (quant.) that embodies the
aromatic C-ring of galanthamine.
The completion of the synthesis of target 1 from arene
15 clearly requires introduction of the heterocyclic D-ring.
The procedure for doing so is shown in Scheme 3 and in-
volved, as the first step, treatment of compound 15 with
Scheme 3. Installation of the D-ring and completion of the synthe-
sis. Reagents and conditions: (a) Mg, MeOH, ultrasonication, 16 h;
(b) EtOCHO, 54 °C, 6 h; (c) Tf2O, 2-chloropyridine, CH2Cl2,
–78 °C to room temp., 20 h; (d) NaB(OAc)3H, CH2Cl2, room
temp., 2 h, then satd. aq. NaHCO3; (e) L-selectride, THF, –78 °C,
3 h.
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magnesium in methanol[22] that resulted in cleavage of the
associated tosyl residue and formation of the secondary
amine 16 (83%). Simple heating of this last compound with
neat ethyl formate provided the formamide 17 in quantita-
tive yield, and this was subjected to a Bischler–Napieralski-
type cyclodehydration reaction under conditions defined by
Movassaghi and Hill.[23] Subsequent and successive treat-
ment of the crude reaction mixture with sodium triacet-
oxy(hydrido)borate followed by saturated aqueous sodium
hydrogen carbonate afforded ()-narwedine (18) in 44 %
yield. The spectroscopic data acquired on this tetracyclic
compound are in complete accord with those reported by
Magnus and co-workers.[11c]
Since racemic narwedine is readily converted into either
(+)- or (–)-galanthamine, the present work constitutes a for-
mal total synthesis of both enantiomeric forms of the title
alkaloid.[24] In order to further corroborate the structural
assignments presented above, ()-narwedine (18) was sub-
jected to diastereoselective reduction with L-selectride,[24,25]
thereby affording ()-galanthamine [()-1] in 83% yield.
The 1H and 13C NMR spectroscopic data obtained on this
material also proved a good match for those recorded on
the natural product.[13]
Conclusions
The work detailed here highlights the effectiveness of the
palladium-catalyzed IMAE reaction for constructing hexa-
hydrobenzofurans bearing angular substituents and,
thereby, quaternary carbon centers such as those associated
with galanthamine (1). Furthermore, the use of a Diels–
Alder reaction to construct the aromatic C-ring of this alka-
loid should provide the means for assembling analogues
that incorporate unusual functionalities in this part of the
molecular framework. Work directed towards such ends are
now underway in these laboratories.
Experimental Section
General Experimental Procedures: Unless otherwise specified, pro-
ton (1H) and carbon (13C) NMR spectra were recorded at room
temperature in base-filtered CDCl3 with a Bruker spectrometer op-
erating at 400 MHz for proton and 100 MHz for carbon nuclei. For
1H NMR spectra, signals arising from the residual protio forms of
the solvent were used as the internal standards. 1H NMR spectro-
scopic data are recorded as follows: chemical shift (δ) [multiplicity,
coupling constant(s) J (Hz), relative integral] where multiplicity is
defined as: s = singlet; d = doublet; t = triplet; q = quartet; m =
multiplet or combinations of thereof. The signal due to residual
CHCl3 appearing at δH = 7.26 ppm and the central resonance of
the CDCl3 “triplet” appearing at δC = 77.0 ppm were used to refer-
ence 1H and 13C NMR spectra, respectively. The signal due to re-
sidual CH2Cl2 appearing at δH = 5.30 ppm and the central reso-
nance of the CD2Cl2 “multiplet” appearing at δC = 53.5 ppm were
used to reference 1H and 13C NMR spectra, respectively. Infrared
spectra (IR: ν˜max) were recorded with a Perkin–Elmer 1800 series
FTIR spectrometer. Samples were analyzed as thin films on KBr
plates. Low-resolution ESI mass spectra were recorded on a single
quadrupole liquid chromatograph–mass spectrometer, while high-
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resolution measurements were conducted on a time-of-flight instru-
ment. Low- and high-resolution EI mass spectra were recorded
with a magnetic-sector machine. Melting points were measured
with an Optimelt automated melting point system and are uncor-
rected. Analytical thin layer chromatography (TLC) was performed
on aluminum-backed 0.2 mm thick silica gel 60 F254 plates. Eluted
plates were visualized with a 254 nm UV lamp and/or by treatment
with a suitable dip followed by heating. These dips included phos-
phomolybdic acid/ceric sulfate/sulfuric acid (concd.)/water
(37.5 g:7.5 g:37.5 g:720 mL) or potassium permanganate/potassium
carbonate/5% sodium hydroxide aqueous solution/water
(3 g:20 g:5 mL:300 mL). Flash chromatographic separations were
carried out according to protocols defined by Still et al.[26] with
silica gel 60 (40–63 μm) as the stationary phase and with the AR-
or HPLC-grade solvents indicated. Starting materials and reagents
were generally available from the Sigma–Aldrich, Merck, TCI,
Strem or Lancaster chemical companies and were used as supplied.
Drying agents and other inorganic salts were purchased from the
AJAX, BDH or Unilab chemical companies. Tetrahydrofuran
(THF), diethyl ether, methanol and dichloromethane were dried by
using a Glass Contour solvent purification system that is based
upon a technology originally described by Grubbs et al.[27] Where
necessary, reactions were performed under nitrogen.
8-{[(Trifluoromethyl)sulfonyl]oxy}-1,4-dioxaspiro[4.5]dec-8-en-7-yl
Benzoate (4): A magnetically stirred solution of ketone 3[15] (9.73 g,
35.2 mmol) in dry THF (190 mL) maintained under nitrogen was
cooled to –78 °C and then treated with LiHMDS (46 mL of a 1 m
solution in THF, 46 mmol). The resulting mixture was stirred at
–78 °C for 0.5 h, then warmed to –40 °C and treated with N-phen-
ylbis(trifluoromethanesulfonimide) (16.4 g, 46 mmol). The re-
sulting mixture was warmed to room temperature over a period
of 3 h before being quenched with NH4Cl (150 mL of a saturated
aqueous solution) and extracted with diethyl ether (3 100 mL).
The combined organic layers were dried (Na2SO4), filtered and
concentrated under reduced pressure, and the ensuing brown oil
was subjected to flash chromatography (silica gel; 4:1 v/v petroleum
ether/ethyl acetate elution). Concentration of the appropriate frac-
tions (Rf = 0.5 in 3:1 v/v petroleum ether/ethyl acetate) afforded
enol triflate 4 (13.37 g, 93%) as a tan solid, m.p. 82–84 °C. 1H
NMR (400 MHz, CDCl3): δ = 8.08 (m, 2 H), 7.59 (m, 1 H), 7.46
(m, 2 H), 6.02 (t, J = 4.0 Hz, 1 H), 5.88 (m, 1 H), 4.05–3.95 (com-
plex m, 4 H), 2.66 (dt, J = 18.4 and 3.1 Hz, 1 H), 2.57–2.42 (com-
plex m, 2 H), 2.14 (dd, J = 13.2 and 7.2 Hz, 1 H) ppm. 13C NMR
(100 MHz, CDCl3): δ = 165.7, 144.9, 133.5, 130.1, 128.6, 120.7,
118.8 (q, J = 320.0 Hz), 106.1, 67.8, 65.0, 64.9, 37.6, 34.8 (one
signal obscured or overlapping) ppm. IR: ν˜max = 2965, 2893, 1726,
1601, 1421, 1267, 1248, 1211, 1142, 1064, 877, 712 cm–1. MS (EI):
m/z (%) = 408 (2) [M+·], 303 (5), 287 (10), 275 (15), 153 (100), 105
(56). HRMS (EI): calcd. for C16H15F3O7S [M+·] 408.0491; found
408.0485.
8-[2-(N,4-Dimethylphenylsulfonamido)ethyl]-1,4-dioxaspiro[4.5]dec-
8-en-7-yl Benzoate (6) and N-[2-(9-Hydroxy-1,4-dioxaspiro[4.5]dec-
7-en-8-yl)ethyl]-N,4-dimethylbenzenesulfonamide (7): A magneti-
cally stirred solution of sulfonamide 5[16] (15.84 g, 75 mmol) in dry
THF (75 mL) maintained under nitrogen was cooled to 0 °C and
then treated dropwise with 9-BBN (150 mL of a 0.5 m solution in
THF, 75 mmol). After 0.17 h at 0 °C, the reaction mixture was
warmed to room temperature and then stirred for 16 h before being
treated dropwise with NaOH (75 mL of a 3 m aqueous solution).
The resulting mixture was stirred at room temperature for 0.33 h
and then treated with a solution of enol triflate 4 (21.76 g,
40 mmol) and PdCl2dppf·CH2Cl2 (6.80 g, 6 mmol, 0.20 mol equiv.)
in dry THF (120 mL). The resulting mixture was stirred at room
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temperature for 2 h, then cooled to 0 °C, quenched with H2O2
(100 mL of a 30% aqueous solution) and extracted with ethyl acet-
ate (3 150 mL). The combined organic layers were dried
(Na2SO4), filtered and concentrated under reduced pressure. The
ensuing brown oil was subjected to flash chromatography (silica
gel; 7:3 v/v petroleum ether/ethyl acetate elution) to give two frac-
tions, A and B.
Concentration of fraction A (Rf = 0.3 in 7:3 v/v petroleum ether/
ethyl acetate) gave benzoate 6 (14.80 g, 79%) as a clear, yellow oil.
1H NMR (400 MHz, CDCl3): δ = 8.05 (d, J = 7.3 Hz, 2 H), 7.61
(d, J = 8.4 Hz, 2 H), 7.56 (d, J = 7.3 Hz, 1 H), 7.44 (t, J = 7.3 Hz,
2 H), 7.24 (d, J = 8.4 Hz, 2 H), 5.77 (t, J = 6.7 Hz, 1 H), 5.72 (t,
J = 3.1 Hz, 1 H), 4.01–3.95 (complex m, 4 H), 3.14 (ddd, J = 13.5,
8.6 and 7.2 Hz, 1 H), 3.06 (ddd, J = 13.5, 8.7 and 5.8 Hz, 1 H),
2.66 (s, 3 H), 2.53–2.42 (complex m, 1 H), 2.40 (s, 3 H), 2.38–2.26
(complex m, 4 H), 1.99 (dd, J = 13.2 and 7.2 Hz, 1 H) ppm. 13C
NMR (100 MHz, CDCl3): δ = 166.3, 143.3, 135.0, 133.3, 132.9,
130.3, 129.7 (6), 129.8 (1), 128.6, 127.5, 126.0, 107.4, 71.2, 64.7,
64.6, 49.2, 37.2, 36.1, 35.2, 31.6, 21.6 ppm. IR: ν˜max = 2969, 2926,
2887, 1713, 1599, 1451, 1339, 1268, 1160, 1108, 949, 715 cm–1. MS
(EI): m/z (%) = 471 (3) [M+·], 349 (10), 273 (9), 198 (100), 155 (52),
91 (47). HRMS (EI): calcd. for C25H29NO6S [M+·] 471.1716; found
471.1712.
Concentration of fraction B (Rf = 0.2 in 1:1 v/v petroleum ether/
ethyl acetate) gave allylic alcohol 7 (1.40 g, 10%) as a clear, yellow
oil. 1H NMR (400 MHz, CDCl3): δ = 7.65 (d, J = 8.0 Hz, 2 H),
7.30 (d, J = 8.0 Hz, 2 H), 5.50 (m, 1 H), 4.13 (dt, J = 10.9 and
4.0 Hz, 1 H), 4.04–3.89 (complex m, 4 H), 3.27 (ddd, J = 13.5, 8.4
and 7.1 Hz, 1 H), 3.06 (ddd, J = 13.5, 8.5 and 5.4 Hz, 1 H), 3.00
(d, J = 10.9 Hz, 1 H), 2.72 (s, 3 H), 2.49–2.42 (complex m, 1 H),
2.41 (s, 3 H), 2.38–2.25 (complex m, 3 H), 2.07–1.96 (complex m,
2 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 143.3, 136.7, 134.9,
129.7, 127.5, 123.1, 108.2, 68.5, 64.5 (3), 64.5 (0), 49.2, 39.0, 36.1,
34.8, 32.4, 21.6 ppm. IR: ν˜max = 3523, 2956, 2921, 2887, 1336, 1159,
1048, 948, 721 cm–1. MS (EI): m/z (%) = 367 (3) [M+·], 349 (2), 281
(18), 198 (100), 155 (70), 91 (53). HRMS (EI): calcd. for
C18H25NO5S [M+·] 367.1453; found 367.1457.
N-[2-(9-Hydroxy-1,4-dioxaspiro[4.5]dec-7-en-8-yl)ethyl]-N,4-di-
methylbenzenesulfonamide (7): A magnetically stirred solution of
benzoate 6 (14.8 g, 31.4 mmol) in methanol (500 mL) was treated
with NaOH (100 mL of a 3 m aqueous solution) and the resulting
solution heated at reflux for 3 h. The cooled reaction mixture was
quenched with NH4Cl (40 mL of a saturated aqueous solution) and
then concentrated under reduced pressure. The ensuing residue was
extracted with diethyl ether (3 50 mL), and the combined organic
phases were dried (Na2SO4), filtered and concentrated under re-
duced pressure. The brown oil thus obtained was subjected to flash
chromatography (silica gel; 4:1 v/v petroleum ether/ethyl acetate
elution) to give, after concentration of the appropriate fractions (Rf
= 0.2 in 1:1 v/v petroleum ether/ethyl acetate), allylic alcohol 7
(8.18 g, 71%) as a clear, yellow oil. This material was identical, in
all respects, with that obtained in the preceding step.
N,4-Dimethyl-N-{2-[9-(prop-2-yn-1-yloxy)-1,4-dioxaspiro[4.5]dec-7-
en-8-yl]ethyl}benzenesulfonamide (8): A magnetically stirred solu-
tion of allylic alcohol 7 (9.50 g, 25.9 mmol) in anhydrous THF
(68 mL) was treated with tetra-n-butylammonium iodide (2.01 g,
4.53 mmol) and propargyl bromide (5.8 mL of a 80% solution in
toluene, 51.8 mmol) before being cooled to 0 °C and treated por-
tionwise with NaH (2.34 g of a 60 % dispersion in mineral oil,
51.8 mmol). After having been stirred at 0 °C for 0.17 h, the reac-
tion mixture was warmed to room temperature and then stirred
for 48 h before being quenched with NH4Cl (50 mL of a saturated
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aqueous solution) and extracted with diethyl ether (3 50 mL).
The combined organic layers were dried (Na2SO4), filtered and
concentrated under reduced pressure, and the ensuing brown oil
was subjected to flash chromatography (silica gel; 7:3 v/v petroleum
ether/ethyl acetate elution) to give, after concentration of the ap-
propriate fractions (Rf = 0.4), propargyl ether 8 (9.30 g, 89%) as a
clear, brown oil. 1H NMR (400 MHz, CDCl3): δ = 7.67 (d, J =
8.1 Hz, 2 H), 7.30 (d, J = 8.1 Hz, 2 H), 5.52 (m, 1 H), 4.31–4.25
(complex m, 1 H), 4.24 (dd, J = 16.0 and 2.4 Hz, 1 H), 4.15 (dd, J
= 16.0 and 2.4 Hz, 1 H), 4.02–3.90 (complex m, 4 H), 3.20–3.05
(complex m, 2 H), 2.75 (s, 3 H), 2.50–2.43 (complex m, 1 H), 2.42
(s, 3 H), 2.38 (t, J = 2.4 Hz, 1 H), 2.35–2.14 (complex m, 4 H),
1.82 (dd, J = 12.8 and 7.9 Hz, 1 H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 143.2, 135.1, 135.0, 129.7, 127.6, 124.0, 107.9, 80.3,
75.0, 74.6, 64.6, 64.5, 56.1, 49.5, 36.6, 35.9, 35.1, 31.6, 21.6 ppm.
IR: ν˜max = 3271, 2956, 2928, 2884, 2115, 1598, 1456, 1337, 1160,
1074, 1019, 948, 817, 731 cm–1. MS (ESI): m/z (%) = 428 (100)
[M + Na]+, 406 (5) [M + H]+, 351 (10). HRMS (ESI): calcd. for
C21H27NNaO5S [M + Na]+ 428.1508; found 428.1506.
N-(2-{9-[(4-Hydroxybut-2-yn-1-yl)oxy]-1,4-dioxaspiro[4.5]dec-7-
en-8-yl}ethyl)-N,4-dimethylbenzenesulfonamide (9): A magnetically
stirred solution of propargyl ether 8 (9.30 g, 22.9 mmol) in anhy-
drous THF (100 mL) was cooled to –78 °C and then treated with
nBuLi (16.7 mL of a 1.5 m solution in hexanes, 25.2 mmol). The
ensuing solution was stirred at this temperature for 1 h before being
treated with paraformaldehyde (2.06 g, 68.7 mmol). The resulting
suspension was warmed to room temperature and, after 48 h,
quenched with NH4Cl (50 mL of a saturated aqueous solution),
then extracted with diethyl ether (3 50 mL). The combined or-
ganic layers were dried (Na2SO4), filtered and concentrated under
reduced pressure, and the ensuing brown oil was subjected to flash
chromatography (silica gel; 1:2 v/v petroleum ether/ethyl acetate
elution) to give, after concentration of the appropriate fractions (Rf
= 0.3), propargyl alcohol 9 (7.28 g, 73 %) as a clear, brown oil. 1H
NMR (400 MHz, CDCl3): δ = 7.68 (d, J = 8.0 Hz, 2 H), 7.30 (d,
J = 8.0 Hz, 2 H), 5.50 (t, J = 3.8 Hz, 1 H), 4.39–4.28 (complex m,
4 H), 4.18 (dt, J = 15.9 and 1.7 Hz, 1 H), 3.95 (m, 4 H), 3.25 (m,
1 H), 3.12 (m, 1 H), 2.73 (s, 3 H), 2.51 (m, 2 H), 2.42 (s, 3 H),
2.36–2.12 (complex m, 4 H), 1.82 (dd, J = 12.8 and 7.3 Hz, 1 H)
ppm. 13C NMR (100 MHz, CDCl3): δ = 143.4, 135.1, 134.8, 129.8,
127.6, 124.3, 107.8, 85.5, 81.5, 73.6, 64.6, 64.5, 55.9, 51.1, 49.4,
36.1, 35.9, 34.8, 31.8, 21.6 ppm. IR: ν˜max = 3468, 2926, 2883, 2250,
1956, 1597, 1335, 1160, 1069, 947, 817, 730 cm–1. MS (ESI): m/z
(%) = 458 (100) [M + Na]+, 350 (85). HRMS (ESI): calcd. for
C22H29NNaO6S [M + Na]+ 458.1613; found 458.1614.
4-({8-[2-(N,4-Dimethylphenylsulfonamido)ethyl]-1,4-dioxaspiro-
[4.5]dec-8-en-7-yl}oxy)but-2-yn-1-yl Acetate (10): A magnetically
stirred solution of propargyl alcohol 9 (7.82 g, 18.0 mmol) in anhy-
drous dichloromethane (100 mL) was cooled to 0 °C and then
treated with triethylamine (3.00 mL, 21.6 mmol), DMAP (220 mg,
1.8 mmol) and acetic anhydride (2.1 mL, 21.6 mmol). The resulting
solution was stirred at 0 °C for 6 h before being quenched with
NH4Cl (50 mL of a saturated aqueous solution) and extracted with
dichloromethane (3 50 mL). The combined organic layers were
dried (Na2SO4), filtered and concentrated under reduced pressure,
and the ensuing brown oil was subjected to flash chromatography
(silica gel; 1:1 v/v petroleum ether/ethyl acetate elution) to give,
after concentration of the appropriate fractions (Rf = 0.7 in 1:2 v/
v petroleum ether/ethyl acetate), propargyl acetate 10 (7.99 g, 93%)
as a clear, yellow oil. 1H NMR (400 MHz, CDCl3): δ = 7.67 (d, J
= 8.01 Hz, 2 H), 7.29 (d, J = 8.1 Hz, 2 H), 5.51 (m, 1 H), 4.68 (t,
J = 1.9 Hz, 2 H), 4.27 (dt, J = 16.1 and 1.9 Hz, 1 H), 4.23 (m, 1
H), 4.19 (dt, J = 16.1 and 1.9 Hz, 1 H), 4.10–3.90 (complex m, 4
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H), 3.19 (ddd, J = 13.2, 9.3 and 6.6 Hz, 1 H), 3.10 (ddd, J = 13.2,
9.3 and 5.3 Hz, 1 H), 2.74 (s, 3 H), 2.42 (s, 3 H), 2.37–2.13 (complex
m, 5 H), 2.07 (s, 3 H), 1.82 (dd, J = 12.8 and 7.8 Hz, 1 H) ppm.
13C NMR (100 MHz, CDCl3): δ = 170.3, 143.2, 135.1, 135.0, 129.7,
127.5, 124.0, 107.9, 83.3, 80.4, 75.1, 64.6, 64.5, 56.3, 52.4, 49.4,
36.5, 35.9, 35.0, 31.6, 21.6, 20.8 ppm. IR: ν˜max = 2958, 2928, 2879,
1956, 1747, 1594, 1338, 1224, 1160, 1071, 1071, 1027, 947,
730 cm–1. MS (ESI): m/z (%) = 500 (100) [M + Na]+, 350 (90).
HRMS (ESI): calcd. for C24H31NNaO7S [M + Na]+ 500.1719;
found 500.1714.
(Z)-2-{(3aS,7aS)-rel-3a-[2-(N,4-Dimethylphenylsulfonamido)ethyl]-
7,7a-dihydro-2H-spiro(benzofuran-6,2-[1,3]dioxolan)-3(3aH)-
ylidene}ethyl Acetate (11): A magnetically stirred solution of prop-
argyl acetate 10 (1.06 g, 2.1 mmol) in anhydrous benzene (30 mL)
was treated with Pd(OAc)2 (71 mg, 0.32 mmol) and N,N-bis(ben-
zylidene)ethylenediamine (BBEDA) (75 mg, 0.32 mmol). The re-
sulting solution was heated at reflux for 5 h and then concentrated
under reduced pressure to give a brown oil that was subjected to
flash chromatography (silica gel; 1:1 v/v petroleum ether/ethyl acet-
ate elution). Concentration of the appropriate fractions (Rf = 0.5
in 1:2 v/v petroleum ether/ethyl acetate) then gave allylic acetate 11
(754 mg, 71 %) as a clear, yellow oil. 1H NMR (400 MHz, CDCl3):
δ = 7.65 (d, J = 7.9 Hz, 2 H), 7.31 (d, J = 7.9 Hz, 2 H), 5.65 (d, J
= 10.4 Hz, 1 H), 5.64 (d, J = 10.4 Hz, 1 H), 5.39 (m, 1 H), 4.58 (d,
J = 14.2 Hz, 1 H), 4.53–4.41 (complex m, 3 H), 4.15 (dd, J = 8.2
and 4.5 Hz, 1 H), 4.01–3.90 (complex m, 4 H), 3.01 (t, J = 8.2 Hz,
2 H), 2.69 (s, 3 H), 2.43 (s, 3 H), 2.06 (s, 3 H), 2.03–1.73 (complex
m, 4 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 170.9, 149.1,
143.5, 134.7, 133.2, 129.8, 127.7, 127.6, 115.9, 104.5, 79.8, 68.1,
65.1, 64.6, 61.7, 48.4, 46.7, 36.4, 35.3, 35.2, 21.7, 21.0 ppm. IR:
ν˜max = 2953, 2926, 2874, 1737, 1339, 1230, 1160, 1064, 1027,
738 cm–1. MS (ESI): m/z (%) = 500 (100) [M + Na]+, 478 (30) [M +
H]+. HRMS (ESI): calcd. for C24H31NNaO7S [M + Na]+ 500.1719;
found 500.1719.
N,4-Dimethyl-N-{2-[(3aS,7aS)-rel-3-vinyl-7,7a-dihydro-3aH-spiro-
(benzofuran-6,2-[1,3]dioxolan)-3a-yl]ethyl}benzenesulfonamide (12):
A magnetically stirred solution of allylic acetate 11 (1.40 g,
2.93 mmol) in anhydrous toluene was treated with Pd(PPh3)4
(339 mg, 0.29 mmol) and the resulting solution stirred at room tem-
perature for 0.17 h before being treated with DBU (1.32 mL,
8.79 mmol) and then heated at reflux for 2 h. The cooled reaction
mixture was subjected without concentration to flash chromatog-
raphy (neutral alumina; 3:1  1:1 petroleum ether/ethyl acetate
gradient elution) to give, after concentration of the appropriate
fractions (Rf = 0.8 in 1:2 v/v petroleum ether/ethyl acetate), diene
12 (1.03 g, 85%) as a viscous, clear and colorless oil. 1H NMR
(400 MHz, CDCl3): δ = 7.65 (d, J = 8.2 Hz, 2 H), 7.31 (d, J =
8.2 Hz, 2 H), 6.42 (s, 1 H), 6.17 (dd, J = 17.9 and 11.5 Hz, 1 H),
5.98 (d, J = 10.3 Hz, 1 H), 5.72 (d, J = 10.3 Hz, 1 H), 5.11 (d, J =
17.9 Hz, 1 H), 4.87 (d, J = 11.5 Hz, 1 H), 4.64 (dd, J = 6.6 and
5.1 Hz, 1 H), 4.05–3.95 (complex m, 4 H), 3.14 (ddd, J = 13.7, 11.6
and 5.0 Hz, 1 H), 2.96 (ddd, J = 13.7, 11.6 and 5.0 Hz, 1 H), 2.72
(s, 3 H), 2.43 (s, 3 H), 2.21 (dd, J = 14.0 and 6.6 Hz, 1 H), 2.12–
1.96 (complex m, 2 H), 1.82 (m, 1 H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 146.3, 143.4, 134.9, 132.4, 129.8, 127.7, 127.5 (4), 127.5
(1), 119.7, 110.0, 103.5, 83.8, 65.1, 64.6, 48.6, 46.6, 35.4, 35.3, 35.0,
21.7 ppm. IR: ν˜max = 2958, 2921, 2883, 2848, 1732, 1633, 1437,
1339, 1160, 1119, 721, 696, 542 cm–1. MS (EI): m/z (%) = 417 (5)
[M+·], 278 (53), 277 (100), 262 (90), 205 (70), 155 (22), 91 (47).
HRMS (EI): calcd. for C22H27NO5S [M+ ·] 417.1610; found
417.1611.
N-{2-[(4aS,9bS)-rel-6-Formyl-4,4a-dihydro-9bH-spiro(dibenzo[b,d]-
furan-3,2-[1,3]dioxolane)-9b-yl]ethyl}-N,4-dimethylbenzenesulfon-
65
J. Nugent, E. Matousˇová, M. G. BanwellFULL PAPER
amide (13): A magnetically stirred solution of diene 12 (530 mg,
1.27 mmol) in anhydrous benzene (30 mL) was treated with 2,6-
di-tert-butyl-4-methylpyridine (DTBMP) (261 mg, 1.27 mmol) and
propynal (140 μL, 2.54 mmol), the ensuing mixture maintained at
room temperature for 48 h and then treated with MnO2 (1.10 g,
12.7 mmol). The resulting mixture was stirred at room temperature
for a further 48 h, then filtered through a pad of Celite and the
filtrate concentrated under reduced pressure. The ensuing orange
oil was subjected to flash chromatography (silica gel; 1:1 v/v petro-
leum ether/ethyl acetate elution) to give, after concentration of the
appropriate fractions (Rf = 0.6 in 1:2 v/v petroleum ether/ethyl acet-
ate), benzaldehyde 13 (363 mg, 61%) as a viscous, yellow oil. 1H
NMR (400 MHz, CDCl3): δ = 10.21 (s, 1 H), 7.64 (dd, J = 7.6 and
1.4 Hz, 1 H), 7.59 (d, J = 8.2 Hz, 2 H), 7.36 (dd, J = 7.6 and
1.4 Hz, 1 H), 7.28 (d, J = 8.2 Hz, 2 H), 7.00 (t, J = 7.6 Hz, 1 H),
5.95 (d, J = 10.1 Hz, 1 H), 5.81 (d, J = 10.1 Hz, 1 H), 4.98 (dd, J
= 8.8 and 5.5 Hz, 1 H), 4.05–3.95 (complex m, 4 H), 3.04 (ddd, J
= 13.7, 10.1 and 5.8 Hz, 1 H), 2.93 (ddd, J = 13.7, 10.1 and 5.8 Hz,
1 H), 2.68 (s, 3 H), 2.41 (s, 3 H), 2.26 (dd, J = 13.4 and 5.3 Hz, 1
H), 2.07 (dd, J = 13.4 and 8.8 Hz, 1 H), 1.97 (m, 2 H) ppm. 13C
NMR (100 MHz, CDCl3): δ = 188.6, 160.3, 143.6, 134.4, 134.0,
131.6, 129.8, 129.5, 129.2, 128.1, 127.5, 121.5, 120.6, 103.9, 86.0,
65.1, 64.8, 47.2, 46.4, 38.2, 36.3, 35.4, 21.6 ppm. IR: ν˜max = 2958,
2925, 2887, 1685, 1610, 1450, 1338, 1160, 1016, 945, 732 cm–1. MS
(ESI): m/z (%) = 492 (100) [M + Na]+, 470 (4) [M + H]+. HRMS
(ESI): calcd. for C25H27NNaO6S [M + Na]+ 492.1457; found
492.1457.
N-{2-[(4aS,9bS)-6-Hydroxy-4,4a-dihydro-9bH-spiro(dibenzo[b,d]-
furan-3,2-[1,3]dioxolane)-9b-yl]ethyl}-N,4-dimethylbenzenesulfon-
amide (14): A magnetically stirred solution of benzaldehyde 13
(300 mg, 0.64 mmol) in anhydrous dichloromethane (42 mL) was
treated with m-CPBA (237 mg of 70% purity, 0.96 mmol). The re-
sulting mixture was maintained at room temperature for 46 h, then
quenched with NaS2O3 (10 mL of a 50% aqueous solution) and
extracted with dichloromethane (3 10 mL). The combined or-
ganic layers were dried (Na2SO4), filtered and concentrated under
reduced pressure, the ensuing brown oil dissolved in MeOH
(56 mL) and the solution thus obtained treated with K2CO3
(884 mg, 6.4 mmol). The ensuing reaction mixture was kept at
room temperature for 16 h, then concentrated under reduced pres-
sure and the residue thus obtained treated with distilled water
(30 mL) and extracted with dichloromethane (3 15 mL). The
combined organic layers were dried (Na2SO4), filtered and concen-
trated under reduced pressure and the resulting brown oil subjected
to flash chromatography (silica gel; 1:4 v/v diethyl ether/dichloro-
methane elution). Concentration of the relevant fractions (Rf = 0.5)
then gave phenol 14 (200 mg, 69%) as a clear, yellow oil. 1H NMR
(400 MHz, CDCl3): δ = 7.60 (d, J = 8.3 Hz, 2 H), 7.29 (d, J =
8.3 Hz, 2 H), 6.85–6.73 (complex m, 2 H), 6.68 (dd, J = 7.0 and
1.7 Hz, 1 H), 5.86 (d, J = 10.1 Hz, 1 H), 5.75 (d, J = 10.1 Hz, 1
H), 4.85 (dd, J = 7.7 and 5.3 Hz, 1 H), 4.05–3.95 (complex m, 4
H), 3.06 (m, 1 H), 2.94 (m, 1 H), 2.68 (s, 3 H), 2.42 (s, 3 H), 2.17
(m, 2 H), 1.96 (m, 2 H) (signal due to phenolic group hydrogen
obscured or overlapping) ppm. 13C NMR (100 MHz, CDCl3): δ =
145.1, 143.5, 141.4, 134.6, 132.4, 132.3, 129.8, 127.8, 127.5, 122.2,
116.0, 114.7, 103.9, 84.7, 65.0, 64.6, 48.6, 46.5, 37.3, 36.0, 35.3,
21.7 ppm. IR: ν˜max = 3400, 2962, 2926, 2883, 1681, 1618, 1597,
1470, 1337, 1159, 1089, 1017, 946, 731, 549 cm–1. MS (EI): m/z (%)
= 457 (70) [M+·], 302 (62), 259 (51), 245 (80), 198 (100), 155 (87),
91 (97). HRMS (EI): calcd. for C24H27NO6S [M+·] 457.1559; found
457.1560.
N-{2-[(4aS,9bS)-rel-6-Methoxy-4,4a-dihydro-9bH-spiro(dibenzo-
[b,d]furan-3,2-[1,3]dioxolane)-9b-yl]ethyl}-N,4-dimethylbenzene-
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sulfonamide (15): A magnetically stirred solution of phenol 14
(220 mg, 0.48 mmol) in anhydrous THF (12 mL) was cooled to
0 °C, treated with NaH (38 mg of a 60% dispersion in mineral oil,
0.96 mmol), kept at this temperature for 1 h and then treated with
MeI (0.18 mL, 2.88 mmol) before being warmed to room tempera-
ture and stirred for 24 h. The ensuing mixture was quenched with
NH4Cl (10 mL of a saturated aqueous solution) and extracted with
ethyl acetate (3 10 mL). The combined organic layers were dried
(Na2SO4), filtered and concentrated under reduced pressure. The
resulting brown oil was subjected to flash chromatography (silica
gel; 1:2 v/v petroleum ether/ethyl acetate) to give, after concentra-
tion of the appropriate fractions (Rf = 0.6), methyl ether 15
(226 mg, quant.) as a colorless, viscous oil. 1H NMR (400 MHz,
CDCl3): δ = 7.60 (d, J = 8.2 Hz, 2 H), 7.28 (d, J = 8.2 Hz, 2 H),
6.87 (m, 1 H), 6.75 (m, 2 H), 5.91 (d, J = 10.1 Hz, 1 H), 5.76 (d, J
= 10.1 Hz, 1 H), 4.83 (dd, J = 8.5 and 5.3 Hz, 1 H), 4.05–3.95
(complex m, 4 H), 3.86 (s, 3 H), 3.08 (ddd, J = 13.7, 10.8 and
5.6 Hz, 1 H), 2.90 (ddd, J = 13.7, 10.8 and 5.6 Hz, 1 H), 2.67 (s, 3
H), 2.42 (s, 3 H), 2.20 (dd, J = 13.5 and 5.3 Hz, 1 H), 2.13 (dd, J
= 13.5 and 8.5 Hz, 1 H), 1.94 (m, 2 H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 146.4, 145.3, 143.4, 134.7, 132.4 (4), 132.3 (6), 129.8,
128.4, 127.6, 121.9, 115.3, 111.9, 104.2, 84.6, 65.0, 64.7, 56.0, 48.4,
46.5, 38.0, 36.3, 35.3, 21.7 ppm. IR: ν˜max = 2953, 2926, 1618, 1593,
1491, 1458, 1339, 1279, 1160, 1015, 951, 732 cm–1. MS (EI): m/z
(%) = 471 (80) [M+·], 316 (60), 259 (100), 216 (35), 198 (40), 155
(40), 91 (63). HRMS (EI): calcd. for C25H29NO6S [M+·] 471.1716;
found 471.1717.
2-[(4aS,9bS)-rel-6-Methoxy-4,4a-dihydro-9bH-spiro(dibenzo[b,d]-
furan-3,2-[1,3]dioxolane)-9b-yl]-N-methylethan-1-amine (16): A
magnetically stirred solution of methyl ether 15 (237 mg,
0.50 mmol) in anhydrous methanol (30 mL) was treated with mag-
nesium turnings (425 mg, 17.5 mmol) and sonicated for 2 h. Fur-
ther magnesium turnings (100 mg, 4.38 mmol) were added, and the
resulting mixture was sonicated for an additional 2 h. This second
addition/ultrasonication process was repeated a further six times.
Then the reaction mixture was quenched with NH4Cl (15 mL of a
saturated aqueous solution) and extracted with ethyl acetate (3
10 mL). The combined organic layers were dried (Na2SO4), filtered
and concentrated under reduced pressure, and the ensuing brown
oil was subjected to flash chromatography (silica gel; 90:12:2 v/v/v
dichloromethane/methanol/triethylamine elution) to give, after
concentration of the appropriate fractions (Rf = 0.4), amine 16
(131 mg, 83%) as colorless, amorphous solid. 1H NMR (400 MHz,
CDCl3): δ = 6.84 (m, 1 H), 6.79–6.70 (complex m, 2 H), 5.89 (d, J
= 10.0 Hz, 1 H), 5.72 (d, J = 10.0 Hz, 1 H), 4.93 (t, J = 6.3 Hz, 1
H), 4.05–3.95 (complex m, 4 H), 3.86 (s, 3 H), 2.65–2.45 (complex
m, 2 H), 2.38 (s, 3 H), 2.23 (d, J = 6.3 Hz, 2 H), 1.89 (t, J = 7.9 Hz,
2 H) (signal due to NH group proton not observed) ppm. 13C
NMR (100 MHz, CDCl3): δ = 146.5, 145.2, 133.2 (6), 133.3 (1),
127.7, 121.7, 115.3, 111.7, 104.1, 84.8, 65.1, 64.7, 56.0, 48.5, 47.5,
39.4, 36.3, 36.1 ppm. IR: ν˜max = 2951, 2922, 2849, 2849, 1617,
1590, 1491, 1458, 1281, 1205, 1120 cm–1. MS (EI): m/z (%) = 317
(47) [M+·], 272 (100), 59 (81). HRMS (EI): calcd. for C18H23NO4
317.1627 [M+·]; found 317.1628.
N-{2-[(4aS,9bS)-rel-6-Methoxy-4,4a-dihydro-9bH-spiro(dibenzo-
[b,d]furan-3,2-[1,3]dioxolane)-9b-yl]ethyl}-N-methylformamide (17):
A magnetically stirred solution of amine 16 (100 mg, 0.32 mmol) in
ethyl formate (5 mL) was heated at reflux for 6 h. Then the cooled
reaction mixture was concentrated under reduced pressure to afford
formamide 17 (109 mg, quant.) as a yellow, viscous oil. 1H NMR
(400 MHz, CDCl3; mixture of rotamers): δ = 7.96 (s, 1 H), 6.87–
6.60 (complex m, 3 H), 5.93 (m, 1 H), 5.80 (m, 1 H), 4.94 (m, 1
H), 4.05–3.95 (complex m, 4 H), 3.88 (s, 1.68 H), 3.86 (s, 1.32 H),
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3.45–3.30 (complex m, 1 H), 3.13 (m, 1 H), 2.87 (s, 1.32 H), 2.80
(s, 1.68 H) 2.26 (m, 1 H), 2.16–2.08 (complex m, 1 H), 1.99–1.80
(complex m, 2 H) ppm. 13C NMR (100 MHz, CDCl3; mixture of
rotamers): δ = 162.7, 162.4, 146.4, 146.3, 145.5, 145.3, 132.7, 132.4,
132.1, 132.0, 129.1, 128.5, 122.2, 121.9, 115.3, 114.9, 112.0, 111.9,
104.3, 104.2, 84.6, 84.5, 65.1, 65.0, 64.8, 64.7, 56.0 (8), 56.0 (5),
48.6, 48.4, 45.6, 40.7, 39.0, 36.5, 36.4, 36.3, 34.7, 29.7 ppm. IR:
ν˜max = 2956, 2927, 2883, 1671, 1617, 1589, 1491, 1458, 1397, 1281,
1207, 1118, 1013 952, 732 cm–1. MS (EI): m/z (%) = 345 (90) [M+·],
286 (93), 259 (100), 241 (50), 215 (63). HRMS (EI): calcd. for
C19H23NO5 [M+·] 345.1576; found 345.1578.
(4aS,8aS)-rel-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-
6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-one (18) [()-Narwedine]: A
magnetical ly st irred solution of formamide 17 (31.0 mg,
0.09 mmol) and 2-chloropyridine (26 μL, 0.27 mmol) in anhydrous
dichloromethane (3 mL) was cooled to –78 °C and then treated
dropwise with a solution of Tf2O (37 μL, 0.23 mmol) in anhydrous
dichloromethane (0.7 mL). The resulting solution was warmed to
0 °C, stirred at this temperature for 0.5 h, then warmed to room
temperature and stirred for a further 20 h. The resulting mixture
was then cooled to 0 °C and treated, portionwise, with NaBH-
(OAc)3. After 0.17 h at 0 °C the reaction mixture was warmed to
room temperature and maintained at this temperature for 2 h be-
fore being quenched with NaHCO3 (5 mL of a saturated aqueous
solution) and extracted with dichloromethane (3 5 mL). The
combined organic layers were dried (Na2SO4), filtered and concen-
trated under reduced pressure. The ensuing brown oil was subjected
to flash chromatography (silica gel; 9:1 v/v dichloromethane/meth-
anol) to give, after concentration of the appropriate fractions (Rf
= 0.3), ()-narwedine (18) (11.2 mg, 44 %) as a light-brown solid
m.p. 185–187 °C (ref.[6] m.p. 187–190 °C). 1H NMR (800 MHz,
CDCl3): δ = 6.95 (d, J = 10.4 Hz, 1 H), 6.70 (d, J = 8.1 Hz, 1 H),
6.66 (d, J = 8.1 Hz, 1 H), 6.04 (dd, J = 10.4 and 1.0 Hz, 1 H), 4.73
(m, 1 H), 4.11 (d, J = 15.5 Hz, 1 H), 3.84 (s, 3 H), 3.75 (d, J =
15.5 Hz, 1 H), 3.25 (t, J = 13.7 Hz, 1 H), 3.16 (m, 2 H), 2.75 (dd,
J = 17.9 and 3.5 Hz, 1 H), 2.44 (s, 3 H), 2.28 (td, J = 13.7 and
3.5 Hz, 1 H), 1.86 (d, J = 13.7 Hz, 1 H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 194.5, 147.2, 144.5, 144.2, 130.7, 129.5, 127.3, 122.2,
112.1, 88.1, 60.8, 56.2, 54.3, 49.1, 42.5, 37.5, 33.4 ppm. IR: ν˜max
= 2926, 2848, 1683, 1622, 1507, 1437, 1280, 1223, 1166, 1145, 1050,
1031, 1008, 802, 771 cm–1. MS (EI): m/z (%) = 285 (100) [M+·], 284
(98), 242 (47), 174 (42), 84 (68), 58 (82). HRMS (EI): calcd. for
C17H19NO3 [M+·] 285.1365; found 285.1363.
(4aS,6R,8aS)-rel-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-
6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol [()-1] [()-Galanth-
amine]: A magnetically stirred solution of ()-narwedine [()-18]
(12.0 mg, 0.042 mmol) in anhydrous THF (2 mL) was cooled to
–78 °C and then treated with L-selectride (0.13 mL of a 1 m solu-
tion in THF, 0.13 mmol). The resulting mixture was maintained at
–78 °C for 3 h and then treated with water (1 mL) and NaOH
(1 mL of a 3 m aqueous solution) before being extracted with ethyl
acetate (3 3 mL). The combined organic layers were dried
(Na2SO4), filtered and concentrated under reduced pressure, and
the ensuing brown oil subjected to flash chromatography (silica gel,
9:1 v/v dichloromethane/methanol) to give, after concentration of
the appropriate fractions (Rf = 0.3), ()-galanthamine [()-1]
(10 mg, 83%) as a light-brown, waxy solid. 1H NMR (800 MHz,
CDCl3): δ = 6.66 (d, J = 8.1 Hz, 1 H), 6.63 (d, J = 8.1 Hz, 1 H),
6.06 (ddd, J = 10.3, 1.4 and 0.7 Hz, 1 H), 6.01 (ddd, J = 10.3, 5.1
and 1.4 Hz, 1 H), 4.61 (m, 1 H), 4.14 (m, 1 H), 4.10 (d, J = 15.4 Hz,
1 H), 3.83 (s, 3 H), 3.70 (dd, J = 15.4 and 0.7 Hz, 1 H), 3.28 (t, J
= 13.5 Hz, 1 H), 3.06 (d, J = 14.3 Hz, 1 H), 2.69 (ddt, J = 15.7,
3.3 and 1.4 Hz, 1 H), 2.41 (s, 3 H), 2.09 (td, J = 13.5 and 3.3 Hz,
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1 H), 2.01 (ddd, J = 15.7, 5.1 and 2.5 Hz, 1 H), 1.59 (dd, J = 13.5
and 2.1 Hz, 1 H) ppm. 13C NMR (100 MHz, CDCl3): δ = 146.0,
144.3, 133.2, 129.2, 127.8, 126.9, 122.3, 111.4, 88.9, 62.2, 60.7, 56.1,
54.0, 48.4, 42.2, 33.9, 30.1 ppm. IR: ν˜max = 3339, 2917, 2835, 1958,
1623, 1590, 1506, 1438, 1281, 1230, 1202, 1166, 1046 cm–1. MS
(EI): m/z (%) = 287 (90) [M+·], 286 (100), 270 (22), 244 (41), 216
(50), 174 (47). HRMS (EI): calcd. for C17H21NO3 [M+·] 287.1521;
found 287.1521.
Supporting Information (see footnote on the first page of this arti-
cle): Tabular comparisons of the 13C NMR spectroscopic data ac-
quired on compounds 18 and ()-1 with those reported in the lit-
erature. 1H and 13C NMR spectra of compounds 4, 6–18 and ()-
1 and a comparison of the 1H NMR spectrum of synthetically de-
rived ()-galanthamine with that recorded on an authentic sample
of (–)-galanthamine.
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Table S1: Comparison of the 13C NMR data 
recorded for (±)-narwedine [(±)-18] obtained by 
the route reported here with those reported in the 
literature. 
13C NMR data 
for 
(±)-narwedine 
(δC)a 
13C NMR data 
reported in the 
literature 
(δC)b 
ΔδC 
194.5 194.4 +0.1 
147.2 146.9 +0.3 
144.5 144.3 +0.2 
144.2 143.9 +0.3 
130.7 130.5 +0.2 
129.5 129.3 +0.2 
127.3 127.0 +0.3 
122.2 122.0 +0.2 
112.1 111.8 +0.3 
88.1 87.9 +0.2 
60.8 60.6 +0.2 
56.2 55.9 +0.3 
54.3 54.0 +0.3 
49.1 48.9 +0.2 
42.6 42.4 +0.2 
37.5 37.3 +0.2 
33.4 33.2 +0.2 
a Data recorded in CDCl3 at 100 MHz. 
b Data obtained from reference 1 and recorded in 
CDCl3 at 100 MHz. 
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Table S2: Comparison of the 13C NMR data 
recorded for (±)-galanthamine [(±)-1 obtained by 
the route reported here with those reported in the 
literature for the (+)-enantiomer. 
13C NMR data 
for 
(±)-galanthamine 
(δC)a 
13C NMR data 
reported in the 
literature 
(δC)b 
ΔδC 
146.0 145.9 +0.1 
144.3 144.3 +0.0 
133.2 133.1 +0.1 
129.2 129.3 –0.1
127.8 127.7 +0.1 
126.9 126.9 +0.0 
122.3 122.2 +0.1 
111.4 111.2 +0.2 
88.9 88.8 +0.1 
62.2 62.2 +0.0 
60.7 60.7 +0.0 
56.1 56.0 +0.1 
54.0 53.9 +0.1 
48.4 48.3 +0.1 
42.2 42.2 +0.0 
33.9 33.9 +0.0 
30.1 30.0 +0.1 
a Data recorded in CDCl3 at 100 MHz. 
b Data obtained from reference 2 and recorded in 
CDCl3 at 75 MHz. 
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ABSTRACT: The racemic form of the title natural product 1 has been synthesized by engaging, as a key step, the iodoarene-
tethered cyclohexene 22 in an intramolecular Heck reaction to give compound 23. This angularly substituted
tetrahydrodibenzo[b,d]furan was elaborated over a further ﬁve steps into target (±)-1.
The Illicium genus of ﬂowering plants is commonlyencountered in various parts of Asia, and a range of
secondary metabolites produced by them, including certain
sesquineolignans,1 display potentially useful neurological
eﬀects.2−5 These include, inter alia, neurite-outgrowth-promot-
ing and acetylcholine-esterase-inhibiting properties.4−7 Re-
cently, Wang and co-workers reported5 the isolation of a series
of such compounds, including simonsol C (1) (Figure 1),8
from the aerial parts of the toxic shrub Illicium simonsii collected
in the Yunnan Province of southwest China. The
tetrahydrodibenzo[b,d]furan substructure associated with com-
pound 19 bears a strong resemblance to the ABC-ring system of
narwedine (2), an important precursor to the alkaloid
galanthamine (3) that is now used clinically in the symptomatic
treatment of Alzheimer’s disease.10
Our continuing interest in the chemistry of galanthamine11
and certain neurotrophically active metabolites derived from
Illicium species12 together with the absence of any reported
synthetic approaches to the structurally distinct framework of
simonsol C or its congeners prompted us to begin
investigations in this area.13,14 Herein we report the successful
total synthesis of the racemic modiﬁcation of compound 1 via a
12-step sequence that should permit access to other members
of this interesting class of natural products.
The presence of three allyl residues, including an angular
one, within the framework of the title compound presents
various challenges including maintaining the positional integrity
of the associated double bonds and achieving the required
chemoselectivity in the reactions to be used. The retrosynthetic
analysis employed in the present study is shown in Figure 2. It
was envisaged that the central furan ring would be accessible
through an intramolecular Heck reaction involving a substrate
of the general form 4, and this could itself be assembled using
an intermolecular Mitsunobu reaction between the 2-
allylcyclohex-2-en-1-ol 5 and a halogenated phenol of the
general form 6.
The synthetic sequence used to generate a seemingly suitable
halogenated phenol is shown in Scheme 1 and involved initial
monoprotection, under standard conditions, of commercially
available magnolol (7) as the corresponding and previously
unreported tert-butyldimethylsilyl (TBS) ether 8 (98%).
Regioselective electrophilic bromination of the phenolate
derived from compound 8 using 1,3-dibromo-5,5-dimethylhy-
dantoin (DBDMH)15 then aﬀorded compound 9 (89%), the
spectral data for which were in complete accord with the
assigned structure.
The synthesis of the A-ring precursor 5 started (Scheme 2)
with the α-benzoyloxylation of commercially available cyclo-
hexane-1,2-dione monoethylene ketal (10).16 The resulting and
previously reported11b,16 oxidation product 11 (78%) was then
Received: June 20, 2016
Published: July 11, 2016
Figure 1. Structures of simsonsol C (1), narwedine (2), and
galanthamine (3).
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converted, by standard methods, into the corresponding enol
triﬂate 1211b (93%) that was itself engaged in a Stille cross-
coupling reaction with allyltri-n-butylstannane in the presence
of Pd(PPh3)4 and lithium chloride to give the nonconjugated
diene 13 in 65% yield. Cleavage of the ester residue within this
last compound was readily achieved using sodium hydroxide in
methanol, and the resulting and targeted alcohol 5 (93%)
participated, at −78 °C,17 in a Mitsunobu reaction with the
halogenated magnolol derivative 9 to give the desired coupling
product 14 in 71% yield when diethyl azodicarboxylate
(DEAD) and triphenylphosphine (PPh3) were used as the
activating agents. Disappointingly, when compound 14 was
exposed to Pd(OAc)2, XPhos, and cesium carbonate in
reﬂuxing toluene,18 a reagent combination shown to be
eﬀective for promoting Heck-type cyclization reactions,19 the
oxepin derivative 15 (18%) proved to be the one isolable and
fully characterizable product of reaction. Only trace amounts of
the coproduced and desired isomer 16 were detected.
Examination of various other reaction conditions led to
essentially the same outcome. Compound 15 is clearly the
product of a 7-exo-trig cyclization process involving the allyl
residue appended to the cyclohexene ring of substrate 14. On
this basis, masking of the oﬀending allyl group was undertaken
in order to ensure that the desired 5-exo-trig Heck cyclization
reaction would take place.
The reaction pathway leading to a congener of compound 5
that lacks an interfering allyl group is shown in Scheme 3. Thus,
Suzuki−Miyaura cross-coupling of the enol triﬂate 12 described
earlier with (E)-(pin)BCHCHOEt20 aﬀorded the enol ether
17 (85%) that was itself treated with methanol and p-
toluenesulfonic acid monohydrate (p-TsOH·H2O) to produce
acetal 18 (66%). The benzoate residue within this last
compound was cleaved under standard conditions to give the
targeted A-ring precursor 19 (96%).
Various aspects of the foregoing study resulted in the
conclusion that the magnolol derivative of the general form 6
(see Figure 2) required for Mitsunobu coupling with
compound 19 should incorporate a MOM protecting group21
and iodine (rather than bromine). Accordingly, magnolol (7)
was ﬁrst treated (Scheme 4) with triethylamine and
chloromethyl methyl ether (MOM-Cl, prepared under
Figure 2. Retrosynthetic analysis of simonsol C used in the present study.
Scheme 1. Synthesis of Magnolol Derivative 9
Scheme 2. Intervention of a 7-exo-trig Heck Cyclization
Reaction
Scheme 3. Synthesis of Acetal 19
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conditions deﬁned by Berliner and Belecki22), thus producing
the targeted ether 20 (94%) that was immediately treated with
bis(sym-collidine)iodine(I) hexaﬂuorophosphate,23,24 thereby
eﬀecting a regioselective iodination reaction to generate the
desired compound 21 in 98% yield.
With compounds 19 and 21 to hand their coupling under
standard Mitsunobu conditions was investigated (Scheme 5).
By such means the substrate, 22, required for the pivotal Heck
reaction was obtained in 78% yield. Treatment of aryl iodide 22
with Pd(OAc)2, 1,3-bis(diphenylphosphino)propane (dppe),
and silver carbonate in reﬂuxing toluene25 for 1 h allowed the
desired 5-exo-trig Heck cyclization reaction to take place and so
producing the tetrahydrodibenzofuran 23 in 92% yield. All the
spectral data recorded on this material were in complete accord
with the assigned structure, but ﬁnal conﬁrmation of this
followed from a single-crystal X-ray analysis (see below).
The elaboration of Heck cyclization product 23 to racemic
simonsol C [(±)-1] followed the route shown in Scheme 6.
This involved the initial and selective hydrolysis of the
associated ethylene ketal moiety within the former compound
using aqueous HCl in THF at 22 °C, aﬀording enone 24 in
99% yield. Reduction of compound 24 with polymer-supported
borohydride proceeded in a highly diasteroselective manner to
give the allylic alcohol 25 in 95% yield,26,27 and this was then
treated, under reﬂux, with aqueous HCl in THF to provide
aldehyde 26 (82%).28 Wittig oleﬁnation of this last compound
gave the triallyl-containing compound 27 (72%), the structure
of which was conﬁrmed by single-crystal X-ray analysis [see
Supporting Information (SI) for details]. Finally, oxidation of
allylic alcohol 27 under the Parikh−Doering conditions29
aﬀorded racemic simonsol C [(±)-1] in 80% yield. All the
spectral data obtained on this material were in complete accord
with the assigned structure and matched those reported for the
natural product by Wang and co-workers (see the SI for
relevant comparisons of the 13C NMR spectral data).5
The synthetic sequence reported here serves to further
highlight the utility of the intramolecular Heck reaction as a
means for eﬀecting the assembly of heterocyclic ring systems
embodying angular substituents25,30 and the capacity of the
Mitsunobu reaction to engage phenolic residues in C−O bond
formation for the purposes of constructing tetrahydrodibenzo-
[b,d]-furans.31,32
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An Eleven-step Synthesis of Galanthamine from Commercially Available 
Materials 
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[a]
 and Martin G. Banwell
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*
Keywords: galanthamine, Heck cyclisation, Mitsunobu reaction, narwedine, reductive 
amination 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Narwedine, an immediate precursor to the therapeutically valuable alkaloid (–)-
galanthamine, has been synthesised by engaging an iodinated isovanillin derivative in 
an intermolecular Mitsunobu reaction with a 2-cyclohexen-1-ol derivative. The 
resulting aryl ether participated in a very efficient intramolecular Heck reaction to give, 
after hydrolysis of the primary cyclisation product, a tetracyclic lactol. This last 
compound is an advanced intermediate associated with the Magnus synthesis of 
narwedine and could be elaborated to narwedine itself under reductive amination 
conditions. As a result, an eleven-step synthesis of galanthamine has been established.  
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Introduction 
(–)-Galanthamine (1, a.k.a. galantamine) is a key alkaloid produced by a number of 
plants including the common snowdrop (Galanthus nivalis), the related species 
Galanthus woronowii and the red spider lily (Lycoris radiate).
1
 In some instances it co-
occurs with normally trace amounts of (–)-narwedine (2), the N-demethyl analogue of 
which is the likely biogenetic precursor (to 1).
2
 Originally galanthamine was used as a
treatment for certain paralytic and neuropathic conditions.
1
 However, the discovery that
it is an orally available and reversible inhibitor of acetylcholine esterase (AChE) 
capable of crossing the blood/brain barrier has led to its use in the symptomatic 
treatment of mild to moderate forms of Alzheimer’s Disease (AD),1,3 the leading cause
of dementia.
4
 Given the projections for the increase in the incidence of AD among
ageing populations in more developed countries, the demand for reliable supplies of 
galanthamine is almost certain to increase.
5
 At the present time it appears that the
required quantities of compound 1 are obtained from a combination of cultivation (and 
extraction) of the producing plants
6
 and by total synthesis.
7
 While the precise
contributions that each of these make to the total supply chain remains unclear, the 
continuing focus on developing more productive cultivars and more effective growing 
methods
6
 suggest the synthetic approach is the less significant one.
Figure 1: The structures of (–)-galanthamine (1) and (–)-narwedine (2). 
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This situation is a reflection, to some extent at least, of the challenges that remain in 
assembling the tetracyclic framework of galanthamine, especially its associated 
quaternary carbon center. The original synthesis of the alkaloid, reported by Barton and 
Kirby in 1962,
8
 was a biomimetic one involving a low-yielding, intramolecular
oxidative phenolic coupling leading to racemic narwedine [(±)-(2)] that can be 
diastereoselectively reduced to the congener 1 under a variety of conditions. A 
significant development in the area was the discovery that racemic narwedine can, 
through a fractional crystallisation process coupled with reversible E1cB/hetero-
Michael addition reactions, be converted, in its entirety, into either of its constituent 
enantiomers using “seeding” quantities of either (+)- or (–)-galanthamine.9 A modified
version of the Barton/Kirby process, when linked with the capacity for the dynamic 
kinetic resolution process just mentioned, allowed Fröhlich and Jordis to develop a 
pilot-plant scale synthesis of (–)-narwedine that now seems to be part of the 
galanthamine supply chain.
7
 In 2009 Magnus and co-workers reported
10
 using an
intramolecular alkylation of a phenol derivative as the basis for establishing a seven-
step synthesis of racemic narwedine and seemingly representing the shortest/most 
efficient route to galanthamine described thus far. In 2000 Trost and Toste exploited an 
intramolecular Heck reaction for assembling the ABC-ring system and the associated 
quaternary carbon centre of galanthamine.
11
 This work inspired a number of related
approaches.
12
 Other ingenious ones have also emerged in the intervening period.
13,14
As part of our ongoing interest in developing new routes to galanthamine
13b
 we have
described two total syntheses to date, one involving a Pd-catalysed intramolecular 
Alder-ene reaction followed by a Diels-Alder cycloaddition (the second step serving to 
effect the de novo assembly of the aromatic A-ring)
13a
 and the other being a
chemoenzymatic approach.
15
 Recently, and as part of a continuing program to identify
new AChE inhibitors,
16
 we reported
17
 the first synthesis of the sesquineolignan
simonsol C (3), a compound that bears a strong structural resemblance to narwedine. 
Accordingly, we sought to apply the key steps used in the assembly of the former 
compound, namely an intermolecular Mitsunobu reaction followed by an intramolecular 
Heck reaction, to a synthesis of the racemic modification of narwedine (2).
18
 The
successful outcome of such work is detailed below. 
Figure 2: The structure of simonsol C (3) and the two key bond-forming events used in 
its synthesis. 
Results and Discussion 
In our first route to racemic narwedine (Scheme 1), the previously reported
17
 allylic
alcohol 4 (available in four steps from commercially available cyclohexane-1,4-dione 
mono-ethylene ketal) was engaged in an intramolecular Mitsunobu reaction
19
 with the
readily available iodinated derivative, 5,
20
 of isovanillin where the latter coupling
partner served as the nucleophile.
21
 The ether 6 (73%) thus formed was subjected to an
178
intramolecular Heck reaction under the indicated conditions
22
 and thus affording the
tricyclic sulfonamide 7 in 96% yield. Finally, successive treatment of the last compound 
with sodium naphthalenide (to cleave the tosyl group) then a solution of sodium 
triacetoxyborohydride in moist acetic acid (to reduce the imine resulting from the 
intramolecular Schiff base condensation reaction and to hydrolyse the ketal residue) 
gave a rather complex mixture from which (±)-narwedine [(±)-2] could be isolated 30% 
yield. This material was identical, in all respects, with an authentic sample of compound 
2 prepared by our earlier route.
13a
Scheme 1. A new route to (±)-narwedine [(±)-2]. Reagents and conditions (a) Bu3P, 
TMAD, THF, 0 to 22 °C, 16 h; (b) Pd(OAc)2, dppp, Ag2CO3, toluene, 112 °C, 3 h; (c) 
NaC10H8, THF, –78°C, 0.2 h then AcOH,  NaBH(OAc)3, 18 °C, 4 h. TMAD = 
N,N,N,N’-tetramethylazodicarboxamide; dppp = 1,3-bis(diphenylphosphino)propane.     
In an effort to establish an improved procedure for closing the D-ring of narwedine the 
reaction sequence shown in Scheme 2 was pursued. Specifically, the previously 
reported
17
 congener 8 of compound 4 was reacted with phenol 5 under Mitsunobu
conditions and the ether 9 (76%) so formed engaged in an intramolecular Heck reaction 
to afford the benzofuran 10 in 90% yield.  Subjection of this last compound to reductive 
amination conditions using methylamine and sodium triacetoxyborohydride in acetic 
acid/dichloromethane then gave the 2°-amine 11 in 57% yield. This modest yield, the 
rather complex mixture of products arising from the various attempts to carry 
compound 11 forward to narwedine, and the outcomes of the studies presented 
immediately below prompted the abandonment of this approach. Part of the difficulty 
associated with finishing this approach most likely arises from orchestrating the 
required sequence of acetal and ketal cleavage reactions. Thus, the latter functionality 
reacts faster than the former
17
 and so introducing the unwanted possibilities of both
intra- and inter-molecular reactions between a 2-cyclohexen-1-one residue and a 
pendant 2°-amine.   
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Scheme 2. Attempts to establish an improved synthesis of the D-ring. Reagents and 
conditions (a) Bu3P, DEAD, THF, 0 to 22 °C, 4 h; (b) Pd(OAc)2, dppp, Ag2CO3, 
toluene, 112 °C, 4 h; (c) H2NMe, AcOH, NaBH(OAc)3, DCM, 22 °C, 16 h. DEAD = 
diethyl azodicarboxylate.     
 
The ultimately more effective route to racemic narwedine found during the course of the 
present study is shown in Scheme 3. This involved the one-pot and acid-catalysed 
hydrolysis of both the acetal and ketal residues within the Heck cyclisation product 10 
using 1 M aqueous HCl in refluxing THF and thereby affording lactol 12 in 86% yield 
and that was found to exist largely in one anomeric form. This compound almost 
certainly arises through the initially produced hemiacetal adding in an intramolecular 
hetero-Michael addition reaction to the 2-cyclohexen-1-one revealed by hydrolysis of 
the ketal moiety. It is the key intermediate associated with the Magnus group’s 
synthesis of (±)-narwedine.
10
 In seeking to effect the conversion 12  2 we chose to 
build upon the somewhat limited amount of experimental detail provided by this 
group
10
 and ultimately found that on sequential treatment of the former compound with 
the hydrochloride salt of methylamine in the presence of sodium cyanoborohyride and 
acetic acid gave a boron complex of narwedine that could be cleaved using 
methanesulfonic acid in refluxing 1,4-dioxane. By such means compound 2 was 
obtained in 48% yield over the two operations involved. Once again, the spectral data 
acquired on this product matched those derived from an authentic sample. In addition, 
the material produced by the route described here was reduced with L-selectride
9,23
 and 
thus providing (±)-galanthamine [(±)-1] in 83% yield. This material was identical, in all 
respects, with an authentic sample.
15
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Scheme 3. A synthesis of (±)-narwedine [(±)-2] via the Magnus lactol 12. Reagents and 
conditions (a) 1 M aq. HCl, THF, 60 °C, 2 h; (b) H3NMeCl, Et3N, AcOH, 
NaBH(OAc)3, 1,4-dioxane, 22 °C, 30 h; (c) 20% v/v aq. MeSO3H, 1,4-dioxane, 101 °C, 
5 h. 
Conclusion 
When the five steps required to obtained compound 8 from commercially available 
cyclohexane-1,4-dione mono-ethylene ketal are taken into account,
17
 the reaction
sequence described here and leading to (±)-narwedine is ten steps in length. This 
compares with the seven involved in the Magnus synthesis
10
 that continues to set the
benchmark for efficiency in this challenging area. That said, the capacities for 
refinement of our approach as well as the opportunities for the generation of novel and 
biologically active analogues of galanthamine are areas of research that continue in our 
laboratories. Establishing a shorter synthesis of compound 8 is clear a priority. The 
present work also serves to emphasize the utility of combining the products of the 
intermolecular Mitsunobu reaction of 2-halogenophenols and allylic alcohols with the 
Heck cyclization reaction for the rapid assembly of benzofurans.
24
 Efforts to extend
such processes in various ways represent an ongoing focus and the results of such 
studies will be reported in due course.  
Experimental Section 
General Experimental Procedures: Unless otherwise specified, proton (
1
H) and
carbon (
13
C) NMR spectra were recorded at room temperature in base-filtered CDCl3 on
a spectrometer operating at 400 MHz for proton and 100 MHz for carbon nuclei. For 
1
H
NMR spectra, signals arising from the residual protio-forms of the solvent were used as 
internal standards. 
1H NMR data are recorded as follows: chemical shift (δ) 
[multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined 
as: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet or combinations of the 
above. The signal due to residual CHCl3 appearing at δH 7.26 and the central resonance 
of the CDCl3 “triplet” appearing at δC 77.0 were used to reference 
1
H and 
13
C NMR
spectra, respectively. Infrared spectra (max) were recorded on a FTIR Spectrometer. 
Samples were analysed as thin films on KBr plates. Low-resolution ESI mass spectra 
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were recorded on a single quadrupole liquid chromatograph-mass spectrometer, while 
high-resolution measurements were conducted on a time-of-flight instrument. Low- and 
high-resolution EI mass spectra were recorded on a magnetic-sector machine. Melting 
points were measured on an automated melting point system and are uncorrected. 
Analytical thin layer chromatography (TLC) was performed on aluminum-backed 0.2 
mm thick silica gel 60 F254 plates. Eluted plates were visualized using a 254 nm UV 
lamp and/or by treatment with a suitable dip followed by heating. These dips included 
phosphomolybdic acid : ceric sulfate : sulfuric acid (conc.) : water (37.5 g : 7.5 g : 37.5 
g : 720 mL) or potassium permanganate : potassium carbonate : 5% sodium hydroxide 
aqueous solution : water (3 g : 20 g: 5 mL : 300 mL). Flash chromatographic 
separations were carried out following protocols defined by Still et al.
25
 with silica gel
60 (40–63 m) as the stationary phase and using the AR- or HPLC-grade solvents 
indicated. Starting materials, reagents and drying agents as well as other inorganic salts 
were generally available from commercial sources and used as supplied. 
Tetrahydrofuran (THF), diethyl ether, methanol and dichloromethane were dried using a 
solvent purification system that is based upon a technology originally described by 
Grubbs et al.
26
 Where necessary, reactions were performed under an nitrogen
atmosphere. 
(±)-N-(2-(9-(3-Formyl-2-iodo-6-methoxyphenoxy)-1,4-dioxaspiro[4.5]dec-7-en-8-
yl)ethyl)-N,4-dimethylbenzenesulfonamide (6): A magnetically stirred solution of 
alcohol 4
17
 (515 mg, 1.40 mmol), phenol 5
20
 (545 mg, 1.96 mmol) and tri-n-
butylphosphine (0.50 mL, 1.96 mmol) in dry THF (25 mL) was cooled to 0 °C then 
treated with TMAD
19
 (341 mg, 1.96 mmol). The resulting yellow solution was 
maintained at this temperature for 0.5 h then warmed to and maintained at room 
temperature for 18 h. The resulting suspension was treated with silica and the mixture 
thus obtained concentrated under reduced pressure. The free-flowing powder thus 
obtained was subjected to flash chromatography (silica, 2:1 v/v hexane/ethyl acetate 
elution) to afford, after concentration of the appropriate fractions (Rf = 0.4 in 1:1 v/v 
hexane/ethyl acetate), compound 6 (641 mg, 73%) as a cream-coloured foam. 
1
H NMR 
(400 MHz, CDCl3): δ 10.03 (s, 1H), 7.73-7.63 (complex m, 3H), 7.26 (d, J = 8.0 Hz, 
2H), 6.97 (d, J = 8.8 Hz, 1H), 5.57 (m, 1H), 5.31 (m, 1H), 3.99-3.77 (complex m, 7H), 
3.32 (m, 2H), 2.77 (s, 3H), 2.59 (m, 2H), 2.43 (m, 1H), 2.40 (s, 3H), 2.20 (m, 2H), 1.86 
(ddd, J = 12.0, 5.9 and 2.2 Hz, 1H) ppm. 
13
C NMR (100 MHz, CDCl3): δ 195.3, 157.1, 
145.6, 143.0, 134.9(4), 134.8(9), 129.5, 129.2, 127.3, 126.7, 123.3, 111.8, 108.1, 101.5, 
78.7, 64.3, 64.2, 56.1, 49.5, 37.8, 35.9, 34.9, 31.0, 21.4 ppm. IR: νmax = 2978, 2937, 
2880, 1682, 1573, 1476, 1336, 1273, 1246, 1159, 1019, 941, 729 cm
–1
. MS (ESI, +ve): 
m/z (%) = 650 (100) [(M+Na)
+
]. HRMS (ESI, +ve): calcd for C26H30INNaO7S 
[(M+Na)
+
] 650.0685; found 650.0685.
rac-N-(2-((4aS,9bS)-9-Formyl-6-methoxy-4,4a-dihydro-9bHspiro-
[dibenzo[b,d]furan-3,2'-[1,3]dioxolane]-9b-yl)ethyl)-N,4-
dimethylbenzenesulfonamide (7): A magnetically stirred and thoroughly degassed 
solution of compound 6 (240 mg, 0.382 mmol) in dry toluene (5 mL) maintained under 
a nitrogen atmosphere was treated, sequentially, with Pd(OAc)2 (8.8 mg, 10 mol%), 
dppp (32.5 mg, 20 mol%) and Ag2CO3 (317 mg, 1.15 mmol). The resulting 
heterogeneous mixture was heated under reflux for 3 h then cooled, filtered through a 
pad of diatomaceous earth and the filtrate concentrated under reduced pressure. The 
residue thus obtained was subjected to flash chromatography (silica, 9:1 v/v 
DCM/diethyl ether elution) to afford, after concentration of the appropriate fractions (Rf 
= 0.8 in 8:2 v/v DCM/diethyl ether), compound 7 (184 mg, 96%) as a light-yellow 
foam. 
1
H NMR (400 MHz, CDCl3): δ 9.80 (s, 1H), 7.60 (d, J = 8.2 Hz, 2H), 7.36 (d, J =
182
8.4 Hz, 1H), 7.28 (m, 2H), 6.90 (d, J = 8.4 Hz, 1H), 6.42 (d, J = 10.3 Hz, 1H), 5.70 (d, J 
= 10.3 Hz, 1H), 4.95 (m, 1H), 4.03-3.90 (complex m, 7H), 3.05 (m, 1H), 2.83 (m, 1H), 
2.68 (s, 3H), 2.41 (s, 3H), 2.37 (m, 1H), 2.23 (m, 2H), 2.03 (m, 1H). 
13
C NMR (100
MHz, CDCl3): δ 190.9, 150.2, 148.1, 143.1, 134.7, 131.6, 131.3, 130.1, 129.5, 128.0, 
127.2, 126.5, 110.6, 103.2, 84.4, 64.8, 64.4, 56.0, 49.6, 46.4, 35.3, 34.7, 34.5, 21.3. IR: 
νmax = 2959, 2932, 2885, 1686, 1607, 1571, 1506, 1436, 1337, 1284, 1159, 1015, 912, 
729 cm
–1
. MS (ESI, +ve): m/z (%) = 522 (100) [(M+Na)
+
]. HRMS (ESI, +ve): calcd for
C26H29NNaO7S [(M+Na)
+
] 522.1562; found 522.1561.
rac-(4aS,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-
benzo[2,3]benzofuro-[4,3-cd]azepin-6-one [(±)-narwedine, 2]: A magnetically stirred 
solution of compound 7 (300 mg, 0.60 mmol) in dry THF (10 mL) was cooled to −78 
°C then treated, dropwise, with sodium naphthalenide [prepared from napthalene (256 
mg, 2.0 mmol) and sodium metal (48 mg, 2.0 mmol) in dry THF (10 mL)] until the 
dark-green colour of the reducing agent remained. The resulting solution was treated 
with acetic acid (2 mL) (CAUTION) then warmed to 0 °C and treated with sodium 
triacetoxyborohydride (200 mg, 0.90 mmol). The solution thus obtained was maintained 
at 22 °C for 4 h then treated with HCl (5 mL of a 1 M aqueous solution), maintained at 
22 °C for 1 h then treated with NaHCO3 (10 mL of a saturated aqueous solution) and 
extracted with CHCl3 (3 x 20 mL). The combined organic phases were washed with 
brine (1 x 20 mL) before being dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The ensuing brown oil was subjected to flash chromatography (silica gel; 9:1 
v/v dichloromethane/methanol) to give, after concentration of the appropriate fractions 
(Rf = 0.3), (±)-narwedine (2)
13a
 (50 mg, 29%) as an off-white powder, m.p. = 185–187 
°C. 
1
H NMR (800 MHz, CDCl3): δ 6.95 (d, J = 10.4 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 
6.66 (d, J = 8.1 Hz, 1H), 6.04 (dd, J = 10.4 and 1.0 Hz, 1H), 4.73 (m, 1H), 4.11 (d, J = 
15.5 Hz, 1H), 3.84 (s, 3H), 3.75 (d, J =15.5 Hz, 1H), 3.25 (t, J = 13.7 Hz, 1H), 3.16 (m, 
2H), 2.75 (dd, J = 17.9 and 3.5 Hz, 1H), 2.44 (s, 3H), 2.28 (td, J = 13.7 and 3.5 Hz, 1H), 
1.86 (d, J = 13.7 Hz, 1H) ppm. 
13
C NMR (100 MHz, CDCl3): δ 194.5, 147.2, 144.5, 
144.2, 130.7, 129.5, 127.3, 122.2, 112.1, 88.1, 60.8, 56.2, 54.3, 49.1, 42.5, 37.5, 33.4 
ppm. IR: νmax = 2926, 2848, 1683, 1622, 1507, 1437, 1280, 1223, 1166, 1145, 1050, 
1031, 1008, 802, 771 cm
–1
. MS (EI): m/z (%) = 285 (100) [M
+·
], 284 (98), 242 (47), 174 
(42), 84 (68), 58 (82). HRMS (EI): calcd for C17H19NO3 [M
+·
] 285.1365; found
285.1363. 
 (±)3-((8-(2,2-Dimethoxyethyl)-1,4-dioxaspiro[4.5]dec-8-en-7-yl)oxy)-2-iodo-4-
methoxy-benzaldehyde (9): A magnetically stirred solution of compound 8
17
 (530 mg, 
2.16 mmol), compound 5 (840 mg, 3.05 mmol) and tri-n-butylphosphine (0.88 mL, 3.05 
mmol) in dry THF (40 mL) was cooled to 0 °C then treated with DEAD (0.48 mL, 3.05 
mmol). The resulting yellow solution was maintained at 0 °C for 0.25 h then warmed 
and maintained at room temperature for 4 h before being concentrated under reduced 
pressure. The residue thus obtained was subjected to flash chromatography  (silica, 1:1 
v/v  hexane/ethyl  acetate  elution) and after  concentration  of  the  appropriate  
fractions  (Rf =  0.3  in  1:1  v/v hexane/ethyl acetate) compound 9 (830 mg, 76%) was 
obtained as a light-yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 10.04 (s, 1H), 7.69 (d, J = 
8.7 Hz, 1H), 6.97 (d, J = 8.7 Hz, 1H), 5.64 (m, 1H), 5.33 (m, 1H), 4.78 (t, J = 5.8 Hz, 
1H), 4.05–3.76 (complex m, 4H), 3.94 (s, 3H), 3.38 (s, 3H), 3.35 (s, 3H), 2.69 (m, 2H), 
2.48 (m, 1H), 2.26 (m, 2H), 1.89 (m, 1H) ppm. 
13
C NMR (100 MHz, CDCl3): δ 195.5, 
157.1, 146.0, 133.5, 129.3, 126.6, 123.8, 111.8, 108.3, 103.6, 101.8, 79.2, 64.4, 64.2, 
56.1, 53.5, 52.8, 38.0, 36.0(4), 36.0(1) ppm. IR: νmax = 2937, 2887, 2829, 1682, 1573, 
1475, 1439, 1272, 1245, 1017, 811, 729 cm
–1
. MS (ESI, +ve): m/z (%) = 527 (100)
183
[(M+Na)
+
]. HRMS (ESI, +ve): calcd for C20H25INaO7 [(M+Na)
+
] 527.0543; found
527.0554. 
rac-(4aS,9bS)-9b-(2,2-Dimethoxyethyl)-6-methoxy-4a,9b-dihydro-4H-
spiro[dibenzo[b,d]furan-3,2'-[1,3]dioxolane]-9-carbaldehyde (10): A magnetically 
stirred and thoroughly degassed solution of compound 9 (1.50 g, 2.97 mmol) in dry 
toluene (60 mL) maintained under a nitrogen atmosphere was treated, sequentially, with 
Pd(OAc)2 (68 mg, 10 mol%), dppp (251 mg, 20 mol%) and Ag2CO3 (2.40 g, 8.9 mmol). 
The resulting heterogeneous mixture was heated at reflux for 4 h then cooled, filtered 
through a pad of diatomaceous earth and the filtrate evaporated under reduced pressure. 
The residue thus obtained was subjected to flash chromatography (silica, 9:1 v/v 
DCM/diethyl ether elution) to afford, after concentration of the appropriate fractions (Rf 
= 0.7 in 9:1 v/v DCM/diethyl ether), compound 10 (1.00 g, 90%) as a white foam. 
1
H 
NMR (400 MHz, CDCl3): δ 9.84 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 8.4 Hz, 
1H), 6.52 (d, J = 10.3 Hz, 1H), 5.72 (d, J = 10.3 Hz, 1H), 5.23 (m, 1H), 4.32 (t, J = 5.2 
Hz, 1H), 3.95 (m, 7H), 3.23 (s, 3H), 3.22 (s, 3H), 2.37–2.16 (complex m, 4H) ppm. 13C 
NMR (100 MHz, CDCl3): δ 190.9, 150.2, 148.3, 132.1, 131.5, 130.6, 127.7, 126.7, 
110.4, 103.4, 102.7, 85.0, 64.9, 64.4, 56.0, 53.1, 53.0, 48.9, 39.8, 35.0 ppm. IR: νmax = 
2934, 2888, 2836, 2730, 1686, 1607, 1570, 1283, 1117, 1045, 1013 cm
–1
. MS (ESI,
+ve): m/z (%) = 399 (100) [(M+Na)
+
]. HRMS (ESI, +ve): calcd for C20H24NaO7
[(M+Na)
+
] 399.1420; found 399.1422.
rac-1-((4aS,9bS)-9b-(2,2-Dimethoxyethyl)-6-methoxy-4a,9b-dihydro-
4Hspiro[dibenzo[b,d]furan-3,2'-[1,3]dioxolan]-9-yl)-N-methylmethanamine (11): A 
magnetically stirred solution of compound 10 (100 mg, 0.265 mmol), methylamine (0.2 
mL of a 2 M solution in THF, 0.4 mmol) and AcOH (0.1 mL) in dry DCM (2 mL) was 
treated with sodium triacetoxyborohydride (85 mg, 0.4 mmol). The resulting mixture 
was maintained at room temperature for 16 h then treated with NaHCO3 (5 mL of a 
saturated aqueous solution) and extracted with DCM (3 x 5 mL). The combined organic 
phases were washed with brine (1 x 10 mL) before being dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The ensuing brown oil was subjected to flash 
chromatography (silica gel; 9:1 v/v dichloromethane/methanol) to give, after 
concentration of the appropriate fractions (Rf = 0.2), compound 11 (60 mg, 57%) as a 
pale-yellow oil. 
1
H NMR (400 MHz, CDCl3): δ 6.83 (d, J = 8.3 Hz, 1H), 6.72 (d, J = 8.3 
Hz, 1H), 6.19 (d, J = 10.2 Hz, 1H), 5.75 (d, J = 10.2 Hz, 1H), 5.07 (m, 1H), 4.37 (t, J = 
5.0 Hz, 1H), 4.31 (broad s, 1H), 3.96 (m, 4H), 3.84 (s, 3H), 3.77 (s, 2H), 3.24 (s, 3H), 
3.21 (s, 3H), 2.46 (s, 3H), 2.24–2.03 (complex m, 4H) ppm. 13C NMR (100 MHz,
CDCl3): δ 146.9, 144.7, 132.2, 130.3, 128.2, 126.8, 122.5, 111.5, 104.1, 102.0, 83.8, 
64.7, 64.5, 55.8, 52.7, 52.6, 51.6, 49.3, 41.3, 35.3, 35.1 ppm. IR: νmax = 2954, 2934, 
2891, 2835, 2789, 1621, 1581, 1506, 1428, 1277, 1203, 1116, 1046, 1014, 966, 948 cm–1
MS (ESI, +ve): m/z (%) = 392 (100) [(M+H)
+
]. HRMS (ESI, +ve): calcd for 
C21H30NO6 [(M+H)
+
] 392.2073; found 392.2075.
Compound 12: A magnetically stirred solution of compound 10 (360 mg, 0.96 mmol) 
in THF (20 mL) was treated with HCl (5 mL of a 1 M aqueous solution) then heated at 
reflux for 2 h. The resulting mixture was cooled to room temperature then treated with 
NaHCO3 (20 mL of a saturated aqueous solution) and extracted with EtOAc (4 x 15 
mL). The combined organic phases were washed with brine (1 x 20 mL) before being 
dried (Na2SO4), filtered, and concentrated under reduced pressure. The ensuing off-
white powder was subjected to flash chromatography (silica gel; 2:1 v/v hexane/EtOAc) 
to give, after concentration of the appropriate fractions (Rf = 0.3), compound 12
10
 (250
mg, 86%) as a white powder, m.p. = 188−192 °C. 1H NMR (400 MHz, CDCl3): δ
184
(major anomer) 9.81 (s, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.02 (d, J = 8.5 Hz, 1H), 6.17 (d, 
J = 11.4 Hz, 1H), 5.64 (m, 1H), 4.79 (t, J = 3.1 Hz, 1H), 4.57 (t, J = 2.9 Hz, 1H), 3.99 
(s, 3H), 3.08–2.98 (complex m, 2H), 2.84 (dd, J = 18.2 and 2.9 Hz, 1H), 2.75 (dd, J = 
18.2 and 3.5 Hz, 1H), 2.34–2.20 (complex m, 2H) ppm. 13C NMR (100 MHz, CDCl3): δ
 
(major anomer)
 
204.6, 192.4, 150.5, 149.6, 133.5, 129.7, 125.9, 111.3, 98.3, 90.1, 77.5, 
56.3, 53.9, 46.9, 39.1, 38.2 ppm. IR: νmax = 3444, 2945, 2916, 2846, 1720, 1681, 1608, 
1572, 1437, 1292, 1240, 1203, 1049 cm
–1
. MS (ESI, +ve): m/z (%) = 327 (100)
[(M+Na)
+
]. HRMS (ESI, +ve): calcd for C16H16NaO6 [(M+Na)
+
] 327.0845; found
327.0844. 
rac-(4aS,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-
benzo[2,3]benzofuro-[4,3-cd]azepin-6-one [(±)-narwedine, (±)-2]: A magnetically 
stirred solution of compound 12 (110 mg, 0.36 mmol) and freshly recrystallised 
methylamine hydrochloride (35 mg, 0.51 mmol) in dry 1,4-dioxane (6 mL) was treated 
with and triethylamine (0.1 mL, 0.7 mmol) then the vessel was sealed and maintained at 
room temperature for 30 h. The resulting suspension was then treated with acetic acid 
(0.5 mL, 8.7 mmol) and sodium cyanoborohydride (42 mg, 0.67 mmol) and maintained 
at room temperature for a further 24 h. The resulting suspension was then treated with 
NaHCO3 (10 mL of a saturated aqueous solution) and extracted with CHCl3 (4 x 10 
mL). The combined organic phases were washed with brine (1 x 20 mL) before being 
dried (Na2SO4), filtered, and concentrated under reduced pressure. The ensuing residue 
was immediately suspended in 1,4-dioxane (5 mL) then treated with MeSO3H (0.5 mL 
of a 20% aqueous solution) and the resulting mixture heated at reflux for 4 h then 
cooled to room temperature and treated with NaHCO3 (10 mL of a saturated aqueous 
solution) and extracted with CHCl3 (4 x 15 mL). The combined organic phases were 
washed with brine (1 x 10 mL) before being dried (Na2SO4), filtered, and concentrated 
under reduced pressure. The ensuing yellow oil was subjected to flash chromatography 
(silica gel; 9:1 v/v DCM:MeOH) to give, after concentration of the appropriate fractions 
(Rf = 0.3), compound (±)-2 (49 mg, 48%) as an off-white powder. This material was 
identical, in all respects, with that obtained by the route detailed above. 
rac-(4aS,6R,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-
benzo[2,3]benzo-furo[4,3-cd]azepin-6-ol [(±)-galanthamine, (±)-1]:A magnetically 
stirred solution of (±)-narwedine [(±)-2] (12.0 mg, 0.042 mmol) in anhydrous THF (2 
mL) was cooled to –78 °C and then treated with L-selectride (0.13 mL of a 1 M solution 
in THF, 0.13 mmol). The resulting mixture was maintained at –78 °C for 3 h and then 
treated with water (1 mL) and NaOH (1 mL of a 3 M aqueous solution) before being 
extracted with ethyl acetate (3 × 3 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated under reduced pressure, and the ensuing brown oil 
subjected to flash chromatography (silica gel, 9:1 v/v dichloromethane/methanol) to 
give, after concentration of the appropriate fractions (Rf = 0.3), (±)-galanthamine [(±)-
1]
15
(10 mg, 83%) as a light-brown, waxy solid. 
1
H NMR (800 MHz, CDCl3): δ 6.66 (d,
J = 8.1 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 6.06 (ddd, J = 10.3, 1.4 and 0.7 Hz, 1H), 6.01 
(ddd, J = 10.3, 5.1 and 1.4 Hz, 1H), 4.61 (m, 1H), 4.14 (m, 1H), 4.10 (d, J = 15.4 Hz, 
1H), 3.83 (s, 3H), 3.70 (dd, J = 15.4 and 0.7 Hz, 1H), 3.28 (t, J = 13.5 Hz, 1H), 3.06 (d, 
J = 14.3 Hz, 1H), 2.69 (ddt, J = 15.7, 3.3 and 1.4 Hz, 1H), 2.41 (s, 3H), 2.09 (td, J = 
13.5 and 3.3 Hz, 1H), 2.01 (ddd, J = 15.7, 5.1 and 2.5 Hz, 1H), 1.59 (dd, J = 13.5 and 
2.1 Hz, 1H) (signal due to hydroxyl group proton not observed) ppm. 
13
C NMR (100
MHz, CDCl3): δ 146.0, 144.3, 133.2, 129.2, 127.8, 126.9, 122.3, 111.4, 88.9, 62.2, 60.7, 
56.1, 54.0, 48.4, 42.2, 33.9, 30.1 ppm.  IR: νmax = 3339, 2917, 2835, 1958, 1623, 1590, 
1506, 1438, 1281, 1230, 1202, 1166, 1046 cm
–1
. MS (EI): m/z (%) = 287 (90) [M
+·
],
185
286 (100), 270 (22), 244 (41), 216 (50), 174 (47). HRMS (EI): calcd for C17H21NO3 
[M
+·
] 287.1521; found 287.1521. 
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ABSTRACT: A rapid and straightforward synthesis of the new and highly reactive reagent N-methoxy-N-methylcyanoforma-
mide from trimethylsilyl cyanide and N-methoxy-N-methylcarbamoylimidazole, is reported. This reagent enables the one-pot
preparation of β-carbonyl Weinreb amides from lithium enolates, one-carbon homologated Weinreb amides, and unsymmetrical
ketones in one-pot procedures from various organometallic species.
The vast synthetic utility of Weinreb amides1 has led to asigniﬁcant amount of research into methods of synthesiz-
ing compounds bearing this functionality.2 Weinreb amides are
usually synthesized from the corresponding activated carboxylic
acid equivalents2 or are installed directly from an organo-
metallic species and an N-methoxy-N-methylcarbamoyl electro-
phile such as 1,3 2,4 or 35 (Figure 1).
β-Keto Weinreb amides are commonly encountered
intermediates in organic synthesis.6 A recent synthetic study
in our laboratory involved the conversion of ketone 57 to the
corresponding β-keto Weinreb amide 6 (Scheme 1). During
our investigation, we discovered that the reaction of the lithium
enolate of 1 with common N-methoxy-N-methylcarbamoylat-
ing reagents such as 1 and 2 either did not proceed or resulted
in O-carbamoylation. Surprisingly, despite Mander’s pioneering
work8 using methyl cyanoformate for the selective C-
carbomethoxylation of enolates, a direct transformation from
ketones to the β-keto Weinreb amides has not been described.
Accordingly, we focused on synthesizing and using the
previously unreported Mander-type cyanoformamide 4.
Initially, access to 4 was achieved using conditions reported
by Weber9 for the synthesis of isobutyl cyanoformate. Thus,
exposure of N-methoxy-N-methylcarbamoyl chloride (2)4c to
potassium cyanide in DCM resulted in the formation of 4
(Scheme 2, pathway a). The lithium enolate derived from 5,
formed upon exposure to LiHMDS, reacted rapidly at −78 °C
with 4 to provide the desired β-keto Weinreb amide 6 in 78%
yield with >99% dr. The moderate yields associated with the
synthesis of 4 and the use of triphosgene prompted us to
explore a more practical and scalable procedure. An assessment
of the literature revealed few examples detailing the preparation
of cyanoformamides,10 the majority of which were unsuitable
for scale-up. Sarpong’s report11 of the use of imidazole
carbamoylating urea reagent 7 encouraged us to use this as a
more accessible alternative to N-methoxy-N-methylcarbamoyl
chloride. To access 7, we opted to use a modiﬁcation of
Received: June 24, 2016
Published: July 19, 2016
Figure 1. N,O-dimethylcarbamoylating reagents.
Scheme 1. Direct Transformation of Ketone 5 to β-Keto
Weinreb Amide 6
Letter
pubs.acs.org/OrgLett
© 2016 American Chemical Society 3834 DOI: 10.1021/acs.orglett.6b01844
Org. Lett. 2016, 18, 3834−3837
209
Padiya’s “In Water” imidazole carbonylation procedure12
(Scheme 2, pathway b), thus generating the required urea
conveniently, rapidly, and in high yield.
The synthesis of 4 from 7 required a cyanide source, and the
restrictions imposed on access to inorganic cyanides
encouraged the use of readily available trimethylsilyl cyanide
(TMSCN). A number of conditions were screened for the
condensation of 7 with TMSCN in various solvents, but
excellent yields were only obtained using a “green”, anhydrous,
solvent-free mixture. This reaction is amenable to scale-up and
can be performed with only 1.05 equiv of TMSCN at 18 °C for
18 h or similarly for 10 min at 100 °C in 93% yield. Eﬀorts to
isolate 4 directly from the reaction ﬂask by fractional distillation
were unfortunately hampered by contamination of 1-
trimethylsilylimidazole, which shares a similar boiling point.
To avoid this issue, the reaction was quenched with an aqueous
workup prior to isolation.13 N-Methoxy-N-methylcyanoforma-
mide is a colorless oil after distillation (bp 81−84 °C, 19
mmHg) and should be stored under an inert atmosphere.
While we did not notice appreciable degeneration of the
reagent after storage in a Schlenk ﬂask under inert, anhydrous
conditions for 2 months at room temperature, we recommend
storage below 0 °C. Care must be taken to avoid exposure to 4,
especially via inhalation and skin contact, and it should be
treated as highly toxic, as the reagent decomposes slowly in
water/moist air, presumably to liberate HCN, CO2, and N,O-
dimethylhydroxylamine, the last of which can react slowly with
4 to form the symmetrical urea 1.14
With an eﬃcient synthesis of 4 in hand, we initiated a
comparison study of this reagent with the recently reported N-
methoxy-N-methylcarbamoylpyrrole (3)5 and imidazole re-
agent 7 in regard to their ability to react with lithium enolates
to directly synthesize β-keto Weinreb amides (Table 1). All of
the carbamoylating reagents were successful in converting 6-
methoxy-1-tetralone to 9a (entry 1), but the reactions involving
reagents 3 and 7 both required extended reaction times and
warming to room temperature. In contrast, reactions with 4
were complete within 15 min at −78 °C. In the case of
hindered ketones (entries 2 and 3) only cyanoformamide 4
eﬃciently formed the product Weinreb amides (9b and 9c) in
high yields.15
We next turned to an investigation of the substrate scope of
cyanoformamide 4 for the formation of β-carbonyl Weinreb
amides. We subjected the reagent to a variety of lithium
enolates (Scheme 3) and discovered that enones (8c−f), aryl
ketones and lactones (8a, 8g, 8h, 8i, and 8l), and saturated
cyclic and aliphatic ketones (8j and 8k) were all suitable
substrates.16 These compounds all underwent clean and
eﬃcient reactions to aﬀord the product β-carbonylamides in
excellent yields at low temperature. Surprisingly, the major
product derived from the reaction of 4 with cyclohexanone, 9j,
was initially found to be the cyanohydrin−product adduct.
However, it was discovered that the cyanohydrin could be easily
transformed directly into the required β-keto Weinreb amide
simply by quenching the reaction with aqueous NaOH and
stirring at room temperature for 1 h. Unfortunately, under our
standard conditions the quaternary products 9l and 9m were
not observed. In the case of 9l, deprotonation at 0 °C and
addition of 4 at −78 °C allowed eﬃcient product formation.
Under our standard conditions, 9m was not observed, but
instead, only the O-carbamoylated product was isolated.
Extended reaction times at higher temperatures (−40 to 18
°C) resulted in complex reaction mixtures. To alleviate this
problem, the reaction was conducted in diethyl ether with the
addition of HMPA, which provided good yields of the
quaternary product 9m. The less toxic additive DMPU gave
similar results.
We next investigated the ability of 4 to act as a general means
to install the Weinreb amide functionality through reaction with
various organometallic species. Lithiated species (Table 2,
entries 1−3) were highly reactive toward 4 and selective for the
single one-carbon-homologated Weinreb amide addition
products (10a−c). No reaction of 4 with Grignard reagents
was observed at −78 °C in THF; however, when the reaction
was conducted at 0 °C and with 1 equiv of nucleophile, only
the single-addition products (10a, 10d, and 10e) were observed
(entries 4−6). Surprisingly, and in contrast with reagent 3,5 the
reaction of sp2-hybridized Grignard reagents with reagent 4
allowed the selective formation of the monoaddition products
(10d and 10e).
We predicted that 4 could act as a carbonyl dication
synthon3a,5 in the one-pot formation of unsymmetrical ketones,
hence, we subjected 4 to various organometallics in a sequential
Scheme 2. Synthesis of N-Methoxy-N-
methylcyanoformamide (4)
Table 1. Screening of N-Methoxy-N-methylcarbamoyl
Reagents 3, 4, and 7 with Lithium Enolates
aReaction conditions: 8 (1.0 mmol), LiHMDS (1.1 mmol), THF, −78
°C, 1 h, then 3 or 7 (1.1 mmol), −78 °C → 18 °C, 20 h. bReaction
conditions: 8 (1.0 mmol), LiHMDS (1.1 mmol), THF, −78 °C, 1 h,
then 4 (1.1 mmol), −78 °C, 0.25 h.
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manner (Table 2, entries 7−9). In all three cases we obtained
excellent yields of the desired ketones (10f−h) regardless of the
nature of the ﬁrst or second nucleophile (i.e., Grignard or
organolithium).5
In summary, we have reported a very useful reagent for the
preparation of β-carbonyl Weinreb amides from their respective
lithium enolates in excellent yields. N-Methoxy-N-methylcya-
noformamide can also be exposed to reactive organometallic
species to aﬀord one-carbon-homologated Weinreb amides or
used as a carbonyl dication synthon to prepare unsymmetrical
ketones in a highly selective manner. Because of the versatility
and reliability of this reagent, it should serve as a useful addition
to the synthetic chemist’s toolbox.
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Scheme 3. Scope of Lithium Enolate Addition to
Cyanoformamide 4
aReaction conditions: 8l (1.0 mmol), LiHMDS (1.1 mmol), THF, 0
°C, 0.5 h, then 4 (1.1 mmol), −78 °C → −40 °C, 0.5 h. bReaction
conditions: 8m (1.0 mmol), LDA (1.1 mmol), Et2O, −78 °C, 1 h, then
0 °C for 0.25 h, −78 °C, 4 (1.1 mmol), then HMPA (1.0 mmol), −78
°C, 0.5 h.
Table 2. Scope of N,O-Dimethylcarbamoylation and
Unsymmetrical Ketone Synthesis
aIsolated yields. For reaction conditions, refer to the Supporting
Information.
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General Experimental Procedures 
Unless otherwise specified, proton (1H) and carbon (13C) NMR spectra were recorded at 18 °C in 
base-filtered CDCl3 on a Varian spectrometer operating at 400 or 500 MHz for proton and 100 or 125 
MHz for carbon nuclei. For 1H NMR spectra, signals arising from the residual protio-forms of the 
solvent were used as the internal standards. 1H NMR data are recorded as follows: chemical shift (d) 
[multiplicity, coupling constant(s) J (Hz), relative integral] where multiplicity is defined as: s = 
singlet; d = doublet; t = triplet; q = quartet; m = multiplet; b = broad or combinations of the above. 
The signal due to residual CHCl3 appearing at δH 7.26 and the central resonance of the CDCl3 “triplet” 
appearing at δC 77.0 were used to reference 1H and 13C NMR spectra, respectively. Low-resolution 
ESI mass spectra were recorded on a single quadrupole liquid chromatograph-mass spectrometer, 
while high-resolution measurements were conducted on a time-of-flight instrument. Low- and high-
resolution EI mass spectra were recorded on a magnetic-sector machine. Melting points were 
measured on an automated melting point system and are uncorrected. Analytical thin layer 
chromatography (TLC) was performed on aluminum-backed 0.2 mm thick silica gel 60 F254 plates. 
Eluted plates were visualized using a 254 nm UV lamp and/or by treatment with a suitable dip 
followed by heating. These dips included phosphomolybdic acid : ceric sulfate : sulfuric acid (conc.) : 
water (37.5 g : 7.5 g : 37.5 g : 720 mL) or potassium permanganate : potassium carbonate : 5% 
sodium hydroxide aqueous solution : water (3 g : 20 g: 5 mL : 300 mL). Flash chromatographic 
separations were carried out following protocols defined by Still et al.1 with silica gel 60 (40-63 mm) 
as the stationary phase and using the AR- or HPLC-grade solvents indicated. Tetrahydrofuran (THF), 
methanol and dichloromethane (DCM) were dried using a Glass Contour solvent purification system 
that is based upon a technology originally described by Grubbs et al.1 Where necessary, reactions 
were performed under a nitrogen atmosphere. 
Specific Experimental Procedures and Product Characterization 
N-Methoxy-N-methylcarbamoyl imidazole 7. 
 
A magnetically stirred solution of N,O-dimethylhydroxylamine hydrochloride (20.0 g, 205 mmol), ice 
(100 g) and NaHCO3 (100 mL of a saturated aqueous solution) in water (100 mL) in a 1L conical 
flask was maintained at 0 °C (ice/water) then treated, portionwise over a period of 2 minutes, with 
N,N′-carbonyldiimidazole (43.2 g, 267 mmol). The resultant mixture was maintained at 0 °C for 0.33 
h then extracted with DCM (4 × 50 mL). The combined organic phases were washed with brine (25 
mL) then dried (Na2SO4), filtered, and concentrated in vacuo to give compound 7 (29.6 g, 93%) as a 
pale yellow oil which was then held under high vacuum (1 mmHg, 18 ºC) for 5 h and used without 
further purification. 
1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.56 (t, J = 1.4 Hz, 1H), 7.05 (s, 1H), 3.68 (s, 3H), 3.38 
(s, 3H). 
Spectra were consistent with those previously reported.2 
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N-Methoxy-N-methylcyanoformamide 4. Preparation at 0 - 18 °C / 18 hours 
 
 
This reaction should be carried out in a well maintained and fully functioning fume-hood, wearing 
appropriate personal protective equipment. Magnetically stirred N-methoxy-N-
methylcarbamoylimidazole 7 (15.5 g, 100 mmol) at 0 °C (ice/water bath) was treated dropwise via a 
pressure equalising dropping addition funnel, under an atmosphere of nitrogen, with trimethylsilyl 
cyanide (13.1 mL, 105 mmol CAUTION!). The cold bath was removed and replaced with an empty 
glass evaporating dish and the reaction stirred for 18 h. The solution was then poured onto a mixture 
of aqueous sodium bicarbonate (50 mL satd. solution) and ice (50 g), stirred for 0.10 h and then 
extracted with DCM (5 × 20 mL). The combined organic layers were washed with brine (20 mL), 
dried (Na2SO4) and concentrated by rotary evaporation (415 mmHg, water bath at 35 °C) and then the 
residue was dissolved in ether (20 mL) and loaded onto a pad of silica (55 g, pre-wetted with ether), in 
a sintered vacuum funnel (60 mm I.D.) and washed through with ether (~400 mL, monitored by TLC 
analysis). The ethereal solution was then concentrated by rotary evaporation (415 mmHg, water bath 
at 35 °C), then held at 10 mmHg at 18 °C for 0.5 h to afford N-methoxy-N-methylcyanoformamide 4 
as a pale yellow, clear, free flowing oil (10.6 g, 93%) and can be used without further purification to 
undertake the described transformations. A portion of the product (4.36 g) was distilled by short-path 
(b.p. 81-84 °C, 19 mmHg) to afford 4 (3.61 g, 83%) as a colorless oil (m.p. 8-11 °C). Distillation 
typically leads to approximately 5% impurity of the symmetrical urea, 1,3-dimethoxy-1,3-
dimethylurea. 
1H NMR (CDCl3, 400 MHz) δ 3.89 (s, 3H), 3.28 (s, 3H).  
13C NMR (CDCl3, 100 MHz) δ 144.1, 110.0, 63.2, 32.3. 
1H NMR (C6D6, 400 MHz) δ 2.92 (s, 3H), 2.38 (s, 3H). 
13C NMR (C6D6, 100 MHz) δ 144.3, 110.9, 62.4, 31.4. 
MS (EI): m/z (%) 114 (M+•, 47%), 99 (9), 88 (18), 84 (68), 83 (19), 71 (19), 60 (77), 57 (31), 54 
(100). 
HRMS (EI) m/z M+• calcd for [C4H6N2O2]+•: 114.0424; found, 114.0430.   
IR (KBr) νmax 2946, 2238 1687, 1460, 1395, 1199, 987, 710 cm-1. 
 
N-Methoxy-N-methylcyanoformamide 4. Preparation at 100 °C / 10 minutes 
This reaction should be carried out in a well maintained and fully functioning fume-hood, wearing 
appropriate personal protective equipment. Magnetically stirred N-methoxy-N-methyl carbamoyl 
imidazole 7 (15.5 g, 100 mmol) in a two necked round-bottomed flask (free from any scratches or 
imperfections) at 0 °C (ice/water bath) fitted with dry ice / acetone condenser, was treated dropwise 
via a pressure equalising dropping addition funnel, under an atmosphere of nitrogen, with 
trimethylsilyl cyanide (13.2 mL, 105 mmol CAUTION!). The cold bath was removed and replaced 
with an oil bath and heated to 100 °C and maintained, with stirring at this temperature for 0.2 h. The 
mixture was cooled to 0 °C and the reaction worked up as above for the preparation at room 
temperature (10.5 g, 92%). 
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N-Methoxy-N-methyl cyanoformamide 4. Preparation from N-methoxy-N-methylcarbamoyl chloride 
2. 
Following a procedure analogous to that used by Weber3 for isobutyl cyanoformate: A magnetically 
stirred solution of N-methoxy-N-methylcarbamoyl chloride4 (9.40 g, 76.1 mmol) in DCM (40 mL) at 
0 °C (ice/water bath) under an atmosphere of nitrogen was treated with potassium cyanide (5.45 g, 
84.0 mmol, CAUTION!) portion-wise over 1 minute followed by 18-crown-6 (100 mg). The reaction 
was warmed to 18 °C over 48 h and then the mixture was vacuum filtered through a 1 cm pad of sand 
and concentrated by distillation at atmospheric pressure. The crude oil was then distilled through a 10 
cm vigreux (b.p. 81-84 °C, 19 mmHg) to afford 4 (4.77 g, 55%) as a colorless oil. 
β-Keto-Weinreb amide 6 
 
A magnetically stirred solution of ketone 55 (200 mg, 0.72 mmol) in dry THF (5 mL) was cooled to 
−78 °C then treated dropwise with LiHMDS [generated from n-butyllithium (675 µL of a 1.6 M 
solution in hexanes, 1.08 mmol) and hexamethyldisilazane (233 µL, 1.11 mmol) in THF (10 mL)] . 
The resulting mixture was maintained at this temperature for 0.5 h then warmed to to 0 °C for 0.08 h 
then recooled to −78 °C and treated with 4 (106 mg, 0.94 mmol). After 0.5 h at −78 °C the mixture 
was treated with NaHCO3 (5 mL of a saturated aqueous solution) and extracted with DCM (3 × 10 
mL). The combined organic phases were washed with brine (1 × 5 mL) then dried (MgSO4), filtered, 
and concentrated under reduced pressure. The residue thus obtained was subjected to flash 
chromatography (silica, 4:1 to 1:1 v/v hexane/ethyl acetate) to afford, after concentration of the 
appropriate fractions compound 6 (205 mg, 78%) as a colorless oil. 
 
1H NMR (CDCl3, 400 MHz) δ 4.81 (dd, J = 7.9, 3.7 Hz, 1H), 4.06 (d, J = 7.9 Hz, 1H), 3.84 (m, 1H), 
3.72 (s, 3H), 3.18 (s, 3H), 2.98 (dddd, J = 11.8, 10.2, 8.5, 2.9 Hz, 1H), 2.63 (td, J = 11.8, 7.9 Hz, 1H), 
2.54 (ddd, J = 6.2, 2.2, 2.2 Hz, 1H), 1.60 (ddd, J = 12.6, 8.5, 2.2 Hz, 1H), 1.52 (s, 3H), 1.46 (ddd, J = 
12.6, 7.9, 2.1 Hz, 1H), 1.35 (s, 3H), 1.27 – 1.16 (m, 1H), 1.05 (s, 3H), 1.04 (s, 3H), 0.96 (s, 3H), 0.70 
(dd, J = 12.6 Hz, 1H) 
13C NMR (CDCl3, 100 MHz) δ 210.3, 170.0, 109.6, 76.8, 73.3, 61.3, 53.0, 48.1, 43.6, 42.5, 38.1 (2C), 
37.5, 31.7, 30.9, 28.6, 27.0, 25.5, 24.0, 15.2. 
MS (EI): m/z (%)  365 (M+•, 3), 350 (22), 279 (100), 219 (60), 218 (55), 217 (45), 161 (38). 
HRMS (EI) m/z M+• calcd for [C20H31NO5]+•: 365.2197; found, 365.2194;   
IR (KBr) νmax 2942, 1733, 1660, 1382, 1208. 1065, 1001, 886. 
 
General procedure for enolisation with LiHMDS and addition of 4: 
 
A magnetically stirred solution of the appropriate ketone or ester (1.0 mmol) in dry THF (5 mL) was 
cooled to −78 °C then treated with LiHMDS (1.10 mL of a 1 M solution in THF, 1.10 mmol). The 
resultant mixture was maintained at this temperature for 1 h then treated with cyanoformamide 4 (125 
mg, 1.10 mmol). After 15 minutes at −78 °C the reaction was treated with NaHCO3 (5 mL of a 
saturated aqueous solution) and extracted with Et2O (3 × 5 mL). The combined organic phases were 
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washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated under reduced pressure. 
The residue thus obtained was subjected to flash chromatography (silica) to afford, after concentration 
of the appropriate fractions, the required Weinreb amide. 
 
 
β-Keto-Weinreb amide 9a 
 
 
Compound 9a was prepared from 6-methoxy-1-tetralone according to the general procedure. Purified 
by flash chromatography (silica, 1:1 hexane/EtOAc) to afford 9a (227 mg, 86%) as a white solid, mp. 
95 – 100 ºC. 
 
1H NMR (CDCl3, 400 MHz) δ 8.01 (d, J = 8.7 Hz, 1H), 6.83 (dd, J = 8.7, 2.6 Hz, 1H), 6.70 (d, J = 
2.6 Hz, 1H), 4.06 (dd, J = 11.4, 3.0 Hz, 1H), 3.86 (s, 3H), 3.74 (s, 3H), 3.29 (s, 3H), 3.06 – 2.97 (m, 
2H), 2.51 (m, 1H), 2.24 (m, 1H). 
13C NMR (CDCl3, 100 MHz) δ 193.1, 171.4, 163.8, 146.4, 130.1, 125.8, 113.3, 112.5, 61.4, 55.4, 
50.9, 32.0, 28.7, 26.2. 
MS (+LRESI) m/z (%) 264 (30) [M+H]+, 286 (100) [M+Na]+ 
HRMS (+ESI) m/z [M+Na]+ calcd for [C14H17NNaO4]+: 286.1050; found, 286.1048;    
IR (KBr) νmax 1667, 1643, 1596, 1423, 1356, 1251, 1237, 987, 814 cm-1. 
 
β-Keto-Weinreb amide 9b 
 
Compound 9b was prepared from (1R)-(+)-camphor according to the general procedure. Purified by 
flash chromatography (silica, 3:1 hexane/EtOAc) to afford 9b (208 mg, 87%, dr 95:5) as a colorless 
oil. 
 
1H NMR (CDCl3, 400 MHz) δ 3.70 (s, 3H), 3.60 (d, J = 3.0 Hz, 1H), 3.18 (s, 3H), 2.38 (dd, J = 4.4, 
4.4 Hz, 1H), 1.84 – 1.75 (complex m, 1H), 1.69 – 1.55 (complex m, 3H), 1.00 (s, 3H), 0.93 (s, 3H), 
0.89 (s, 3H). 
13C NMR (CDCl3, 100 MHz) δ 213.1, 170.7, 61.5, 58.4, 53.7, 47.0, 46.0, 32.0, 29.4, 22.2, 19.6, 18.9, 
9.6. 
MS (+LRESI) m/z (%) 262 (100) [M+Na]+, 501 (30) [2M+Na]+ 
HRMS (+ESI) m/z [M+Na]+ calcd for [C13H21NNaO3]+: 262.1414; found, 262.1411;    
IR (KBr) νmax 2963m 1750, 1656, 1447, 1379, 1176, 1102, 730 cm-1. 
[α]D = + 76.7 (c 0.6, CDCl3)  
 
β-Keto-Weinreb amide 9c 
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Compound 9c was prepared from (S)-(+)-carvone according to the general procedure. Purified by 
flash chromatography (silica, 1:1 hexane/EtOAc) to afford 9c (197 mg, 83%, dr >99:1) as a pale 
yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 6.78 (m, 1H), 4.81 (m, 2H), 4.10 (d, J = 12.9 Hz, 1H), 3.72 (s, 3H), 
3.32-3.20 (complex m, 4H), 2.51 (dt, J = 18.6, 5.4 Hz, 1H), 2.34 (m, 1H), 1.80 (dt, J = 2.6, 1.3 Hz, 
3H), 1.76 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 196.0, 170.8, 145.4, 144.6, 135.1, 112.0, 61.4, 54.0, 44.9, 32.0, 31.1, 
20.4, 15.8. 
MS (EI) m/z (%) = 237 (M+•, 3), 177 (60), 149 (100). 
HRMS (EI) m/z M+• calcd for C13H19NO3: 237.1365. Found: 237.1354. 
IR (KBr) νmax 2973, 2923, 1673, 1650, 1380 cm-1. 
[α]D = + 88.9 (c 1.0, CHCl3). 
 
β-Keto-Weinreb amide 9d 
 
 
Compound 9d was prepared from dihydrojasmone according to the general procedure. Purified by 
flash chromatography (silica, 1:1 hexane/EtOAc) to afford 9d (208 mg, 82%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 3.93 (m, 1H), 3.75 (s, 3H), 3.12 (s, 3H), 2.75 (d, J = 18.1 Hz, 1H), 
2.53 (dd, J = 18.1, 7.0 Hz, 1H), 2.05 (m, 2H), 1.98 (s, 3H), 1.26(m, 2H), 1.16 (m, 4H), 0.75 (t, J = 7.0 
Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 204.0, 170.7, 170.4, 139.0, 139.0, 61.8, 47.5, 32.1, 31.6, 27.8, 23.2, 
22.4, 17.1, 13.9. 
MS (EI): m/z (%) = 253 (M+•, 42), 193 (100), 149 (100). 
HRMS (EI) m/z M+• calcd for C14H23NO3: 253.1672. Found: 253.1671. 
IR (KBr) νmax 2951, 2930, 2856, 1700, 1659, 1640, 1383 cm-1. 
 
β-Keto-Weinreb amide 9e 
 
Compound 9e was prepared from (R)-(+)-pulegone according to double the scale of the general 
procedure. Purified by flash chromatography (silica, 4:1 hexane/EtOAc) to afford 9e (42 mg, 93%, dr 
95:5) as a colorless oil. 
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1H NMR (CDCl3, 500 MHz) δ 3.70 (s, 3H), 3.52 (d, J = 10.5 Hz, 1H), 3.27 (s, 3H), 2.72 (dt, J = 15.6, 
4.1 Hz, 1H), 2.48 – 2.38 (m, 1H), 2.33 (m, 1H), 1.99 (d, J = 1.4 Hz, 3H), 1.94 (ddt, J = 13.2, 4.6, 3.5 
Hz, 1H), 1.80 (s, 3H), 1.42 (qd, J = 12.6, 4.6 Hz, 1H), 0.99 (d, J = 6.4 Hz, 3H). 
13C NMR (CDCl3, 100 MHz) δ 199.6, 171.5, 144.0, 130.9, 61.5, 61.3, 33.9, 31.9, 31.7, 28.3, 23.1, 
22.3, 20.8. 
IR (KBr) νmax 2929, 1651, 1444, 1380, 1290, 1170, 974, 765 cm-1. 
[α]D = − 16.38 (c 1.7, CDCl3)  
 
β-Keto-Weinreb amide 9f 
 
Compound 9f was prepared from (+)-4-cholesten-3-one according to the general procedure. Purified 
by flash chromatography (silica, 1:10 hexane/EtOAc) to afford 9f (400 mg, 85%, dr 97:3) as a white 
solid, mp. 147 – 149 ºC. 
 
1H NMR (CDCl3, 400 MHz) δ 5.74 (d, J = 1.2 Hz, 1H), 4.00 (dd, J = 13.6, 2.8 Hz, 1H), 3.69 (s, 3H), 
3.26 (s, 3H), 2.36 (m, 1H), 2.27 (ddd, J = 14.6, 4.5, 2.5 Hz, 1H), 2.16 (dd, J = 13.9, 13.9 Hz, 1H), 
2.06 – 1.96 (complex m, 2H), 1.89 – 1.76 (complex m, 2H), 1.63 – 1.43 (complex m, 4H), 1.43 – 1.19 
(complex m, 5H), 1.22 (s, 3H), 1.18 – 0.94 (m, 10H), 0.89 (d, J = 6.5 Hz, 3H), 0.85 (d, J = 6.6 Hz, 
3H), 0.85 (d, J = 6.6 Hz, 3H), 0.69 (s, 3H). 
13C NMR (CDCl3, 100 MHz) δ 194.9, 171.4, 171.2, 123.1, 61.4, 55.9, 55.7, 53.9, 45.9, 42.3, 39.5, 
39.4, 38.7, 38.5, 36.1, 35.7, 35.5, 32.7, 32.0, 31.9, 28.1, 28.0, 24.1, 23.7, 22.8, 22.5, 20.8, 18.6, 17.7, 
11.9. 
MS (+LRESI) m/z (%) 472 (100) [M+H]+, 494 (50) [M+Na]+. 
HRMS (+ESI) m/z [M+Na]+ calcd for [C30H49NNaO3]+: 494.3605; found, 494.3604. 
IR (KBr) νmax 2934, 2866, 1668, 1651, 1451, 1384, 1173, 966 cm-1. 
[α]D = + 94.5 (c 1.0, CDCl3)  
 
β-Keto-Weinreb amide 9g 
 
 
Compound 9g was prepared from 3′,4′-dimethoxyacetophenone according to double the scale of the 
general procedure. Purified by flash chromatography (silica, 5:1 hexane/EtOAc) to afford 9g (356 mg, 
67%) as an 87:13 mixture of keto and enol tautomers as a cream solid, mp. 60 – 65 ºC. 
 
1H NMR (CDCl3, 500 MHz) Keto tautomer δ 7.60 (dd, J = 8.4, 2.0 Hz, 1H), 7.56 (d, J = 2.0 Hz, 1H), 
6.90 (d, J = 8.4 Hz, 1H), 4.09 (s, 2H), 3.95 (s, 3H), 3.93 (s, 3H), 3.68 (s, 3H), 3.24 (s, 3H). 
1H NMR (CDCl3, 500 MHz) Enol tautomer δ 7.42 (dd, J = 8.5, 2.1 Hz, 1H), 7.36 (d, J = 2.1 Hz, 1H), 
6.89 (d, J = 8.5 Hz, 1H), 6.00 (s, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.76 (s, 3H), 3.27 (s, 3H). 
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13C NMR (CDCl3, 125 MHz) 87:13 Mixture of keto and enol tautomers  δ 191.8, 172.8, 171.4, 168.6, 
153.6, 151.3, 149.0, 148.7, 129.5, 123.3, 119.3, 110.6, 110.3, 110.0, 109.0, 83.0, 61.2, 60.2, 55.9, 
55.9, 55.8, 44.0, 32.1. 
MS (+LRESI) m/z (%) 290 (100) [M+Na]+. 
HRMS (+ESI) m/z [M+Na]+ calcd for [C13H17NNaO5]+: 290.0933; found, 290.0999. 
IR (KBr) νmax 2972, 1667, 1634, 1584, 1512, 1417, 1321, 1268, 1152, 1025, 1008, 884, 796 cm-1. 
 
β-Keto-Weinreb amide 9h 
 
 
Compound 9h was prepared from 1-indanone according to the general procedure. Purified by flash 
chromatography (silica, 2:1 hexane/EtOAc) to afford 9h (182 mg, 83%) as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 
1H), 7.37 (t, J = 7.6 Hz, 1H), 4.29 (m, 1H), 3.83 (s, 3H), 3.45 (m, 1H), 3.33 (m, 1H), 3.27 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 201.4, 170.2, 154.1, 135.5, 135.0, 127.4, 126.4, 124.2, 61.6, 50.1, 
32.2, 30.6. 
MS (EI): m/z (%) = 219 (M+•, 33), 159 (100), 131 (80). 
HRMS (EI) m/z M+• calcd for C12H13NO3: 219.0890. Found: 219.0895. 
IR (KBr) νmax 2973, 2935, 1713, 1649 cm-1. 
 
β-Carbonyl-Weinreb amide 9i 
 
 
Compound 9i was prepared from 3,4-dihydrocoumarin according to the general procedure. Purified 
by flash chromatography (silica, 2:1 hexane/EtOAc) to afford 9i (204 mg, 87%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.28-7.19 (complex m, 2H), 7.10 (m, 1H), 7.04 (m, 1H), 4.18 (dd, J = 
12.9, 6.3 Hz, 1H), 3.72 (s, 3H), 3.27 (s, 3H), 3.49 (dd, J = 16.1, 12.9 Hz, 1H), 2.96 (dd, J = 16.1, 6.3 
Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 167.6, 165.6, 151.2, 128.3, 128.0, 124.6, 121.7, 116.5, 61.5, 42.2, 
32.1, 26.7. 
MS (EI): m/z (%) = 235 (M+•, 20), 175 (39), 147 (100). 
HRMS (EI) m/z M+• calcd for C12H13NO4: 235.0839. Found: 235.0846. 
IR (KBr) νmax 2976, 2943, 1760, 1659, 1138 cm-1. 
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β-Keto-Weinreb amide 9j 
 
 
Compound 9j was prepared from cyclohexanone according to the general procedure. Purified by flash 
chromatography (silica, 4:1 hexane/EtOAc) to afford 9j (140 mg, 76%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 3.79 (m, 1H), 3.64 (s, 3H), 3.23 (s, 3H), 2.53 (m, 1H), 2.37 (m, 1H), 
2.24-1.92 (complex m, 4H), 1.88-1.62 (complex m, 2H). 
13C NMR (100 MHz, CDCl3) δ 207.0, 170.8, 61.2, 53.7, 41.9, 32.0, 29.7, 27.2, 23.7. 
MS (EI): m/z (%) = 185 (M+•, 20), 125 (100). 
HRMS (EI) m/z M+• calcd for C9H15NO3: 185.1046. Found: 185.1055. 
IR (KBr) νmax 2939, 2865, 1711, 1653, 1385 cm-1. 
 
β-Keto-Weinreb amide 9k 
 
 
Compound 9k was prepared according to the general procedure. Purified by flash chromatography 
(silica, 4:1 hexane/EtOAc) to afford 9k (130 mg, 77%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 3.75 (m, 1H), 3.66 (s, 3H), 3.20 (s, 3H), 2.50 (m, 2H), 1.33 (d, J = 7.2 
Hz, 3H), 1.05 (t, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 207.1, 171.9, 61.1, 49.8, 33.6, 32.4, 13.1, 7.5. 
MS (EI): m/z (%) = 173 (M+•, 3), 113 (42). 
HRMS (EI) m/z M+• calcd for C8H15NO3: 173.1046. Found: 173.1048. 
IR (KBr) νmax 2980, 2941, 1719, 1661, 1460, 1381 cm-1. 
 
β-Keto-Weinreb amide 9l 
 
 
A magnetically stirred solution of 3-methylchroman-2-one (168 mg, 1.0 mmol) in dry THF (5 mL) 
was cooled to 0 °C then treated with LiHMDS (1.1 mL of a 1 M solution in THF, 1.1 mmol). The 
resulting mixture was maintained at this temperature for 0.5 h then cooled to −78 °C and treated with 
cyanoformamide 4 (125 mg, 1.1 mmol). After 0.1 h at −78 °C the mixture was warmed to −40 °C and 
maintained at this temperature for 0.5 h before being treated with NaHCO3 (5 mL of a saturated 
aqueous solution) and extracted with diethyl ether (3 × 10 mL). The combined organic phases were 
washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated under reduced pressure. 
The residue thus obtained was subjected to flash chromatography (silica, 4:1 v/v hexane/ethyl acetate) 
221
S10 
 
to afford, after concentration of the appropriate fractions compound 9l (230 mg, 92%) as a pale yellow 
oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.23 (m, 1H), 7.18 (m, 1H), 7.08 (m, 1H), 7.03 (m, 1H), 3.64 (s, 3H), 
3.56 (d, J = 15.6 Hz, 1H), 3.12 (s, 3H), 2.78 (d, J = 15.6 Hz, 1H), 1.56 (m, 3H). 
13C NMR (100 MHz, CDCl3) δ 170.6, 168.9, 151.1, 128.4, 128.2, 124.5, 121.4, 116.2, 60.4, 47.9, 
35.0, 33.0, 21.6. 
MS (EI): m/z (%) = 249 (M+•, 20), 234 (39), 161 (100). 
HRMS (EI) m/z M+• calcd for C13H15NO4: 249.1001. Found: 249.1003. 
IR (KBr) νmax 2985, 2939, 1759, 1655, 1457, 1231 cm-1. 
 
β-Keto-Weinreb amide 9m 
 
 
A magnetically stirred solution of 6-methoxy-2-methyl-1-tetralone (190 mg, 1.00 mmol) in dry ether 
(3 mL) was cooled to −78 °C then treated dropwise with lithium diisopropylamide (1.29 mL, 1.05 
mmol, 0.81 M solution in ether [generated from n-butyllithium (7.00 mL of a 1.5 M solution in 
hexanes) and diisopropylamine (1.60 mL, 11.5 mmol) in ether (4.3 mL)]. The resulting mixture was 
maintained at this temperature for 1 h then warmed to 0 °C for 0.25 h then recooled to −78 °C and 
treated with 4 (125 mg, 1.10 mmol) followed by hexamethylphosphoramide (HMPA) (179 µL, 1.00 
mmol) After 0.5 h at −78 °C the mixture was treated with NaHCO3 (5 mL of a saturated aqueous 
solution) and extracted with DCM (3 × 10 mL). The combined organic phases were washed with 
lithium chloride (10 mL, 5% w/v), brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated 
under reduced pressure. The residue thus obtained was subjected to flash chromatography (silica, 4:1 
v/v hexane/ethyl acetate) to afford, after concentration of the appropriate fractions compound 9m (174 
mg, 63%) as white crystals, m.p. 89 – 92 ºC. The reaction was carried out in duplicate with 1,3-
dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) (250 µL) in place of HMPA to afford 9m 
(173 mg, 63%) as white crystals, m.p. 89 – 92 ºC. 
 
1H NMR (CDCl3, 400 MHz) δ 7.96 (d, J = 8.7 Hz, 1H), 6.79 (dd, J = 8.7, 2.5 Hz, 1H), 6.64 (d, J = 
2.5 Hz, 1H), 3.81 (s, 3H), 3.29 (s, 3H), 3.12 (s, 3H), 2.96 (ddd, J = 16.6, 11.6, 4.8 Hz, 1H), 2.81 (ddd, 
J = 16.6, 4.6, 4.6 Hz, 1H), 2.54 (ddd, J = 13.0, 11.6, 4.8 Hz, 1H), 1.81 (dt, J = 13.0, 4.6 Hz, 1H), 1.41 
(s, 3H). 
13C NMR (CDCl3, 100 MHz) δ 194.3, 174.3, 163.3, 144.8, 129.8, 125.1, 113.3, 112.2, 59.0, 55.3, 
52.7, 32.7, 31.9, 25.7, 20.1. 
MS (EI): m/z (%)  277 (M+•, 8), 217 (9), 189 (30), 161 (100), 91 (10). 
HRMS (EI) m/z M+• calcd for [C15H19NO4]+•: 277.1309; found, 277.1316;   
IR (KBr) νmax 1653, 1598, 1457, 1374, 1346, 1262, 1230, 1093, 999, 858 cm-1. 
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Weinreb amide 10a – Prepared from lithium phenyl acetylide 
 
 
A magnetically stirred solution of phenyl acetylene (102 mg, 1.0 mmol) in dry THF (5 mL) was 
cooled to −78 °C then treated with LiHMDS (1.1 mL of a 1M solution in THF, 1.1 mmol). The 
resulting mixture was maintained at this temperature for 20 minutes then treated with 
cyanoformamide 4 (125 mg, 1.1 mmol). The resulting mixture was maintained at −78 °C for 15 
minutes then treated with NaHCO3 (5 mL of a saturated aqueous solution) and extracted with diethyl 
ether (3 × 10 mL). The combined organic phases were washed with brine (1 × 5 mL) then dried 
(MgSO4), filtered, and concentrated under reduced pressure. The residue thus obtained was subjected 
to flash chromatography (silica, 4:1 v/v hexane/ethyl acetate) to afford, after concentration of the 
appropriate fractions compound 10a (174 mg, 92%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.1 Hz, 2H), 7.43 (m, 1H), 7.37 (m, 2H), 3.84 (s, 3H), 3.29 
(br m, 3H). 
 
All spectra were consistent with those previously reported.6 
 
Weinreb amide 10a – Prepared from magnesium phenyl acetylide 
 
 
A magnetically stirred solution of phenyl acetylene (102 mg, 1.0 mmol) in dry THF (5 mL) was 
cooled to 0 °C then treated with MeMgBr (0.33 mL of a 3M solution in Et2O, 1.1 mmol). The 
resulting mixture was maintained at this temperature for 1 h then treated with cyanoformamide 4 (125 
mg, 1.1 mmol). After 0.25 h at 0 °C the reaction was treated with NaHCO3 (5 mL of a saturated 
aqueous solution) and extracted with diethyl ether (3  10 mL). The combined organic phases were 
washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated under reduced pressure. 
The residue thus obtained was subjected to flash chromatography (silica, 4:1 v/v hexane/ethyl acetate) 
to afford, after concentration of the appropriate fractions compound 10a (144 mg, 76%) as a pale 
yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.1 Hz, 2H), 7.43 (m, 1H), 7.37 (m, 2H), 3.84 (s, 3H), 3.29 
(br m, 3H). 
 
All spectra were consistent with those previously reported.6 
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Weinreb amide 10b 
 
 
A magnetically stirred solution of 2-bromopyridine (158 mg, 1.0 mmol) in dry THF (5 mL) was 
cooled to −78 °C then treated with n-butyllithium (0.8 mL of a 1.45 M solution in hexanes, 1.1 
mmol). The resulting solution was stirred at −78 °C for 1 hour then treated with cyanoformamide 4 
(125 mg, 1.1 mmol) and warmed to 0 °C over 20 minutes. The reaction was treated with NaHCO3 (5 
mL of a saturated aqueous solution) and extracted with diethyl ether (3 × 10 mL). The combined 
organic phases were washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated 
under reduced pressure. The residue thus obtained was subjected to flash chromatography (silica, 1:1 
v/v hexane/ethyl acetate) to afford, after concentration of the appropriate fractions compound 10b 
(125 mg, 75%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 4.8 Hz, 1H), 7.78 (td, J = 7.7, 1.7 Hz, 1H), 7.66 (broad s, 
1H), 7.35 (dd, J = 7.7, 4.8 Hz, 1H), 3.75 (s, 3H), 3.40 (s, 3H). 
 
All spectra were consistent with those previously reported.7 
 
Weinreb amide 10c 
 
A magnetically stirred solution of tert-butyl(ethynyl)dimethylsilane (228 mg, 2.0 mmol) in dry THF 
(8 mL) was cooled to −78 °C then treated with n-Butyl lithium (1.0 mL of a 2.05 M solution in 
hexanes, 2.05 mmol). The resulting mixture was maintained at this temperature for 0.25 h then treated 
with cyanoformamide 4 (228 mg, 2.0 mmol). The resulting mixture was maintained at −78 °C for 0.1 
h then treated with NaHCO3 (5 mL of a saturated aqueous solution) and extracted with diethyl ether (3 
× 5 mL). The combined organic phases were washed with brine (1 × 5 mL) then dried (MgSO4), 
filtered, and concentrated under reduced pressure. The residue thus obtained was subjected to flash 
chromatography (silica, 4:1 v/v hexane/ethyl acetate) to afford, after concentration of the appropriate 
fractions compound 10c (399 mg, 88%) as a colorless oil. 
 
1H NMR (CDCl3, 500 MHz) δ 3.77 (s, 3H), 3.23 (s, 3H), 0.98 (s, 9H), 0.19 (s, 6H). 
13C NMR (CDCl3, 125 MHz) δ 153.7, 109.9, 95.8, 62.0, 32.2, 25.9 (3C), 16.4, -5.3 (2C). 
MS (+LRESI) m/z (%) 228 (100) [M+H]+. 
HRMS (+ESI) m/z [M+Na]+ calcd for [C11H21NNaO2Si]+: 250.1234; found, 250.1236. 
IR (KBr) νmax 2955, 2932, 1647, 1472, 1463, 1410, 1381, 1252, 1118, 1007, 940, 842, 828, 779, 724 
cm-1.  
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Weinreb amide 10d 
 
 
A magnetically stirred solution of cyanoformamide 4 (125 mg, 1.1 mmol) in dry THF (5 mL) at 0 °C 
was treated, dropwise, with a solution of phenylmagnesium bromide (1.0 mL of a 1M solution in THF, 
1.0 mmol). The resulting mixture was maintained at this temperature for 15 minutes then treated with 
NaHCO3 (5 mL of a saturated aqueous solution) and extracted with diethyl ether (3 × 10 mL). The 
combined organic phases were washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and 
concentrated under reduced pressure. The residue thus obtained was subjected to flash 
chromatography (silica, 4:1 v/v hexane/ethyl acetate) to afford, after concentration of the appropriate 
fractions compound 10d (152 mg, 92%) as a pale yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.67 (m, 2H), 7.41 (m, 3H), 3.55 (s, 3H), 3.36 (s, 3H). 
All spectra were consistent with those previously reported.8 
 
Weinreb amide 10e 
 
 
A magnetically stirred solution of 4-bromoanisole (0.126 mL, 1.0 mmol), magnesium turnings (26 
mg, 1.0 mmol) and a crystal of iodine in dry THF (5 mL) was heated at 50 °C for 30 minutes. The 
resulting suspension was cooled to 0 °C and treated with cyanoformamide 4 (125 mg, 1.1 mmol). 
After 15 minutes at this temperature the mixture was treated with NaHCO3 (5 mL of a saturated 
aqueous solution) and extracted with diethyl ether (3 × 10 mL). The combined organic phases were 
washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated under reduced pressure. 
The residue thus obtained was subjected to flash chromatography (silica, 4:1 v/v hexane/ethyl acetate) 
to afford, after concentration of the appropriate fractions compound 10e (171 mg, 88%) as a pale 
yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 3.56 (s, 
3H), 3.35 (s, 3H). 
 
All spectra were consistent with those previously reported.88 
 
Ketone 10f 
 
 
A magnetically stirred solution of phenyl acetylene (102 mg, 1.0 mmol) in dry THF (5 mL) was 
cooled to −78 °C then treated with LiHMDS (1.1 mL of a 1M solution in THF, 1.1 mmol). The 
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resulting mixture was maintained at this temperature for 0.33 h then treated with cyanoformamide 4 
(125 mg, 1.1 mmol). The resulting mixture was maintained at −78 °C for 15 minutes then warmed to 
0 °C and treated with PhMgBr (1.5 mL of a 1M solution in THF, 1.5 mmol). The resulting mixture 
was maintained at this temperature for 30 minutes then treated with NaHCO3 (5 mL of a saturated 
aqueous solution) and extracted with diethyl ether (3 × 10 mL). The combined organic phases were 
washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated under reduced pressure. 
The residue thus obtained was subjected to flash chromatography (silica, 4:1 v/v hexane/ethyl acetate) 
to afford, after concentration of the appropriate fractions compound 10f (184 mg, 89%) as a pale 
yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 8.24 (m, 2H), 7.70 (m, 2H), 7.64 (m, 1H), 7.56 – 7.47 (complex m, 
3H), 7.43 (m, 2H). 
All spectra were consistent with those previously reported.9 
 
Ketone 10g 
 
 
A magnetically stirred solution of cyanoformamide 4 (125 mg, 1.1 mmol) in dry THF (5 mL) at 0 
°C was treated, dropwise, with a solution of phenylmagnesium bromide (1.0 mL of a 1M solution in 
THF, 1.0 mmol). The resulting mixture was maintained at this temperature for 0.25 h then cooled to 
−78 °C and treated with n-butyllithium (1 mL of a 1.5 M solution in hexanes, 1.5 mmol). The reaction 
was maintained at this temperature for 20 minutes then treated with NaHCO3 (5 mL of a saturated 
aqueous solution) and extracted with diethyl ether (3 × 10 mL). The combined organic phases were 
washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated under reduced pressure. 
The residue thus obtained was subjected to flash chromatography (silica, 4:1 v/v hexane/ethyl acetate) 
to afford, after concentration of the appropriate fractions compound 10g (140 mg, 86%) as a pale 
yellow oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.96 (m, 2H), 7.55 (m, 1H), 7.46 (m, 2H), 2.97 (dd, J = 7.4 Hz, 2H), 
1.73 (m, 2H), 1.42 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 
 
All spectra were consistent with those previously reported.10 
 
Ketone 10h 
 
 
A magnetically stirred solution of 2-bromopyridine (158 mg, 1.0 mmol) in dry THF (5 mL) was 
cooled to  ̶ 78 °C then treated with n-butyllithium (0.8 mL of a 1.45 M solution in hexanes, 1.1 mmol). 
The resulting solution was stirred at   ̶78 °C for 1 h then treated with cyanoformamide 4 (125 mg, 1.1 
mmol) and warmed to 0 °C over 0.33 h then treated with PhMgBr (1.5 mL of a 1M solution in THF, 
1.5 mmol). The reaction was maintained at this temperature for 20 minutes then treated with NaHCO3 
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(5 mL of a saturated aqueous solution) and extracted with diethyl ether (3 × 10 mL). The combined 
organic phases were washed with brine (1 × 5 mL) then dried (MgSO4), filtered, and concentrated 
under reduced pressure. The residue thus obtained was subjected to flash chromatography (silica, 4:1 
v/v hexane/ethyl acetate) to afford, after concentration of the appropriate fractions compound 10h 
(159 mg, 86%) as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.73 (dt, J = 4.8, 1.3 Hz, 1H), 8.06 (m, 3H), 7.91 (td, J = 7.7, 1.7 Hz, 
1H), 7.60 (m, 1H), 7.49 (m, 3H). 
 
All spectra were consistent with those previously reported.11 
 
Half-life determination experiment. 
 
An NMR tube was charged with cyanoformamide 4 (5 µL), acetonitrile (2 µL) and D2O (0.5 mL) 
and shaken vigorously for 30 seconds. The 1H NMR spectrum was recorded at regular intervals and 
the ratio of the NCH3 to CH3CN integral was recorded. The t1/2 was calculated to be 2344 minutes (39 
h). 
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Procedure 
 
Caution!  Trimethylsilyl cyanide is highly toxic and flammable. Ensure that 
trimethylsilyl cyanide is used only in a well ventilated fumehood with 
appropriate protective equipment.  
 
A. N-methoxy-N-methyl-1H-imidazole-1-carboxamide (1).  A 1-L conical 
flask open to the atmosphere is equipped  with a Teflon-coated , octagonal 
shaped  stir bar (51 × 8 mm) then charged  with N ,O-
d imethylhydroxylamine hydrochloride (20.0 g, 205 mmol, 1.0 equiv) 
(Note 1), ice (100 g), NaHCO
3
 (100 mL of a saturated  aqueous solution) 
and  water (100 mL, at 0-4 °C) (Figure 1). The reaction vessel is maintained  
at 0 °C in an ice-water bath then treated , portionwise over a period  of two 
minutes, with N ,N ′-carbonyld iimidazole (CDI) (43.2 g, 267 mmol) (Note 2) 
(Note 3). The resulting mixture is maintained  at 0 °C for 0.33 h then the 
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mixture is transferred  to a 500-mL separatory funnel and  extracted  with 
DCM (4 × 50 mL)(Note 4). The combined  organic phases are washed  with 
brine (1 × 40 mL), transferred  to a 500-mL conical flask then dried  over 
Na
2
SO
4 
(22 g). Half of the solution is gravity filtered , using a cotton wool 
plug in a glass funnel, into a 150-mL round-bottomed flask with 
concentration of the filtrate under reduced  pressure (40 °C, 430 mmHg, 
rotary evaporation). The above filtration and  concentration procedure is 
repeated  on the remaining half of the d ried  organic layer. The resulting 
pale-yellow colored  oil is then held  at high vacuum (0.5 mmHg, 18 ºC, 4 
h) with stirring, to remove traces of DCM to yield  N -methoxy-N -methyl-
1H-imid azole-1-carboxamide (1) (28.0-29.6 g, 88-93% yield  at 98.8% 
purity) as a lemon-gold  colored  oil that is used  without further 
purification (Note 5). 
 
 
 
Figure 1.  (i) Setup for procedure A; (ii) release of CO
2
 during final stages of 
addition of CDI; (iii) separation of layers; (iv) product 1 after rotary 
evaporation. 
B. N-methoxy-N-methylcyanoformamide (2). A flame-dried  50-mL 
single-necked , round-bottomed flask equipped  with a Teflon-coated , egg-
shaped  stir bar (10 × 19 mm) is fitted  with 25-mL pressure-equalising 
dropping addition funnel fitted  with a glass gas inlet adapter which is 
connected  to a nitrogen-vacuum d ouble manifold  (Figure 2). The flask is 
charged  with a portion of N -methoxy-N -methyl-1H-imid azole-1-
carboxamide (1, 15.5 g, 100 mmol) prepared  as described  above then 
placed  under vacuum (1 mmHg) and  backfilled  with nitrogen three times. 
The reaction vessel is cooled  to 0 °C and  the pressure equalising dropping 
addition funnel charged  with trimethylsilyl cyanide (13.1 mL, 105 mmol 
CAUTION!) (Note 6). Trimethylsilyl cyanide is then added  to the flask 
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dropwise over 5 min. When the add ition is complete the reaction vessel is  
warmed to room temperature (18 °C) and  stirred  at this temperature for 
24 h. The reaction mixture is then poured  into a 250-mL conical flask 
equipped  with a Teflon-coated , octagonal shaped  stir bar (51 × 8 mm) 
then charged  with NaHCO
3
 (50 mL satd . aqueous solu tion) and  ice (50 g). 
The resulting mixture is stirred  for 0.10 h then extracted  with DCM (5 × 20 
mL)(Note 4). The combined  organic layers are washed  with brine (1 × 20 
mL), d ried  over anhydrous Na
2
SO
4 
(22 g), and  the filtrate concentrated by 
rotary evaporation (415 mmHg, 35 °C).  
 
Figure 2.  (i) Setup for procedure B before addition of TMSCN ; (ii) 24 h 
after addition of TMSCN ; (iii) quenching of reaction with aqueous 
NaHCO
3
; (iv) TLC analysis of crude reaction mixture after 24 h (elution 
with diethyl ether): (1) N-methoxy-N-methylcyanoformamide (2) N-
methoxy-N-methyl-1H-imidazole-1-carboxamide.  
 
The residue is d issolved  in d iethyl ether (20 mL) (Note 7) and  the 
resulting solution loaded  onto a pad  of silica (55 g, pre-wetted  with 
d iethyl ether on top of 10 mm of sand )(Note 8) by p ipette in a sintered  
vacuum funnel (60 mm internal d iameter , 350 mL total volume, grade 1 
sinter) and  elu ted  through with d iethyl ether (400 mL) into a 500-mL 
round  bottom flask by gentle vacuum suction (~400 mmHg) and  
monitored  by TLC analysis (Note 9) (Figure 3). The ethereal solution is 
then concentrated  by rotary evaporation (415 mmHg, 35 °C) until 
approximately 25 mL of the original solution remained  then transferred  
by funnel to a 100-mL pear shaped  flask (for convenience). The solution is 
then concentrated  further by rotary evaporation and  then at the pump for 
4 h (10 mmHg, 18 °C) to remove traces of d iethyl ether to afford  N-
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methoxy-N-methylcyanoformamide 2 (9.4 - 10.6 g, 82 - 93% yield  at 96.2 % 
purity) as a pale-yellow, clear, free-flowing oil that can be used  without 
further purification (Note 10. Distillation (9.35 g) through a short-path 
d istillation bridge (Note 11) affords compound 2 as colourless free-
flowing liqu id  (8.60 g, 92% at 94.4% purity) (Note 12). 
 
Figure 3.  (i) Setup for purification of N-methoxy-N-
methylcyanoformamide (2); (ii) loading ; (iii) elution with diethyl ether; 
(iv) product after rotary evaporation. 
 
Notes 
1. N ,O-Dimethylhydroxylamine hydrochloride (99%) was purchased  
from AK Scientific and  used  as supplied . 
2. N ,N ′-Carbonyld iimid azole (CDI) (98%) was purchased  from AK 
Scientific and  used  as supplied . 
3. When all N ,O-d imethylhydroxylamine hydrochlorid e has reacted , 
add ition of excess N ,N ′-carbonyld iimid azole resu lts in carbon d ioxide 
evolution.  
4. Dichloromethane EMSURE®, ACS, 99.8% was purchased  from Merck 
and  used  as supplied . 
5. The reaction has been performed three times at th e scale described  
above by the submitters. On one of these occasions trace amounts 
(~4%) of imidazole was observed . Spectral d ata for (1) were consistent 
with those reported .
2
 
1
H NMR (400 MHz, CDCl
3
) δ 8.20 (s, 1H), 7.52 (t, 
J = 1.4 Hz, 1H), 7.00 (s, 1H), 3.63 (s, 3H), 3.34 (s, 3H); 
13
C NMR (100 
MHz, CDCl
3
) δ 149.2, 137.7, 129.3, 118.6, 77.0, 61.2, 34.4. 
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6. Trimethylsilyl cyanide (98%) was purchased  from Sigma-Aldrich and
used  as supplied .
7. Diethyl ether was purchased  from Honeywell (Burd ick and  Jackson
99.9%, preservative free) and  used  after purification through activated
alumina using a Glass Contour solvent purification system that is
based  upon a technology originally described  by Grubbs et al.
3
8. Silica (Davisil
®
, 40-63 µm) was purchased  from Grace and  used  as
supplied . Sand  (acid  washed , LR) was purchased  from UNILAB and
used  as supplied .
9. Only trace amounts of compound 2 were evident by TLC after elution
with 400 mL of d iethyl ether. Analysis using d iethyl ether elution and
staining with potassium permanganate solution, prod uct 2 R
f
 = 0.84.
10. Product 2 after purification through silica contained  approximately 1-
2% 1,3-d imethoxy-1,3-d imethylurea.
4
 Product 2 has the following
physical and  spectroscopic data: 1H NMR 97:3 mixture of rotamers (400
MHz, CDCl
3
) δ 3.89 (s, OCH
3
, major) & 3.76 (s, OCH
3
, minor), 3.47 (s,
NCH
3
, minor) 3.28 (s, NCH
3
, major); 
13
C NMR (100 MHz, CDCl
3
) δ
144.0, 110.0, 63.2, 32.2; MS (EI): m/z (%) 114 (M
+∙, 47%), 99 (9), 88 (18),
84 (68), 83 (19), 71 (19), 60 (77), 57 (31), 54 (100); HRMS (EI) m/z M
+•
calcd  for [C
4
H
6
N
2
O
2
]
+•
: 114.0424; found , 114.0430; IR (KBr) ν
max
 2946,
2238 1687, 1460, 1395, 1199, 987, 710 cm
−1
.
11. The d istillation is carried  out using a fractional short-path d istillation
bridge with a 5 cm Vigreux (see Figure 4). Vigorous magnetic stirring
is employed  throughout the duration of the d istillation and  a CO
2(s)
/ ethanol trap is in place between the Schlenk line and  the vacuum
pump. Chilled  water is circulated  through the condenser and  the
setup is evacuated  to 19 mmHg and  heating of the oil bath to 110 °C is
initiated . The first ~300 µL of d istillate is d iscarded  and  the fraction
boiling at 81-84 °C, 19 mmHg (25 mbar) is collected  into a 25-mL
Schlenk flask.
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Figure 4. Setup used by submitters for the distillation of compound 
2. 
12. Product 2 after d istillation contained  approximately 2% 1,3-
d imethoxy-1,3-d imethylurea. 
 
Working with Hazardous Chemicals 
 
The procedures in Organic Syntheses are intended  for use only by 
persons with proper training in experimental organic chemistry.  All 
hazardous materials should  be handled  using the standard  procedures for 
work with chemicals described  in references such as "Prudent Practices in 
the Laboratory" (The National Academies Press, Washington, D.C., 2011; 
the full text can be accessed  free of charge at 
http:/ / www.nap.edu/ catalog.php?record_id=12654).  All chemical waste 
should  be d isposed  of in accordance with local regulations.  For general 
guidelines for the management of chemical waste, see Chapter 8 of 
Prudent Practices.  
In some articles in Organic Syntheses, chemical-specific hazards are 
highlighted  in red  “Caution Notes” within a procedure.  It is important to 
recognize that the absence of a caution note does not imply that no 
significant hazards are associated  with the chemicals involved  in that 
procedure.  Prior to performing a reaction, a thorough risk assessment 
should  be carried  out that includes a review of the potential hazards 
associated  with each chemical and  experimental operation on the scale 
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that is planned  for the procedure.  Guidelines for carrying out a risk 
assessment and  for analyzing the hazards associated  with chemicals can 
be found  in Chapter 4 of Prudent Practices. 
The procedures described  in Organic Syntheses are provided  as 
published  and  are conducted  at one's own risk.  Organic Syntheses, Inc., its 
Ed itors, and  its Board  of Directors do not warrant or guarantee the safety 
of ind ividuals using these procedures and  hereby d isclaim any liability 
for any injuries or damages claimed  to have resulted  from or related  in 
any way to the procedures herein. 
 
Discussion 
 
 In 1983 Mander and  colleagues reported  the use of methyl 
cyanoformate for the selective C-acylation of ketone enolates to form -
ketoesters.
5
 Since this report cyanoformates have been the preferred  
reagent for this transformation, other reagents regu larly give varying 
amounts of the unwanted  O-acylation products.
6
 In recent times the 
ethyl
7
, benzyl
8
 and  allyl
9
 cyanoformates have all been successfully 
employed  for the synthesis of the corresponding -ketoesters in organic 
synthesis. Despite the popularity and  widespread  use of cyanoformates 
the analogous cyanoformamides have never been exploited  in the 
synthesis of -ketoamides from the corresponding ketones.  
Recently, our laboratory required  a concise synthesis of a -keto 
Weinreb amide from the correspond ing ketone. Our investigations 
established  that the reagents commonly used  for the synthesis of Weinreb 
amides from organometallic reagents were unsuccessful when applied  in 
the reaction of ketone enolates.
10
 This prompted  our investigation into the 
reactivity of N -methoxy-N -methylcyanoformamide, a compound we 
anticipated  would  exhibit similar reactivity to the related  cyanoformates . 
We d iscovered  that, when treated  with N -methoxy-N -
methylcyanoformamide, a wide range of ketone enolates efficiently 
underwent selective C-carbamoylation to form the product -ketoamides 
in excellent yields (Table 1).  
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The procedure reported  herein was derived  from our original 
communication
10
 and  is both operationally simple and  requires a minimal 
amount of purification. The ease of synthesis of 2 coupled  with the 
efficiency and  versatility of the reaction of compound 2 with enolates 
suggests that this reagent is an excellent add ition to the synthetic 
chemist’s toolbox. 
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Appendix 
Chemical Abstracts Nomenclature (Registry Number) 
N ,O-d imethylhydroxylamine hydrochloride: Methanamine, N -methoxy-, 
hydrochloride; (6638-79-5) 
N ,N ′-carbonyld iimid azole: 1H-Imid azole, 1,1'-carbonylbis-; (530-62-1) 
trimethylsilyl cyanide: Silanecarbonitrile, trimethyl-; (7677-24-9) 
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Crystal structure of C54H56O6 — banBDS_21
Jeremy Nugent, Martin G. Banwell and Brett D. Schwartz* 
Research School of Chemistry, The Australian National University, Canberra, A. C. T. 2601, Australia 
Correspondence email: u4691352@anu.edu.au 
Abstract
The crystal structure of C54H56O6. is reported. 
1. Comment
The crystallographic asymmetric unit consists of two molecules of C27H28O3.
2. Synthesis and crystallization
The compound was prepared by JN is a racemate and was recrystallized from ethanol / water The sample ID is JN-di-
hydrosimonsolC
Related literature
Computing details
Data collection: CrysAlis PRO, (Agilent, 2015); cell refinement: CrysAlis PRO, (Agilent, 2015); data reduction: CrysAlis 
PRO, (Agilent, 2015); program(s) used to solve structure: SUPERFLIP (Palatinus & Chapuis, 2007); program(s) used to 
refine structure: CRYSTALS (Betteridge et al., 2003); molecular graphics: PLATON (Spek, 2008); software used to pre-
pare material for publication: CRYSTALS (Betteridge et al., 2003).
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(banBDS_21) 
Crystal data 
C27H28O3
Mr = 400.47
Triclinic, P1
Hall symbol: -P 1
a = 9.9759 (2) Å
b = 13.6806 (3) Å
c = 17.6508 (4) Å
α = 109.1900 (19)°
β = 96.4682 (17)°
γ = 98.2575 (16)°
V = 2218.30 (5) Å3
Z = 4
F(000) = 855.891
Dx = 1.199 Mg m−3
Cu Kα radiation, λ = 1.54184 Å
Cell parameters from 10944 reflections
θ = 5–72°
µ = 0.61 mm−1
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T = 150 K
Rod, colourless
0.44 × 0.07 × 0.04 mm
Data collection 
Oxford Diffraction SuperNova 
diffractometer
Graphite monochromator
ω scans
Absorption correction: multi-scan 
CrysAlis PRO, (Agilent, 2015)
Tmin = 0.75, Tmax = 0.98
24412 measured reflections
8471 independent reflections
7181 reflections with I > 2.0σ(I)
Rint = 0.027
θmax = 72.0°, θmin = 3.5°
h = −11→9
k = −16→16
l = −21→21
Refinement 
Refinement on F2
Least-squares matrix: full
R[F2 > 2σ(F2)] = 0.052
wR(F2) = 0.143
S = 0.99
8471 reflections
604 parameters
44 restraints
Primary atom site location: Other
Hydrogen site location: difference Fourier map
H atoms treated by a mixture of independent and 
constrained refinement
Method = Modified Sheldrick w = 1/[σ2(F2) + ( 
0.07P)2 + 1.21P] , 
where P = (max(Fo2,0) + 2Fc2)/3
(Δ/σ)max = 0.009
Δρmax = 0.36 e Å−3
Δρmin = −0.46 e Å−3
Special details 
Refinement 
H atoms were added at calculated positions and were rided to atoms to which they were bonded. Disorder was observed in several of the 
allyl side-chains. Additional atom sites were added as appropriate and restraints in distances and angles were applied during refinement. 
The major features of the final difference map are largely within the disorder. Some peaks suggest further disorder existed which was not 
modelled here as its apparent occupancy was insignificant. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
x y z Uiso*/Ueq Occ. (<1)
O6 0.27481 (13) 0.73850 (9) 0.24961 (8) 0.0351
O14 0.27042 (15) 0.70687 (11) 0.07930 (9) 0.0424
O27 0.27654 (15) 0.91133 (10) 0.19061 (8) 0.0386
O36 0.67824 (12) 0.03905 (9) 0.08966 (8) 0.0341
O44 0.7079 (2) 0.01195 (11) −0.07272 (9) 0.0565
O57 0.77502 (15) 0.22650 (10) 0.04834 (8) 0.0400
C1 −0.0087 (2) 0.60270 (14) 0.14403 (11) 0.0372
C2 0.0491 (2) 0.60634 (14) 0.08096 (11) 0.0395
C3 0.1982 (2) 0.60642 (14) 0.07754 (12) 0.0403
C4 0.2653 (2) 0.57227 (15) 0.14420 (13) 0.0429
C5 0.2246 (2) 0.62475 (13) 0.22531 (12) 0.0367
C7 0.17964 (18) 0.78667 (13) 0.29130 (10) 0.0314
C8 0.19887 (19) 0.89428 (14) 0.33343 (10) 0.0326
C9 0.0900 (2) 0.92876 (14) 0.37123 (11) 0.0368
C10 −0.0327 (2) 0.86114 (16) 0.36582 (12) 0.0412
C11 −0.0480 (2) 0.75417 (15) 0.32078 (12) 0.0395
C12 0.05906 (19) 0.71723 (14) 0.28424 (10) 0.0335
C13 0.06828 (19) 0.60981 (14) 0.22519 (11) 0.0356
C15 0.0089 (2) 0.51577 (15) 0.24936 (13) 0.0455
C16 0.0563 (3) 0.5249 (2) 0.33568 (16) 0.0445 0.779
C17 −0.0173 (4) 0.5329 (3) 0.3928 (2) 0.0642 0.779
C18 −0.1492 (3) 0.90371 (19) 0.40639 (15) 0.0574
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C19 −0.2747 (4) 0.8844 (3) 0.35158 (19) 0.0716 0.836
C20 −0.3887 (3) 0.8172 (3) 0.3439 (3) 0.1128
C21 0.32470 (19) 0.96798 (13) 0.33498 (11) 0.0332
C22 0.4075 (2) 1.03517 (14) 0.40828 (11) 0.0378
C23 0.5251 (2) 1.10435 (15) 0.41068 (12) 0.0437
C24 0.5601 (2) 1.10664 (16) 0.33685 (13) 0.0465
C25 0.4790 (2) 1.04296 (15) 0.26307 (12) 0.0417
C26 0.3614 (2) 0.97400 (13) 0.26192 (11) 0.0346
C28 0.6136 (3) 1.17471 (19) 0.49080 (15) 0.0613
C29 0.6015 (6) 1.2894 (3) 0.5145 (2) 0.0880 0.762
C30 0.5288 (9) 1.3307 (4) 0.4749 (3) 0.1438 0.762
C31 0.8933 (2) −0.10967 (14) 0.02527 (11) 0.0362
C32 0.8499 (2) −0.10828 (15) −0.04808 (12) 0.0440
C33 0.7075 (2) −0.09476 (14) −0.07423 (12) 0.0461
C34 0.6082 (2) −0.12460 (14) −0.02314 (12) 0.0414
C35 0.66481 (19) −0.07620 (13) 0.06678 (11) 0.0338
C37 0.79111 (18) 0.08394 (13) 0.15013 (10) 0.0307
C38 0.82412 (19) 0.19039 (13) 0.19730 (11) 0.0324
C39 0.9405 (2) 0.22072 (14) 0.25792 (11) 0.0356
C40 1.0211 (2) 0.14999 (14) 0.27026 (11) 0.0360
C41 0.98607 (19) 0.04421 (14) 0.21923 (11) 0.0331
C42 0.87025 (18) 0.01156 (13) 0.15943 (10) 0.0309
C43 0.80946 (18) −0.09449 (13) 0.09315 (10) 0.0304
C45 0.8041 (2) −0.18713 (14) 0.12498 (12) 0.0379
C46 0.7344 (2) −0.29089 (15) 0.06209 (14) 0.0452
C47 0.6277 (3) −0.3525 (2) 0.0700 (2) 0.0721
C48 1.1441 (2) 0.18934 (16) 0.33768 (13) 0.0460
C49 1.1137 (4) 0.2196 (3) 0.42196 (17) 0.0482 0.731
C50 0.9941 (4) 0.2080 (3) 0.44254 (19) 0.0633 0.731
C51 0.74336 (18) 0.26958 (13) 0.18621 (11) 0.0327
C52 0.6919 (2) 0.33274 (14) 0.25131 (12) 0.0373
C53 0.6225 (2) 0.41217 (15) 0.24587 (13) 0.0421
C54 0.6067 (2) 0.42863 (15) 0.17196 (13) 0.0420
C55 0.6557 (2) 0.36701 (14) 0.10572 (12) 0.0382
C56 0.72353 (18) 0.28697 (13) 0.11212 (11) 0.0333
C58 0.5618 (3) 0.47513 (18) 0.31656 (15) 0.0570
C59 0.4090 (3) 0.4363 (3) 0.30621 (19) 0.0547 0.779
C60 0.3264 (3) 0.3673 (3) 0.2416 (2) 0.0593 0.779
C116 0.0659 (15) 0.4176 (11) 0.1899 (8) 0.0834* 0.221
C117 0.1634 (19) 0.3670 (15) 0.2075 (11) 0.1047* 0.221
C119 −0.2808 (13) 0.8269 (12) 0.3858 (9) 0.0616* 0.164
C129 0.713 (2) 1.2694 (13) 0.5012 (13) 0.1371 0.238
C130 0.695 (3) 1.3621 (13) 0.5069 (15) 0.1635 0.238
C149 1.1330 (16) 0.2666 (13) 0.4137 (8) 0.0913* 0.269
C150 1.243 (2) 0.3066 (16) 0.4744 (11) 0.1400* 0.269
C159 0.491 (2) 0.4240 (19) 0.3669 (15) 0.0600* 0.091
C160 0.380 (2) 0.45227 (10) 0.39296 (10) 0.0600* 0.091
C259 0.6766 (18) 0.5368 (14) 0.3944 (9) 0.0600* 0.130
C260 0.712 (2) 0.5262 (16) 0.4659 (10) 0.0600* 0.130
H1 0.270 (2) 0.753 (2) 0.1250 (16) 0.0500*
H2 0.287 (2) 0.9369 (19) 0.1544 (15) 0.0500*
H3 0.717 (2) 0.052 (2) −0.0239 (16) 0.0500*
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H4 0.756 (2) 0.2446 (19) 0.0072 (15) 0.0500*
H11 −0.1059 0.5948 0.1379 0.0452*
H21 −0.0076 0.6091 0.0350 0.0473*
H31 0.2035 0.5553 0.0268 0.0491*
H41 0.3623 0.5903 0.1494 0.0519*
H42 0.2383 0.4980 0.1291 0.0519*
H51 0.2666 0.5997 0.2645 0.0448*
H91 0.0999 1.0016 0.4022 0.0444*
H111 −0.1314 0.7071 0.3151 0.0475*
H151 −0.0884 0.5079 0.2410 0.0555* 0.779
H152 0.0340 0.4543 0.2145 0.0555* 0.779
H153 0.0427 0.5277 0.3048 0.0555* 0.221
H154 −0.0887 0.5032 0.2405 0.0555* 0.221
H161 0.1511 0.5251 0.3501 0.0514* 0.779
H171 0.0245 0.5383 0.4455 0.0769* 0.779
H172 −0.1128 0.5331 0.3821 0.0769* 0.779
H181 −0.1210 0.9779 0.4325 0.0698* 0.836
H182 −0.1657 0.8723 0.4460 0.0698* 0.836
H183 −0.1675 0.9602 0.3893 0.0698* 0.164
H184 −0.1198 0.9295 0.4637 0.0698* 0.164
H191 −0.2764 0.9244 0.3166 0.0876* 0.836
H201 −0.4661 0.8114 0.3050 0.1345* 0.836
H202 −0.3937 0.7748 0.3771 0.1345* 0.836
H203 −0.3987 0.8658 0.3167 0.1345* 0.164
H204 −0.4634 0.7621 0.3378 0.1345* 0.164
H221 0.3818 1.0334 0.4581 0.0453*
H241 0.6412 1.1527 0.3371 0.0565*
H251 0.5037 1.0465 0.2135 0.0503*
H281 0.7070 1.1700 0.4872 0.0751* 0.762
H282 0.5868 1.1497 0.5321 0.0751* 0.762
H283 0.5513 1.1995 0.5263 0.0751* 0.238
H284 0.6625 1.1303 0.5098 0.0751* 0.238
H291 0.6527 1.3348 0.5659 0.1047* 0.762
H301 0.5302 1.4043 0.4968 0.1825* 0.762
H302 0.4754 1.2896 0.4231 0.1825* 0.762
H311 0.9842 −0.1209 0.0361 0.0437*
H321 0.9118 −0.1163 −0.0858 0.0531*
H331 0.6770 −0.1412 −0.1289 0.0557*
H341 0.5894 −0.1992 −0.0382 0.0503*
H342 0.5254 −0.1010 −0.0336 0.0503*
H351 0.6022 −0.1010 0.0962 0.0409*
H391 0.9657 0.2926 0.2924 0.0426*
H411 1.0411 −0.0047 0.2255 0.0405*
H451 0.8956 −0.1920 0.1429 0.0460*
H452 0.7558 −0.1730 0.1696 0.0460*
H461 0.7701 −0.3139 0.0129 0.0544*
H471 0.5886 −0.4175 0.0274 0.0853*
H472 0.5893 −0.3320 0.1184 0.0853*
H481 1.1962 0.1350 0.3304 0.0555* 0.731
H482 1.1977 0.2495 0.3327 0.0555* 0.731
H483 1.2180 0.2190 0.3175 0.0555* 0.269
H484 1.1659 0.1298 0.3492 0.0555* 0.269
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H491 1.1902 0.2500 0.4650 0.0586* 0.731
H501 0.9860 0.2301 0.4985 0.0775* 0.731
H502 0.9142 0.1780 0.4019 0.0775* 0.731
H521 0.7047 0.3211 0.3016 0.0452*
H541 0.5615 0.4832 0.1668 0.0510*
H551 0.6425 0.3791 0.0556 0.0461*
H581 0.5778 0.5469 0.3205 0.0691* 0.779
H582 0.6057 0.4694 0.3652 0.0691* 0.779
H583 0.6357 0.5304 0.3491 0.0691* 0.0910
H584 0.4944 0.5037 0.2927 0.0691* 0.0910
H585 0.5165 0.5240 0.3013 0.0691* 0.13
H586 0.4976 0.4288 0.3309 0.0691* 0.13
H591 0.3677 0.4656 0.3523 0.0652* 0.779
H601 0.3611 0.3350 0.1934 0.0694* 0.779
H602 0.2315 0.3498 0.2433 0.0694* 0.779
H1161 0.0239 0.3896 0.1318 0.1000* 0.221
H1171 0.2119 0.3882 0.2605 0.1257* 0.221
H1172 0.1884 0.3097 0.1648 0.1257* 0.221
H1191 −0.2791 0.7752 0.4109 0.0739* 0.164
H1291 0.8040 1.2560 0.4986 0.1990* 0.238
H1301 0.7751 1.4121 0.5114 0.2203* 0.238
H1302 0.6089 1.3831 0.5104 0.2203* 0.238
H1491 1.0474 0.2873 0.4220 0.1096* 0.269
H1501 1.3287 0.2859 0.4661 0.1680* 0.269
H1502 1.2354 0.3579 0.5245 0.1680* 0.269
H1591 0.5239 0.3678 0.3785 0.0720* 0.091
H1601 0.3464 0.5084 0.3816 0.0720* 0.091
H1602 0.3353 0.4189 0.4253 0.0720* 0.091
H2591 0.7394 0.5908 0.3871 0.0720* 0.13
H2601 0.7884 0.5707 0.5051 0.0720* 0.13
H2602 0.6540 0.4740 0.4782 0.0720* 0.13
Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
O6 0.0332 (7) 0.0270 (6) 0.0418 (7) 0.0049 (5) 0.0003 (5) 0.0100 (5)
O14 0.0537 (9) 0.0344 (7) 0.0365 (7) 0.0087 (6) 0.0092 (6) 0.0085 (6)
O27 0.0506 (8) 0.0323 (6) 0.0294 (6) 0.0018 (6) 0.0020 (6) 0.0103 (5)
O36 0.0321 (6) 0.0257 (6) 0.0431 (7) 0.0082 (5) −0.0021 (5) 0.0118 (5)
O44 0.1057 (14) 0.0271 (7) 0.0326 (7) 0.0091 (7) −0.0029 (8) 0.0114 (6)
O57 0.0528 (8) 0.0339 (7) 0.0350 (7) 0.0171 (6) 0.0045 (6) 0.0116 (5)
C1 0.0370 (10) 0.0288 (8) 0.0392 (10) 0.0036 (7) −0.0028 (8) 0.0075 (7)
C2 0.0451 (11) 0.0314 (9) 0.0367 (9) 0.0094 (8) −0.0039 (8) 0.0076 (7)
C3 0.0494 (11) 0.0293 (9) 0.038 (1) 0.0091 (8) 0.0070 (8) 0.0058 (7)
C4 0.0427 (11) 0.0328 (9) 0.0519 (11) 0.0150 (8) 0.0038 (9) 0.0112 (8)
C5 0.0399 (10) 0.0250 (8) 0.0428 (10) 0.0067 (7) −0.0035 (8) 0.0119 (7)
C7 0.0337 (9) 0.0299 (8) 0.0303 (8) 0.0073 (7) 0.0004 (7) 0.0114 (7)
C8 0.0392 (10) 0.0305 (8) 0.0269 (8) 0.0047 (7) −0.0003 (7) 0.0111 (7)
C9 0.0480 (11) 0.0319 (9) 0.0288 (8) 0.0083 (8) 0.0056 (8) 0.0086 (7)
C10 0.0462 (11) 0.0428 (10) 0.0355 (9) 0.0085 (9) 0.0104 (8) 0.0137 (8)
C11 0.0379 (10) 0.0408 (10) 0.0392 (10) 0.0027 (8) 0.0058 (8) 0.0154 (8)
C12 0.0364 (9) 0.0304 (8) 0.0320 (8) 0.0034 (7) −0.0009 (7) 0.0123 (7)
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C13 0.0380 (10) 0.0276 (8) 0.0388 (9) 0.0038 (7) −0.0006 (8) 0.0117 (7)
C15 0.0532 (12) 0.0316 (9) 0.0485 (11) 0.0010 (9) 0.0004 (9) 0.0156 (8)
C16 0.0463 (15) 0.0413 (13) 0.0496 (15) 0.0018 (11) 0.0030 (12) 0.0252 (12)
C17 0.079 (2) 0.065 (2) 0.0519 (17) 0.0081 (17) 0.0157 (16) 0.0257 (15)
C18 0.0581 (14) 0.0515 (13) 0.0598 (14) 0.0102 (11) 0.0252 (11) 0.0114 (11)
C19 0.067 (2) 0.091 (3) 0.0509 (17) 0.049 (2) 0.0091 (14) 0.0044 (16)
C20 0.0519 (19) 0.114 (3) 0.125 (3) 0.0247 (19) 0.0052 (19) −0.020 (2)
C21 0.0388 (10) 0.0253 (8) 0.0340 (9) 0.0050 (7) 0.0012 (7) 0.0103 (7)
C22 0.0469 (11) 0.0300 (9) 0.0336 (9) 0.0050 (8) 0.0004 (8) 0.0107 (7)
C23 0.0484 (12) 0.0338 (9) 0.0429 (10) −0.0004 (8) −0.0049 (9) 0.0133 (8)
C24 0.0441 (11) 0.0379 (10) 0.0548 (12) −0.0039 (8) 0.0022 (9) 0.0199 (9)
C25 0.0491 (12) 0.0362 (9) 0.0418 (10) 0.0053 (8) 0.0086 (9) 0.0172 (8)
C26 0.0415 (10) 0.0265 (8) 0.0334 (9) 0.0053 (7) 0.0017 (7) 0.0092 (7)
C28 0.0641 (15) 0.0528 (13) 0.0522 (13) −0.0149 (11) −0.0139 (11) 0.0176 (11)
C29 0.142 (5) 0.0345 (17) 0.056 (2) −0.018 (2) −0.034 (3) 0.0060 (15)
C30 0.276 (10) 0.047 (2) 0.078 (3) 0.017 (4) −0.032 (4) 0.009 (2)
C31 0.0349 (9) 0.0304 (9) 0.0410 (10) 0.0051 (7) 0.0067 (8) 0.0100 (7)
C32 0.0564 (12) 0.0328 (9) 0.0388 (10) 0.0008 (8) 0.0110 (9) 0.0096 (8)
C33 0.0721 (14) 0.0251 (9) 0.0352 (9) 0.0056 (9) −0.0072 (9) 0.0096 (7)
C34 0.0405 (10) 0.0247 (8) 0.0533 (11) 0.0052 (7) −0.0104 (9) 0.0127 (8)
C35 0.0330 (9) 0.0245 (8) 0.0461 (10) 0.0077 (7) 0.0042 (7) 0.0150 (7)
C37 0.0305 (9) 0.0300 (8) 0.0325 (8) 0.0073 (7) 0.0024 (7) 0.0126 (7)
C38 0.0355 (9) 0.0295 (8) 0.0343 (9) 0.0092 (7) 0.0053 (7) 0.0130 (7)
C39 0.0425 (10) 0.0293 (8) 0.0331 (9) 0.0076 (7) 0.0015 (7) 0.0098 (7)
C40 0.0389 (10) 0.0362 (9) 0.0337 (9) 0.0081 (8) 0.0012 (7) 0.0145 (7)
C41 0.0346 (9) 0.0345 (9) 0.0352 (9) 0.0113 (7) 0.0048 (7) 0.0171 (7)
C42 0.0331 (9) 0.0293 (8) 0.0341 (8) 0.0093 (7) 0.0073 (7) 0.0142 (7)
C43 0.0311 (9) 0.0266 (8) 0.0359 (9) 0.0078 (7) 0.0034 (7) 0.0136 (7)
C45 0.0413 (10) 0.0312 (9) 0.0467 (10) 0.0114 (8) 0.0051 (8) 0.0201 (8)
C46 0.0425 (11) 0.0313 (9) 0.0643 (13) 0.0095 (8) −0.0029 (9) 0.0230 (9)
C47 0.0553 (15) 0.0512 (14) 0.114 (2) −0.0026 (11) −0.0060 (15) 0.0461 (15)
C48 0.0508 (12) 0.0382 (10) 0.0469 (11) 0.0064 (9) −0.0078 (9) 0.0182 (9)
C49 0.0570 (19) 0.0411 (17) 0.0343 (14) 0.0071 (14) −0.0142 (13) 0.0053 (11)
C50 0.077 (3) 0.076 (2) 0.0369 (16) 0.0270 (19) 0.0052 (15) 0.0156 (15)
C51 0.0320 (9) 0.0247 (8) 0.0398 (9) 0.0058 (7) 0.0023 (7) 0.0101 (7)
C52 0.0405 (10) 0.0323 (9) 0.0415 (10) 0.0094 (8) 0.0087 (8) 0.0144 (8)
C53 0.0439 (11) 0.0320 (9) 0.0505 (11) 0.0115 (8) 0.0126 (9) 0.0112 (8)
C54 0.0417 (11) 0.0332 (9) 0.0551 (12) 0.0156 (8) 0.0069 (9) 0.0179 (8)
C55 0.0389 (10) 0.0343 (9) 0.0425 (10) 0.0107 (8) 0.0006 (8) 0.0155 (8)
C56 0.0323 (9) 0.0267 (8) 0.0372 (9) 0.0058 (7) 0.0000 (7) 0.0084 (7)
C58 0.0707 (16) 0.0472 (12) 0.0614 (14) 0.0285 (11) 0.0243 (12) 0.0186 (11)
C59 0.0603 (19) 0.0634 (18) 0.0568 (17) 0.0341 (15) 0.0293 (15) 0.0272 (15)
C60 0.0531 (18) 0.0553 (17) 0.081 (2) 0.0185 (14) 0.0276 (16) 0.0298 (17)
C129 0.199 (17) 0.098 (10) 0.099 (11) 0.023 (12) −0.013 (13) 0.029 (9)
C130 0.258 (19) 0.067 (9) 0.148 (14) −0.002 (11) 0.050 (14) 0.023 (10)
Geometric parameters (Å, º) 
O6—C5 1.465 (2) C32—C33 1.499 (3)
O6—C7 1.377 (2) C32—H321 0.950
O14—C3 1.446 (2) C33—C34 1.513 (3)
O14—H1 0.84 (3) C33—H331 0.950
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O27—C26 1.370 (2) C34—C35 1.509 (3)
O27—H2 0.83 (3) C34—H341 0.950
O36—C35 1.4750 (19) C34—H342 0.950
O36—C37 1.372 (2) C35—C43 1.546 (2)
O44—C33 1.451 (2) C35—H351 0.950
O44—H3 0.84 (3) C37—C38 1.388 (2)
O57—C56 1.362 (2) C37—C42 1.390 (2)
O57—H4 0.85 (3) C38—C39 1.398 (2)
C1—C2 1.322 (3) C38—C51 1.488 (2)
C1—C13 1.513 (2) C39—C40 1.397 (3)
C1—H11 0.950 C39—H391 0.950
C2—C3 1.495 (3) C40—C41 1.398 (3)
C2—H21 0.950 C40—C48 1.507 (3)
C3—C4 1.525 (3) C41—C42 1.384 (2)
C3—H31 0.950 C41—H411 0.950
C4—C5 1.506 (3) C42—C43 1.521 (2)
C4—H41 0.950 C43—C45 1.543 (2)
C4—H42 0.950 C45—C46 1.496 (3)
C5—C13 1.543 (3) C45—H451 0.950
C5—H51 0.950 C45—H452 0.950
C7—C8 1.387 (2) C46—C47 1.310 (3)
C7—C12 1.387 (3) C46—H461 0.950
C8—C9 1.397 (3) C47—H471 0.950
C8—C21 1.485 (3) C47—H472 0.950
C9—C10 1.398 (3) C48—C49 1.486 (4)
C9—H91 0.950 C48—C149 1.437 (12)
C10—C11 1.393 (3) C48—H481 0.950
C10—C18 1.520 (3) C48—H482 0.950
C11—C12 1.382 (3) C48—H483 0.950
C11—H111 0.950 C48—H484 0.950
C12—C13 1.519 (2) C49—C50 1.289 (5)
C13—C15 1.545 (3) C49—H491 0.950
C15—C16 1.502 (3) C50—C149 1.711 (17)
C15—C116 1.629 (12) C50—H501 0.950
C15—H151 0.950 C50—H502 0.950
C15—H152 0.950 C51—C52 1.392 (3)
C15—H153 0.950 C51—C56 1.402 (3)
C15—H154 0.950 C52—C53 1.392 (3)
C16—C17 1.298 (4) C52—H521 0.950
C16—H153 0.562 C53—C54 1.391 (3)
C16—H161 0.950 C53—C58 1.510 (3)
C17—H171 0.950 C54—C55 1.384 (3)
C17—H172 0.950 C54—H541 0.950
C18—C19 1.427 (4) C55—C56 1.395 (2)
C18—C119 1.485 (12) C55—H551 0.950
C18—H181 0.950 C58—C59 1.510 (4)
C18—H182 0.950 C58—C159 1.480 (16)
C18—H183 0.950 C58—C259 1.587 (14)
C18—H184 0.950 C58—H581 0.950
C19—C20 1.319 (5) C58—H582 0.950
C19—H191 0.950 C58—H583 0.950
C20—C119 1.199 (12) C58—H584 0.950
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C20—H201 0.950 C58—H585 0.950
C20—H202 0.950 C58—H586 0.950
C20—H203 0.950 C59—C60 1.315 (5)
C20—H204 0.950 C59—H584 1.263
C21—C22 1.400 (2) C59—H586 0.975
C21—C26 1.404 (3) C59—H591 0.950
C22—C23 1.385 (3) C60—H601 0.950
C22—H221 0.950 C60—H602 0.950
C23—C24 1.396 (3) C116—C117 1.337 (15)
C23—C28 1.512 (3) C116—H152 0.690
C24—C25 1.387 (3) C116—H1161 0.987
C24—H241 0.950 C117—H1171 0.934
C25—C26 1.389 (3) C117—H1172 0.978
C25—H251 0.950 C119—H1191 0.950
C28—C29 1.511 (5) C129—C130 1.279 (16)
C28—C129 1.461 (15) C129—H1291 0.950
C28—H281 0.950 C130—H1301 0.950
C28—H282 0.950 C130—H1302 0.950
C28—H283 0.950 C149—C150 1.352 (15)
C28—H284 0.950 C149—H1491 0.950
C29—C30 1.265 (7) C150—H1501 0.950
C29—C129 1.22 (2) C150—H1502 0.950
C29—C130 1.32 (2) C159—C160 1.305 (18)
C29—H291 0.950 C159—H1591 0.950
C30—C130 1.64 (3) C160—H1601 0.950
C30—H301 0.950 C160—H1602 0.950
C30—H302 0.950 C259—C260 1.331 (16)
C31—C32 1.325 (3) C259—H2591 0.950
C31—C43 1.513 (3) C260—H2601 0.950
C31—H311 0.950 C260—H2602 0.950
C5—O6—C7 106.29 (13) C34—C33—H331 107.6
C3—O14—H1 108.6 (17) C33—C34—C35 112.28 (16)
C26—O27—H2 109.9 (17) C33—C34—H341 108.8
C35—O36—C37 106.69 (12) C35—C34—H341 108.8
C33—O44—H3 108.0 (17) C33—C34—H342 108.7
C56—O57—H4 109.4 (16) C35—C34—H342 108.8
C2—C1—C13 124.91 (18) H341—C34—H342 109.5
C2—C1—H11 117.5 C34—C35—O36 107.25 (13)
C13—C1—H11 117.5 C34—C35—C43 115.72 (15)
C1—C2—C3 124.03 (17) O36—C35—C43 105.67 (13)
C1—C2—H21 118.0 C34—C35—H351 109.4
C3—C2—H21 118.0 O36—C35—H351 109.3
C2—C3—O14 111.85 (15) C43—C35—H351 109.3
C2—C3—C4 111.12 (17) O36—C37—C38 124.00 (15)
O14—C3—C4 112.15 (16) O36—C37—C42 112.98 (15)
C2—C3—H31 107.1 C38—C37—C42 123.02 (16)
O14—C3—H31 107.2 C37—C38—C39 115.67 (15)
C4—C3—H31 107.1 C37—C38—C51 123.72 (16)
C3—C4—C5 112.25 (15) C39—C38—C51 120.61 (16)
C3—C4—H41 108.7 C38—C39—C40 122.98 (16)
C5—C4—H41 108.7 C38—C39—H391 118.5
303
structure report
9publCIF
C3—C4—H42 108.9 C40—C39—H391 118.6
C5—C4—H42 108.8 C39—C40—C41 119.07 (16)
H41—C4—H42 109.5 C39—C40—C48 119.44 (17)
C4—C5—O6 107.75 (15) C41—C40—C48 121.49 (16)
C4—C5—C13 114.93 (16) C40—C41—C42 119.24 (16)
O6—C5—C13 106.21 (14) C40—C41—H411 120.4
C4—C5—H51 109.3 C42—C41—H411 120.4
O6—C5—H51 109.3 C37—C42—C41 119.96 (16)
C13—C5—H51 109.2 C37—C42—C43 108.10 (15)
O6—C7—C8 123.87 (16) C41—C42—C43 131.85 (15)
O6—C7—C12 113.17 (15) C35—C43—C42 100.53 (13)
C8—C7—C12 122.90 (17) C35—C43—C31 111.51 (15)
C7—C8—C9 115.61 (17) C42—C43—C31 108.47 (14)
C7—C8—C21 121.86 (17) C35—C43—C45 112.53 (14)
C9—C8—C21 122.48 (16) C42—C43—C45 112.67 (14)
C8—C9—C10 123.08 (17) C31—C43—C45 110.69 (14)
C8—C9—H91 118.5 C43—C45—C46 113.28 (15)
C10—C9—H91 118.4 C43—C45—H451 108.5
C9—C10—C11 118.91 (18) C46—C45—H451 108.4
C9—C10—C18 120.73 (18) C43—C45—H452 108.5
C11—C10—C18 120.34 (19) C46—C45—H452 108.6
C10—C11—C12 119.38 (18) H451—C45—H452 109.5
C10—C11—H111 120.4 C45—C46—C47 124.7 (3)
C12—C11—H111 120.3 C45—C46—H461 117.7
C7—C12—C11 120.07 (16) C47—C46—H461 117.6
C7—C12—C13 107.92 (16) C46—C47—H471 120.1
C11—C12—C13 131.57 (17) C46—C47—H472 119.9
C5—C13—C12 100.36 (14) H471—C47—H472 120.0
C5—C13—C1 110.77 (16) C40—C48—C49 116.0 (2)
C12—C13—C1 105.23 (14) C40—C48—C149 118.4 (6)
C5—C13—C15 114.33 (15) C40—C48—H481 107.8
C12—C13—C15 114.54 (16) C49—C48—H481 107.8
C1—C13—C15 110.85 (15) C40—C48—H482 108.0
C13—C15—C16 115.89 (17) C49—C48—H482 107.8
C13—C15—C116 103.4 (6) H481—C48—H482 109.5
C13—C15—H151 107.9 C40—C48—H483 107.3
C16—C15—H151 107.8 C149—C48—H483 107.3
C13—C15—H152 107.9 C40—C48—H484 107.1
C16—C15—H152 107.7 C149—C48—H484 107.0
H151—C15—H152 109.5 H483—C48—H484 109.5
C13—C15—H153 110.9 C48—C49—C50 126.5 (3)
C116—C15—H153 110.3 C48—C49—H491 116.7
C13—C15—H154 111.2 C50—C49—H491 116.7
C116—C15—H154 111.5 C49—C50—H501 119.8
H153—C15—H154 109.5 C149—C50—H501 119.2
C15—C16—C17 127.4 (3) C49—C50—H502 120.2
C15—C16—H161 116.2 C149—C50—H502 115.8
C17—C16—H161 116.4 H501—C50—H502 120.0
C16—C17—H171 119.7 C38—C51—C52 120.26 (16)
C16—C17—H172 120.3 C38—C51—C56 121.47 (16)
H171—C17—H172 120.0 C52—C51—C56 118.17 (16)
C10—C18—C19 114.2 (2) C51—C52—C53 122.83 (18)
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C10—C18—C119 115.3 (6) C51—C52—H521 118.5
C10—C18—H181 108.2 C53—C52—H521 118.7
C19—C18—H181 107.8 C52—C53—C54 117.56 (18)
C10—C18—H182 108.4 C52—C53—C58 121.15 (19)
C19—C18—H182 108.7 C54—C53—C58 121.25 (18)
H181—C18—H182 109.5 C53—C54—C55 121.29 (17)
C10—C18—H183 107.8 C53—C54—H541 119.4
C119—C18—H183 106.8 C55—C54—H541 119.3
C10—C18—H184 108.4 C54—C55—C56 120.28 (18)
C119—C18—H184 109.0 C54—C55—H551 119.8
H183—C18—H184 109.5 C56—C55—H551 119.9
C18—C19—C20 127.3 (4) C51—C56—C55 119.85 (17)
C18—C19—H191 116.4 C51—C56—O57 118.65 (15)
C20—C19—H191 116.3 C55—C56—O57 121.47 (16)
C19—C20—H201 119.5 C53—C58—C59 111.9 (2)
C19—C20—H202 120.5 C53—C58—C159 121.2 (9)
H201—C20—H202 120.0 C53—C58—C259 111.5 (7)
C119—C20—H203 118.9 C53—C58—H581 108.8
C119—C20—H204 121.1 C59—C58—H581 108.8
H203—C20—H204 120.0 C53—C58—H582 108.9
C8—C21—C22 121.66 (16) C59—C58—H582 108.9
C8—C21—C26 120.17 (15) H581—C58—H582 109.5
C22—C21—C26 118.14 (17) C53—C58—H583 104.5
C21—C22—C23 122.31 (18) C159—C58—H583 111.1
C21—C22—H221 118.8 C53—C58—H584 104.6
C23—C22—H221 118.9 C159—C58—H584 105.5
C22—C23—C24 118.00 (18) C53—C58—H585 109.4
C22—C23—C28 121.1 (2) C259—C58—H585 109.4
C24—C23—C28 120.9 (2) C53—C58—H586 109.5
C23—C24—C25 121.34 (19) C259—C58—H586 107.6
C23—C24—H241 119.4 H583—C58—H584 109.5
C25—C24—H241 119.3 H585—C58—H586 109.5
C24—C25—C26 119.80 (18) C58—C59—C60 128.2 (3)
C24—C25—H251 120.1 C58—C59—H591 115.7
C26—C25—H251 120.1 C60—C59—H591 116.1
C21—C26—C25 120.38 (17) C59—C60—H601 120.5
C21—C26—O27 117.80 (16) C59—C60—H602 119.5
C25—C26—O27 121.82 (17) H601—C60—H602 120.0
C23—C28—C29 114.0 (2) C15—C116—C117 129.8 (12)
C23—C28—C129 124.4 (8) C15—C116—H1161 117.2
C23—C28—H281 108.6 C117—C116—H1161 113.0
C29—C28—H281 108.4 C116—C117—H1171 120.4
C23—C28—H282 108.0 C116—C117—H1172 120.7
C29—C28—H282 108.3 H1171—C117—H1172 118.8
H281—C28—H282 109.5 C18—C119—C20 132.7 (12)
C23—C28—H283 105.6 C18—C119—H1191 113.6
C129—C28—H283 104.3 C20—C119—H1191 113.7
C23—C28—H284 106.0 C28—C129—C130 130.2 (19)
C129—C28—H284 106.7 C28—C129—H1291 112.4
H283—C28—H284 109.5 C29—C129—H1291 172.2
C28—C29—C30 127.5 (3) C130—C129—H1291 117.1
C30—C29—C129 124.4 (11) C129—C130—H1301 116.5
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C28—C29—C130 123.0 (11) C129—C130—H1302 123.3
C28—C29—H291 115.8 H1301—C130—H1302 120.0
C30—C29—H291 116.7 C48—C149—C150 120.0 (13)
C28—C29—H1302 158.9 C48—C149—H1491 119.9
C129—C29—H1302 102.8 C150—C149—H1491 120.1
C29—C30—H301 119.1 C149—C150—H1501 120.2
C29—C30—H302 120.8 C149—C150—H1502 119.8
C130—C30—H302 131.8 H1501—C150—H1502 120.0
H301—C30—H302 120.0 C58—C159—C160 120.8 (15)
C32—C31—C43 125.08 (18) C58—C159—H1591 119.6
C32—C31—H311 117.4 C160—C159—H1591 119.5
C43—C31—H311 117.5 C159—C160—H1601 119.9
C31—C32—C33 123.05 (19) C159—C160—H1602 120.1
C31—C32—H321 118.5 H1601—C160—H1602 120.0
C33—C32—H321 118.5 C58—C259—C260 135.0 (15)
C32—C33—O44 110.86 (17) C58—C259—H2591 113.0
C32—C33—C34 111.58 (16) C260—C259—H2591 111.8
O44—C33—C34 111.22 (17) C259—C260—H2601 122.7
C32—C33—H331 107.6 C259—C260—H2602 117.2
O44—C33—H331 107.8 H2601—C260—H2602 120.0
Hydrogen-bond geometry (Å, º) 
D—H···A D—H H···A D···A D—H···A
O14—H1···O6 0.84 (3) 2.27 (3) 2.887 (2) 130 (2)
O14—H1···O27 0.84 (3) 2.08 (3) 2.828 (2) 147 (2)
O27—H2···O44i 0.83 (3) 1.80 (3) 2.630 (2) 174 (2)
O44—H3···O36 0.84 (3) 2.14 (3) 2.822 (2) 138 (2)
O44—H3···O57 0.84 (3) 2.26 (3) 2.936 (2) 137 (2)
O57—H4···O14i 0.85 (3) 1.86 (3) 2.711 (2) 175 (2)
Symmetry code: (i) −x+1, −y+1, −z. 
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